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7Foreword
The European Monitoring Centre for Drugs and Drug Addiction hereby presents its 
thirteenth General report of activities to the European Parliament, the Council of the 
European Union, the European Commission, the Court of Auditors and the Member 
States, following its adoption by the Management Board in June 2008.
The report provides an account of the EMCDDA’s activities and accomplishments in 
2007, the first year of its ambitious 2007–2009 strategy and work programme. Working 
more efficiently, investing more in analysis and communicating more effectively with key 
audiences are among the goals of this new strategy.
A notable development for the Centre in 2007 was the recast of its founding regulation, 
which entered into force in January. The new regulation broadens the scope of the 
EMCDDA’s tasks, enabling it to provide a fuller picture of today’s drug problem. For 
example, it grants the Centre a more active role in monitoring new methods of drug 
use and related trends. Specifically, it allows the Centre to collect, register and analyse 
information on emerging trends in polydrug use. A key aspect of the new remit is 
providing information on best practice in the EU Member States and facilitating exchange 
of such practice between them, in areas such as drug prevention and reducing supply 
and drug-related harm. The Centre is also called on to develop tools and instruments to 
help Member States and the European Commission monitor and evaluate national and EU 
drug policies. 
The recast stipulated some changes to the Centre’s own administration too. The 
Management Board is now assisted by a six-member Executive Committee and the 
Scientific Committee is composed of 15 members chosen through a public selection 
process.
An external evaluation of the Centre was carried out in 2007, which provided a useful 
opportunity to view the EMCDDA ‘from the outside’, that is from the point-of-view of its 
stakeholders. Its overall purpose was to assess the Centre’s effectiveness and examine 
ways of enhancing its operations. The exercise covered the period of two EMCDDA 
three-year work programmes (2001–2003 and 2004–2006) and is part of the system of 
checks and balances in place to ensure good governance in EU agencies.
I am satisfied to report that the results of the evaluation exercise were positive overall. 
The EMCDDA is ‘performing well’ in its core mission to provide factual, objective, 
reliable and comparable information at European level concerning drugs and drug 
addiction and is ‘closely aligned with wider EU policy aims’, such as those set by EU 
drugs strategies and action plans. However, the evaluation also highlighted various ways 
in which the EMCDDA’s performance as an information provider could be enhanced. And 
it pointed out that the data-collection system is only implemented to a level of 60–70% 
at Member State level, and that there is still variation in the quality of the data collected 
nationally. 
During 2007, the EMCDDA continued to provide support to the EU institutions in their 
various activities in the drugs field. The Centre contributed to the European Commission’s 
work on the Action plan on drugs (2005–2008) by providing thematic papers on key 
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objectives and further assisting in elaborating the framework for its evaluation. The 
EMCDDA plays an important role in the implementation of the Council Decision on the 
information exchange, risk assessment and control of new psychoactive substances and, 
in March, was asked by the Council to conduct a risk assessment of the stimulant drug 
BZP. 
Relations with the European Parliament were strengthened, particularly with the 
Committee on Civil Liberties, Justice and Home Affairs. In November, the Centre 
presented to the Committee the key findings of its Annual report on the state of the 
drugs problem in Europe and gave an update of progress made in implementing a 
methodologically-sound and sustainable information system to monitor drug use.
At the close of another year’s work, I would like to express my gratitude to colleagues of 
the Management Board and the Scientific Committee for their support and commitment to 
the objectives of the Centre. My special thanks go also to Mr Wolfgang Götz, Director, 
the staff of the Centre and to the Reitox national focal points for their dedication and 
direct contribution to the results achieved. 
Marcel Reimen 
Chairman of the EMCDDA Management Board
Introduction
In the last General report of activities I described how 2006 had been a road-building 
year for the Centre. I also outlined the changes I had made to improve efficiency and 
effectiveness. During 2007, the Centre began to reap the benefits of these changes and was 
able to forge ahead with its new three-year strategy and work programme (2007–2009).
A thrust of this new strategy is to concentrate on the core business of monitoring the drugs 
phenomenon and to ensure that full value is secured from investments made. In particular, 
emphasis is placed on ensuring that maximum analytical value is derived from the data 
collected and that information is disseminated in products tailored to the needs of the 
EMCDDA’s key audiences. The strategy also sets out the underlying principles of commitment 
to scientific excellence, to partnership and to good governance and efficiency. The work 
executed in 2007 reflects these new priorities. 
Monitoring activities are a fundamental aspect of the Centre's work, and so the progress 
made in 2007 on Fonte, our new tool for data acquisition and management, is particularly 
significant. This is the largest transversal project at the EMCDDA and has been developed in 
close cooperation with the Reitox network. The successful launch of the first phase of Fonte 
has already streamlined key aspects of the Centre's data collection, validation and quality 
control. This development represents a key step towards more efficient management of our 
ever-growing data sets and is in line with my goal to free up time spent by scientific staff on 
routine tasks in order to carry out more in-depth analysis. 
As regards enhanced analysis, we concentrated on improving our statistical approach 
for analysing long-term and medium-term trends. We also placed increasing emphasis on 
identifying science-based practices and analysing the extent to which European responses 
meet estimated needs. Analytical work also commenced on several topics of particular policy 
interest: better quantification and delimitation of the size of the European drug problem; 
sharing experiences on best practices on drug prevention and responding to needs of those 
most at risk; reviewing how advances in genetics and neuroscience will affect the way we 
work with drug problems in the future; improving reporting on the levels and responses 
to polydrug use problems; and obtaining a better estimate of the drug market through a 
synthesis of supply and demand data. 
Reviewing how we deliver our information to the outside world, we carried out a root-
and-branch update to our communication strategy in 2007. The new strategy provides an 
overarching vision that coordinates and links the individual elements of data collection, 
analysis and reporting into a coherent process that results in a stream of clearly-delineated 
outputs. Implementation of the strategy will lead to improvements in the nature and quality 
of information available and in the communication and dissemination techniques used. The 
2007 external evaluation also carried out research on how we reach our target audiences 
and how they perceive the quality and usefulness of our products, the results of which will 
feed into this work.
Our Annual report on the state of the drugs problem in Europe remains a key product by 
which the Centre’s work and impact is measured by European decision makers and citizens. 
Member States play an increasingly important role in raising the visibility of the report’s 
findings and in 2007 over a dozen marked its release with national launches and events, 
combining European and national drugs perspectives. 
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Boosting the frequency with which we engage with the outside world, there were numerous 
examples of our output-oriented focus during the year. Our publications are tailored to 
audience needs, respond to prevailing trends in Europe’s drug use, and illustrate our progress 
in methodological developments. For example, two publications on cocaine treatment – a 
literature review and a policy briefing – served to help practitioners deal with rising demand 
for cocaine-related services. A policy briefing sought to define drug-related crime and another 
dealt with topical concerns on hallucinogenic mushrooms. In the area of new drug trends, a 
risk assessment on BZP was produced jointly with Europol. 
On the administrative front, in 2007 we continued to seek a greater degree of efficiency in 
financial and human resources management and ICT, and further oriented these services to 
provide better support for our core business. The recruitment process ran smoothly and at 
the end of the year the Centre numbered 93 staff, up from 87 in 2006 and 72 in 2005. 
Considerable progress was made on the construction of the Centre’s new premises, the 
Ribeira das Naus complex, and after several years of working at two different sites in Lisbon I 
look forward to uniting all staff in a single premises in 2008.
The risk in reporting once a year on the Centre's tasks in the General report of activities is 
to overlook achievements that are spread across a number of years. The Centre's important 
work continues all the time, and many projects mature as years go by. So early in 2008, we 
will see the completion of a number of major tasks for which the bulk of work was carried out 
during 2007: a two-volume cannabis monograph, the first module of a Best practice portal 
on drug prevention, and the Key indicator gateway. Also looking forward to 2008, this is 
an important year as the international community evaluates progress made in respect of the 
goals set in the EU action plan (2005–2008) and the 1998 special session of the United 
Nations on combating the world drugs problem. The EMCDDA has played a crucial role in 
supplying information to both these processes to assess the European situation.
As in previous years, I would like to thank the members of the Management Board, the 
Scientific Committee and the Reitox network for their valued input and cooperation. Most of 
all, I would also like to thank my staff for the commitment they show every day in building the 
Centre’s reputation and expertise.
Wolfgang Götz  
Director, EMCDDA
11I
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Chapter 1 
Chapter I: Synthesis of main results compared with 
goals of 2007 work programme
This synthesis section analyses the Centre's activities with reference to the 2007 work 
programme (1). The 2007 work programme reflected a need to streamline the Centre's 
activities in order to cope with current and expected budgetary constraints, and also 
the priorities defined in the EU drug strategy and action plan. Emphasis was placed on 
increasing performance, investing more in analysis, and becoming more output-oriented. 
Two strategic development areas were also targeted: an improved strategy for monitoring 
and reporting on drug treatment; and more sensitivity to polydrug use and non-opioid use 
in reporting on problem drug use in Europe.
The sections below highlight some of the year's activities, organised by the strategic 
objectives of the 2007 work programme. 2007 was also the first year of a new triennial 
work programme (2007–2009), with many projects embarked upon that will be brought 
to fruition in 2008 and 2009. A table has been added to this chapter to illustrate how 
the year's activities have already begun to achieve the goals set for this three-year 
timeframe. Note that a more detailed description of activities by programme area can be 
found in Chapter 2.
Objective II.2.1: Consolidate monitoring and reporting activities
The EMCDDA is a key provider of data on European drug use to the EU institutions 
and international organisations such as the UNODC and WHO. The Centre continued 
in 2007 to enhance its key indicators to monitor trends in drug use, and to produce 
strong snapshots of the current situation in the Annual report and Statistical bulletin. 
Notable activities during 2007 in this area included: annual expert meetings on the key 
indicators; a quality report package presented to National focal points in May; and 
short overviews (Implementation needs profiles) of the status of the indicators across 
the Reitox network. The year also saw the launch of the Fonte data management tool, 
the centrepiece in the Centre's current efforts to bring increased efficiency to its data 
monitoring, validation and reporting tasks.
Objective II.2.2: Enhanced analysis of data
A new founding regulation, or 'recast', entered into force in January. The recast 
broadened the role of the Centre, placing emphasis on, amongst others, analysis of 
emerging patterns of drug use, information on best practices and polydrug use. As 
stipulated in the recast, 2007 saw the appointment of a new slimmed-down, 15-member 
Scientific Committee, which will guide and inform the analysis of the Centre in line with 
the latest scientific knowledge over the coming years.
In terms of specific issues examined in 2007, the Centre’s Selected issue on drug use 
among very young people (under-15s) examined the consequences of drug use in this 
population. Considerable work took place during 2007 on cannabis treatment demand. 
A typology of cocaine and crack users was also developed. Work on the treatment 
13
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(1) 2007 work programme: http://www.emcdda.europa.eu/html.cfm/index25312EN.html 
2007–2009 triennial work programme:  
http://www.emcdda.europa.eu/html.cfm/index25311EN.html
demand indicator looked at increasing the Centre’s reach into data that may be available 
from sources which are currently under-represented in data collection: for example, low-
threshold agencies, units in prisons, general practitioners and accident-and-emergency 
admissions. 
The Centre continued its cyclical work to improve the quality of its data, particularly with 
regard to coverage, comparability and representativeness. Recruitment in the scientific 
units focused on building a team specifically to analyse drug supply (markets, prices, 
supply networks), to enable the Centre, during its three-year work programme, to build 
a better estimate on the size of drugs markets and a framework for describing supply 
reduction efforts.
Objective II.2.3: Communicate more effectively with key audiences
A new communication strategy was approved in 2007 by the Management Board. The 
strategy places emphasis on publishing and disseminating scientific outputs tailored for 
different audiences (policymakers, researchers, practitioners etc.). 
As in previous years, the Centre continued to produce quality publications aimed at 
providing rich, broad data on all aspects of Europe’s drug problem. For example, the 
2007 Statistical bulletin contained over 200 tables and 100 graphics, together with extra 
notes and analysis. The Centre's website remains the key platform for communication 
between the Centre and the outside world. In 2007, many developments on the website 
were aimed at improving access to the scientific outputs of the Centre. Innovations 
included the launch of a website newsfeed; an online version of the Drugnet Europe 
newsletter; integration of the Annual report package of sites into the main website; 
'tagging' of the Statistical bulletin with meta-data to make it easier to find statistics of 
interest; and a templating mechanism, which allows for more flexible page designs. 
During the year, the Scientific partners and documentation (SCD) unit improved the 
Centre's networking among scientists, academics, students and researchers focused on 
addiction science, policy and practice. It provided, for example, support to staff for 
publishing in journals through strengthened cooperation with International Society of 
Addiction Journal Editors. 
Such routine communication tasks were complemented by a number of formal agreements 
with partner organisations during the year. In 2007, the Centre signed, for example, 
a Memorandum of Understanding with the World Customs Organization and Russian 
Federal Drugs Control Service, and a cooperation agreement with the European Centre 
for Disease Prevention and Control (ECDC). Working with such partner organisations 
is vital to our work in obtaining a sharper view of the drug situation in Europe in all its 
aspects.
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Progress made in achieving the main goals of the new three-year work programme 
In 2007, the EMCDDA’s began its three-year work programme (2007–2009). This table 
provides a list of the main goals set in the work programme, with examples of how these 
goals have already been translated into concrete products and projects. 
Better quantification and delimitation of the size of the European drug problem 
Interesting and innovative work was conducted during 2007 across our units to be able to quantify the 
drugs problem, including analysis of cocaine in wastewater, public expenditure on the drugs problem, 
psychometric scales for intensive cannabis use and retail drug prices. Such data complements the work 
on the Centre's key indicators, which are subject to ongoing improvement year on year.
Understanding the dynamics of drug use in Europe and how provision of services for drug users reflects 
prevailing trends
The Centre continued its work on improving the quality of its data on provision of services in Europe, 
much of it linked to the treatment demand indicator. Some specific products in this area were 
developed in 2007, including a Drugs in focus policy briefing released in November, which advised 
policymakers in Europe on providing services to people encountering cocaine-related health problems. 
Furthermore, a study of cannabis treatment provision in Europe also examined the variety of services 
offered for cannabis use disorders across Europe.
Exploring drug use and broader mental health issues
Investigation into drugs and mental health problems were featured in a number of outputs and projects 
during 2007. The Centre hosted a meeting in January of the Network of European researchers in the 
use of drugs and alcohol (NERUDA), which included discussion of a new European masters programme 
on addiction. A Selected issue on Drug use among very young people (under 15s) examined mental 
health problems associated with drug use, and a number of chapters in a forthcoming cannabis 
monograph look at the association between cannabis and mental health problems.
Modelling how different drugs impact on health and social problems at individual (relative risk) and 
society level (population risk) 
Drugs in focus 15, released in June, appealed for a common language to describe drug-related crime, 
which is currently reported under a variety of labels in Europe, hampering comparability. A specific 
focus area in 2007 was drug-impaired driving, which led to a Selected issue on drugs and driving and 
an Insights publication, 'Drug use, impaired driving and traffic accidents', planned for 2008. 
Modelling the spread of HIV and hepatitis C among drug users
A protocol for data collection for studies on HIV prevalence and risk behaviour was produced, and 
a preliminary analysis comparing the EU with some large countries (including the US and Russia) in 
terms of incidence of diagnosed HIV among IDUs. For an expert meeting in 2007, a new analysis on 
mortality caused by HIV infection among injecting drug users was conducted, based on Eurostat and 
EuroHIV data. 
Best practice on drug prevention and responding to the needs of those most at risk
2007 saw considerable work on a new Best practice portal for the Centre’s website, which compiles 
information on science-based prevention interventions (prevention programmes, early intervention 
programmes) across Member States, together with guidance for evaluating programmes. A Reitox 
academy organised in Oslo in September 2007 presented the general concepts surrounding science-
based practices, and in particular criteria for evaluating evidence on the public health impact of 
interventions. 
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Reviewing how advances in genetics and neuroscience will affect the way we work with drug problems 
in the future
The Centre has planned the majority of work on neuroscience and genetics for later in the three-
year work programme. Nonetheless, two reports with a focus on neuroscience were finalised during 
2007. Researchers from the UK and Australia were also contracted to analyse the implications of new 
developments in neurobiological research on addiction. 
Best practice for treating problems caused by cannabis, cocaine and amphetamines
A Reitox academy in Berlin in March discussed the state-of-the-art in current prevention and treatment 
programmes on cannabis in Europe, and targeted Reitox staff and consultants who are working in the 
field at the national or supranational level. For practitioners, a Literature review on cocaine treatment 
released in May 2007 summarised the state-of-the-art in current treatment options for cocaine.  
Improving reporting on the levels of and responses to polydrug use problems
Work in the polydrug area during 2007 focused in particular on cooperation with the ESPAD (school 
surveys) project. Analysis focused on polydrug combinations and confirmed a typology of students 
based on their patterns of drug use and also explored gender differences. A study on ageing drug 
users looked in particular at alcohol-related problems among older drug users, and the issue of 
prescription drug misuse among the elderly, often including benzodiazepines and opioid analgesics.
Improving identification of new drug trends and threats 
2007 was the third implementation year of the 2005 Council Decision on new psychoactive 
substances. 16 new psychoactive substances were officially notified. Specific products were developed 
for BZP, mCPP and GHB/GBL. A policy briefing on hallucinogenic mushrooms was published in June, 
based on a case study published in 2006, which addressed the wider challenges of responding to 
naturally-occurring psychoactive substances.
Undertaking analysis to provide a better understanding of the costs associated with the use of drugs 
and how much European Member States are spending on drug problems
The 2007 Annual report included for the first time an estimate of the total drug-related public 
expenditure by European countries, which was based on data supplied by six countries. The Centre 
found that total drug-related public expenditure by European countries is between EUR 13 billion and 
EUR 36 billion. A Reitox academy on public expenditure analysis in the field of drugs was organised 
in May in Luxembourg. A planned 2008 Selected issue on public expenditure will examine the topic in 
more detail.
Obtaining a better estimate of the size of the drug market through a synthesis of supply and demand 
data 
Europol participated in a June expert meeting at the Centre on drug prices, and a joint project was 
launched for developing guidelines on drug prices. UNODC cooperation was strong and frequent 
throughout the year, and included work on cannabis trafficking in Europe, taking into account a 
recent shift in the market from Morocco-sourced resin to domestically-grown herbal cannabis. Two new 
economic analysts were recruited during 2007, to focus on building the EMCDDA’s competence in 
analysing and modelling drugs markets, and mining supply and demand-side data.
17
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Chapter 2 
Overview of activities by programme
The scientific coordination mechanism: transversal work
Activities and results
Monitoring drugs and drug addiction in Europe requires integrating and analysing 
information and analysis from different disciplines (pharmacological, public health and 
prevention, legislative, law enforcement etc.). At the managerial level the scientific work 
of the Centre is divided into two scientific units: Epidemiology, crime and markets (EPI) 
and Interventions, law and policies (RES), together with a third scientific support sector, 
the scientific coordination mechanism.
During 2007, the scientific coordination mechanism reinforced its position with regards 
to ‘transversal’ — or cross-unit — activities, providing a platform for strategic discussions 
around the scientific aspects of the drafting of the new 2008 work programme. The 
mechanism set overall priorities for studies and meetings, including the preparation of 
draft tender documents for the implementation of the 2007 work programme (2). Tenders 
included, for example, outsourcing policy briefings and technical support for development 
of research and analytical potential.
Among the transversal activities during 2007 were: revising the Centre’s reporting tools; 
support for drafting the 2006 General report of activities for the scientific units; support 
for drafting the Annual report and other publications where input from more than one unit 
is required (e.g. the Statistical bulletin, Selected issues).
Reporting tools The revision of prevention tools which took place in 2006 led to 
successful Structured questionnaire submission and data collection on universal and 
selective prevention during 2007. Data partly allow for longitudinal comparisons, for the 
years 2004–07. In 2007, the focus was on the tools on 'treatment' and 'harm reduction'. 
In 2008, the revision of the remaining tools will include the structured questionnaires on 
'social rehabilitation', 'alternatives to prison', and 'policy and iinstitutional framework'. 
National report guidelines, which instruct Reitox national focal points on how to draft 
and produce their annual national report of the situation in their Member State (3), will be 
under revision in the the period 2008–09, requiring collaborative work between all units 
concerned.
EU drugs strategy and action plan evaluation A priority task for the EMCDDA is to 
provide technical support to the Commission for its work on the EU drugs strategy and EU 
drugs action plans (4). This support typically requires cooperation from different parts of 
the Centre. During 2007, the EMCDDA worked closely with the Drugs Coordination unit 
of the European Commission’s DG for Justice, Freedom and Security (DG JLS), particularly 
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(2) The EMCDDA's work programmes are available at: 
http://www.emcdda.europa.eu/html.cfm/index378EN.html 
(3) National reports for all EU Member States and Norway are available at: 
http://www.emcdda.europa.eu/index.cfm?fuseaction=public.Content&nNodeID=435 
(4) The EU drugs strategy and Action plan can be viewed at: 
http://www.emcdda.europa.eu/html.cfm/index1337EN.html  
in tracking the implementation of the EU Action plan on drugs (2005–2008). To respond 
to information needs of DG JLS, the ongoing revision of the Centre's tools has taken into 
account the deadlines set by the current EU action plan, namely its mid-term evaluation 
and final impact assessment.
In 2007, the EMCDDA contributed to the second European Commission progress review 
of the action plan. Numerous different thematic papers were prepared or updated for the 
Commission to facilitate their assessment of the progress made in achieving the action 
plan objectives in 2005 and 2006 (see p. 89). Thematic papers provided: an up-to-
date overview of available data sources relevant to the objectives, summarised baseline 
information, and presented a critical analysis of the options for mid-term and final 
evaluation in each area. 
The following action plan objectives were covered, and are here numbered to show 
their location in the text of the action plan: national strategies and action plans in the 
field of drugs (1); coordination in the field of drugs (2); coverage and effectiveness of 
drug demand reduction measures (7); drug use prevention at school: coverage access 
and effectiveness (8.1); joint prevention programmes in the Community (8.2); quality 
and best practice in drug treatment services (12); alternatives to prison for drug abusers 
(13.1); EMCDDA–Europol 'Annual report on the implementation of the Council decision 
on information exchange, risk assessment and control of new psychoactive substances' 
(20.3); drug-related crime — progress towards a common definition (25.1); identifying 
emerging trends (41.1); HIV–AIDS literature review on protective factors (43.2).
The EMCDDA is also participating in the steering group of the final evaluation of the 
current EU action plan, and will provide data and analysis in due course.
E-POD and Early Warning System (EWS) The cross-unit E-POD project is a methodological 
tool for the early detection of emerging trends, which uses the Centre's EWS for 
additional data on new patterns of drug use. 
An extensive case study on hallucinogenic mushrooms was published in 2006. In 2007, 
the case study was used to inform a second risk assessment exercise in the Netherlands, 
reported in the 2007 Annual report. In June 2007, a related Drugs in focus policy 
briefing was released, entitled 'Hallucinogenic mushrooms: the challenge of responding 
to naturally occurring substances in an electronic age' (5). The 2006 case study had 
already highlighted the importance of lifestyle trends and economic interests in the 
diffusion of and responses to an emerging drug trend. The policy briefing observed that 
future work in the field of emerging drug trends must take account of the crucial part that 
contextual forces play in reinforcing or legitimating forms of regulation. A second E-POD 
case study on GHB and its precursor GBL was prepared throughout 2007 and released 
in March 2008 (6).
E-POD also began exploring the use of hospital and ambulance data as a particularly 
responsive indicator for detecting, tracking and responding to emerging trends. Other 
general work included a progress review of methods for analysing emerging trends, 
conducted for the European Commission in the framework of the evaluation of the 
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(5) http://www.emcdda.europa.eu/html.cfm/index439EN.html 
(6) http://www.emcdda.europa.eu/html.cfm/index7079EN.html 
EU action plan (Thematic paper 41). Among the new topics under investigation, the 
EMCDDA supported a literature review on the use of anabolic steroids which helped to 
identify a vulnerable group of young people using steroids. 
Cross-unit treatment group The work of the treatment group, which pools tasks — and 
ideas — from the scientific staff of the EPI and RES units, was presented at the heads 
of focal point meeting in November 2007. The group aims in particular to analyse any 
overlaps, shortfalls or gaps between treatment demand in Europe (i.e. patients) and 
treatment supply (i.e. clinics, service provision). Highlights in 2007 included a significant 
role in the revision of the tools on treatment and harm reduction, and the proposed 
revision of national reporting guidelines to ensure more coherence. 
Drugs and driving The topic of drugs and driving, and in particular the risks of driving 
under the influence of drugs, was a recurrent item of much cross-unit work during 2007. 
One of the three Selected issues in the Annual report dealt with the topic of cannabis and 
benzodiazepines among drivers on European roads, based on the information provided 
by the National focal points. This overview was presented in two different papers during 
the ICADTS-TIAF conference held in Seattle in August (7). The meeting gathered more 
than 800 worldwide experts, researchers and toxicologists working in the field. Another 
report, planned for publication in 2008, will compile a comprehensive overview of 
the drugs and driving situation in and outside Europe. This report will concentrate on 
methodological issues pertaining to experimental and epidemiological studies of drugs 
and driving. It will also compile the results of recently-implemented surveys, as well as 
studies of the effects and risks associated with drug use and driving for all the major illicit 
drugs and relevant prescription medicines.
Other cross-unit tasks during 2007 The coordination mechanism supported a number 
of other general activities during the year. These included: the update and further 
development of Drug profiles (8) (see p.86), contributions to the Centre’s newsletter 
Drugnet Europe and ad hoc technical collaborations such as collaborating on the 
selection of drug-related indicators to be used within a list of the main indicators of 
public health in Europe. The coordination mechanism also continued its support role 
as facilitator to other projects in the Centre: for example, improving the process with 
which technical contracts were managed, ensuring that regular progress reviews were 
conducted to ensure the effective implementation of the 2007 work programme, and 
generally ensuring that any technical problems were addressed promptly.
21
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(7) International Council on Alcohol, Drugs, and Traffic Safety (ICADTS) and The International 
Association of Forensic Toxicologists (TIAFT) — http://www.icadts2007.org 
Selected issue available at: http://www.emcdda.europa.eu/publications/selected-issues/driving 
(8) http://www.emcdda.europa.eu/index.cfm?nnodeid=25328
Epidemiology, crime and markets
Activities and results 
The Epidemiology, crime and markets (EPI) unit is responsible for describing the overall 
drug situation based on social survey, public health and criminal justice data sets. 
In addition, activities conducted by the Centre in support of the Council decision on 
new psychoactive substances (Council Decision 2005/387/JHA (9) also fall under the 
responsibility of the unit. The key indicators and core data sets which form the basis 
for quantitative reporting on the drug situation are primarily derived from the analysis 
of quantitative registry-based data sets (10). This means that the principal activities of 
the unit must be sensitive to and reflect the external reporting cycle of national data 
collection efforts. The annual cycle of activities is thus on data processing and analysis 
between November and March, and on technical meetings and developmental activities 
between April and October.
EPI unit 2007: general comments
A key task of the EPI unit is to process, clean and analyse quantitative data and to 
manage qualitative and methodological information. The unit was reinforced during 
the year with the arrival of a new data manager, who provided added impetus to 
streamlining and improving the efficiency of data management and analysis tasks. These 
tasks were even more important than usual for the unit in 2007: first, to follow up the 
further implementation of the Fonte tool, especially given that the National focal points 
used the new database interface for reporting for the first time in October 2007; second, 
to address the need to process an increasing volume of data in a shorter time period and 
deal with different types of system for reporting and data processing (i.e. Fonte, and its 
predecessor EISDD, with added submission of Excel spreadsheet data).
Each indicator is supported by a network of technical experts who contribute, together 
with the national focal points, to developing reporting methods, to building a common 
understanding of the indicator, and to brokering a comprehensive overview of the 
European situation. For each indicator, annual technical meetings were held as well as a 
number of smaller technical collaborations and working groups. During 2007, a number 
of projects were conducted to improve the quality of the reporting tools (i.e. guidelines, 
and resolution of methodological and analytical issues) and some modifications were 
made to the standard reporting tables. Support was provided, where required, to 
Member States to aid reporting, and considerable efforts went into data checking, 
management and analysis to prepare the Annual report.
The Centre continued in 2007 to refine its annual Statistical bulletin, which was 
first produced with the 2004 Annual report. Enhancements in particular focused on 
using available data to report on long- and medium-term drug trends. The 2007 
issue contained more than 200 tables, 100 graphics and methodological notes and 
supplementary analysis. As the Centre's data grows, such a 'full disclasure' approach 
offers not just facts and figures, but also describes the methods and sources used by 
the Centre to report on the European drug situation. The Statistical bulletin furthermore 
enables external experts and students to access the full European quantitative data 
set, facilitating secondary analysis of the data: for example, to produce cross-country 
comparisons or wider reports on public health in Member States. 
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(9) http://europa.eu.int/eur-lex/lex/LexUriServ/LexUriServ.do?uri=CELEX:32005D0387:EN:HTML  
(10) The five key indicators are: Prevalence and patterns of drug use among the general population 
— population surveys; prevalence of problem drug use; demand for treatment by drug users; drug-
related deaths and mortality among drug users; and drug-related infectious diseases.
Highlights of the EPI unit during 2007
Key indicators A note on the implementation of the five key indicators (KIs), conducted 
in the context of objective 39 of the EU action plan on drugs, was presented to the 
Management Board in December 2007. The overall analysis suggests that information 
resources have increased considerably, although some problem areas still exist. A 
positive development is that improvements have been made in the capacity to assess 
implementation levels, and a conceptual framework has been developed that identifies 
key domains for making assessments. Nonetheless, the current approach still has 
limitations and actions are required to define more concretely minimum implementation 
levels and improve the precision by which compliance is assessed. Among the most 
important analytical tasks specifically related to the KIs developed in 2007 were:
• General population surveys (GPS): continuous analysis and reflection on the scale of 
problematic use of cannabis. 
• Treatment demand indicator (TDI): coverage project and prevalence project (people in 
continuous treatment). 
• Drug-related infectious diseases (DRID): modelling project, draft protocol was 
developed for the more uniform data collection on infectious diseases and risk behaviour 
by the Member States. 
• Drug-related deaths (DRD): insight on cocaine deaths, improvement of estimate of 
overall mortality. 
• Problem drug use (PDU): continuing work to model the concept of problem drug use 
and its measurement, in particular by developing methods to estimate the incidence of 
PDU. 
• All indicators: incorporating more sensitivity in the data collection instruments to 
polydrug use and the combined use of more than one substance. 
Drug consumption estimates A number of specific analyses on topics of policy importance 
were addressed during the year. An expert meeting reviewed national and international 
experiences in estimating aggregated drug consumption. This meeting discussed 
relevant methodological questions and data availability issues, and assessed options for 
developing drug consumption estimates at European level.
Drug-related crime A conceptual framework for defining drug-related crime was 
suggested to policymakers in a Drugs in focus policy briefing entitled 'Drugs and crime 
– a complex relationship' (11). The paper also identifies possibilities for better monitoring 
and reporting on the relationship between drug use and criminality. In addition, a 
thematic paper was drafted to respond to the objective 25.1 of the EU action plan on 
drugs, on the adoption of a common definition of drug-related crime.
Polydrug use A number of tasks focused on polydrug use. Analysis began on individual 
data collected from around 100 000 school students in 24 EU countries that were made 
available to the EMCDDA from the ESPAD database. Analysis focused on polydrug 
combinations, and confirmed a typology of students based on their patterns of drug use. 
Work on the ESPAD data also explored gender differences, while data on 'onset' or 
initiation (age of first use) offered insights on pathways into drug use. The result for the 
Centre was a better understanding and description of drug use for a Selected issue on 
drug use among very young people (under-15s) published alongside the Annual report in 
November (12).
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Cocaine and crack cocaine One of the current priorities for the Centre is to monitor use 
of non-opioid drugs. A Selected issue (13) and Drugs in focus policy briefing (14) were 
published on cocaine use in Europe in 2007, fed by an in-depth analysis of the Centre's 
data. Both publications provided a typology of the different types of cocaine users in 
Europe. The Selected issue in particular benefited from the integration of information 
from several indicators and perspectives, for example population and school surveys, 
qualitative work, problem cocaine use estimations, treatment information and market 
indicators. Work on the publications also provided an opportunity to further work on 
health problems and deaths related to cocaine use, in the form of an internal literature 
review, in particular cocaine co-consumption with alcohol and heroin. 
Substitution treatment deaths The year 2007 saw a particular impulse at the Centre to 
better analyse deaths related to substitution treatment (methadone and buprenorphine). 
Specific products of work in the area included expert meeting presentations on treatment 
guidelines, on assessing the quality of substitution treatment and the abuse of substitution 
substances.
Substance combinations in drug-related deaths A field trial was launched in 2007 to 
collect information on combinations of substances involved in drug-related deaths. A call 
for tender to assess alternative methods for the estimation of overall mortality related to 
drugs was also prepared. 
Measuring drug use in wastewater The unit's 'wastewater' project comprised a first 
exchange between experts to build a picture of the 'state-of-the-art in 2007' for 
measuring drug use based on the presence of drugs in wastewater. A group of experts 
working in various disciplines met in Lisbon in April 2007. Issues discussed included: 
the bio-chemical fate of parent drugs and their main metabolites in wastewater treatment 
plants; drug degradation and system behaviour of wastewater treatment plants (WWTPs); 
human metabolism and release of substances; sampling strategies and appropriate geo-
codification of samples. The area offers considerable promise for producing precise 
estimates about consumption in a given geographical area. One product of the April 
meeting was a report entitled 'Assessing illicit drugs in wastewater: chances and 
limitations of a new monitoring approach', completed in July 2007. In October 2007, 
the group prepared the first draft for an editorial on wastewater drug use measures for 
the journal Addiction, for later finalisation.
Key indicator: Prevalence and patterns of use among the general population (GPS)
A mainstay of the Centre’s reporting on the drug situation is data from surveys of drug 
use in the general and specific populations. In 2007 particular emphasis was placed 
on the analysis of stimulant trends and cocaine in particular, and on developments in 
intensive cannabis use, based on a review of all current European reporting instruments 
and measures. 
Intensive cannabis use Activities in 2007 included a review of work currently being 
carried out in Europe in the field of measuring problematic cannabis use, together with 
problems in available survey data. This review dovetailed with the Centre's cooperation 
on a new Spanish school survey (ESTUDES), which has been working on intensive 
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cannabis use. Between May and December 2007, the Centre analysed data from the 
ESTUDES survey, which included three psychometric scales measuring various forms of 
intensive cannabis use. A first draft of the report was prepared by the end of 2007. 
Furthermore, the annual expert meeting in June 2007 included a special session on 
cannabis intensive use scales, preceded by some data collection from Member State 
experts attending the event. The meeting provided some insight into the feasibility of the 
potential inclusion of such scales into the EMCDDA standards for general population 
surveys, together with some preferences for the best approach to take. A call for tender 
was issued to explore the area further, and the successful tenderer will summarise the 
available evidence during 2008, ahead of more concrete proposals from the Centre.
Other work in the area of GPS focused, as every year, on improving the Centre's data 
collection and disseminating information. Projects included: 
• A European survey databank: The June expert meeting examined the different options 
for developing a European survey databank, an overview of available surveys on drugs 
and drug use. As many of the countries expressed their interest, this will be followed up 
in 2008.  
• Cocaine use: A conceptual review of patterns of cocaine use was performed and 
presented in May during an expert meeting at the Spanish National focal point in 
Madrid. Work in this area was further developed for an international conference in 
November 2007 which looked at cocaine problems, also organised by the Spanish 
national focal point in Madrid. 
• EMQ: The EMQ module, on drug availability for inclusion in population surveys, was 
tested in three countries during 2007, and results are expected in 2008. 
• ESPAD: Close collaboration with the ESPAD (15) school survey group was also 
maintained, leading to a number of joint analyses and EMCDDA support for the field 
testing of new ESPAD instruments.  
• School survey data: data from ESPAD, WHO and HBSC (16) projects and other national 
exercises — notably in Spain and the United Kingdom — are now an established part of 
EMCDDA data resources.  
• Complementary surveys: In addition to general population surveys, complementary 
sources examined during 2007 included internet monitoring and data on club surveys 
derived from site sampling in dance music settings. These data provide a useful window 
on general trends and new developments in drug use in recreational settings. They were 
in particular extensively used in the Selected issue on very young people (see p. 23).
Key indicator: Problem drug use
The problem drug use indicator (PDU) uses various statistical techniques to generate 
estimates of the scale of problematic drug use in Europe. Work continued in 2007 to 
improve the data collection instrument with regard to differentiating between opioid 
and non-opioid problem drug use and taking better account of polydrug use. Close 
collaboration with the other indicators was continued and progress was made in 
analysing different components of the overall PDU estimate. Work is currently focused 
on improving the current definition of PDU and the availability and quality of PDU 
prevalence and incidence estimates. This was supported by specific sessions in the 
PDU expert meeting and included the formation of a small expert network on incidence 
estimation and via helpdesk advice using an expert consultant, resulting in a new set 
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of guidelines for estimating the incidence of PDU which are being applied in several 
MS and which form a core instrument for improved analysis of time trends in PDU and 
injecting. Also a start was made on developing a special analysis of trends in injecting 
drug use, following a successful selection by NFPs from a list of different topics, that will 
be finalised during 2008. The core data collection tools (standard tables 7 and 8) were 
transformed into online formats in Fonte. The PDU instruments and data managers formed 
an important contribution to a special Fonte training that was provided for national focal 
points in Ankara.
Key indicator: Treatment demand indicator (TDI)
Work in support of the treatment demand indicator (TDI) continued to focus on improving 
data quality and coverage. In parallel with regular dialogue with European experts, this 
work has resulted in the steady improvement of data quality of the treatment demand 
indicator in recent years.
The first results of the coverage project were presented during the TDI expert meeting 
in September 2007, and its findings identified both positive findings and room for 
improvement. Currently, the TDI data cover a significant proportion of existing specialised 
drug treatment services (outpatient and inpatient). However, very few low threshold 
agencies, units in prison and general practitioners are included in the Centre's data 
collection. Furthermore, the nature of treatment centres varies greatly between countries, 
and TDI data do not always cover the most representative part of the treatment system. 
The coverage project thus underlined the need to better understand the profile of the 
treatment system in order to assess the level of representativeness of treatment data. 
During 2007, a pilot project on prevalence also received approval. This will extend data 
collection on prevalence to all countries on a voluntary basis, with the aim of estimating 
the total number of clients in treatment in Europe.
Key indicator: Drug-related deaths and mortality among drug users (DRD)
In 2007 the Centre focused on two items within the drug-related deaths (DRD) indicator: 
acute drug-related deaths in the population, and overall mortality among drug users. To 
gain a better insight into overall drug mortality, efforts continued tentative work begun 
in 2006, with several projects being run in parallel during 2007. These were: mortality 
caused by HIV infection; a call for tender for estimating overall mortality; and a field 
trial. 
For the 2007 drug-related deaths expert meeting, a new analysis on mortality caused 
by HIV infection related to injecting drug use was conducted, based on EuroHIV and 
Eurostat data. The results of this analysis should be included in the 2008 Annual report, 
ana a related paper was submitted for the IHRA's Harm Reduction 2008 conference 
in Barcelona. Unfortunately, the planned analysis of mortality related to psychoactive 
medicines, and broader analysis of drug mortality in context of young adults (suicide, 
accidents etc.) was not realised. 
During the expert meeting, alternatives for estimation of total mortality were introduced 
to delegates. An external contractor was selected who will during 2008 write a report 
summarising all methodological and data requirements of these two approaches, and 
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conduct a survey of the feasibility of their application in several EU countries. The 
contractor will also field test the two approaches using the national data available to the 
contractor in the Czech Republic.
Work continued on improving reporting of non-heroin drug-related deaths. An internal 
working report built on a 2006 field trial on substance and substance combinations 
involved in drug-related deaths. The 2006 field trial had provided improved information 
on substances involved in drug-related deaths, and had developed and tested the 
reporting tool and guidelines in several countries. A working report of the first field trial 
(November 2006) allowed the initial identification of polydrug patterns, and a new 
field trial was launched at the November 2007 expert meeting to consolidate this data 
collection.
For the July Management Board meeting, a methodological paper analysing progress 
in comparability and validity of the drug-related deaths indicator was drafted. This 
document was used to facilitate a Management Board discussion on the comparability of 
data and factors impacting on drug-related deaths.
Key indicator: Drug-related infectious diseases
Infectious diseases are one of the more serious consequences of drug use, and drug 
injecting in particular. The EMCDDA’s infectious disease indicator systematically monitors 
data on drug-related HIV, hepatitis C (HCV) and and hepatitis B (HBV) in Europe. 
Reporting in this area is closely coordinated with other relevant public health bodies, 
including in particular the new European Centre for Disease Prevention and Control 
(ECDC) in Sweden (16). A number of important new analytical projects were finalised 
for this indicator during 2007. Among these were a literature review on low-prevalence 
countries and protective factors for HIV, and a modelling exercise to explore the factors 
that may account for low prevalence of this virus in some European countries. The 
modelling work will continue in the form of a European study network for which funding 
is being sought. This work was conducted to directly support the EU action plan on drugs. 
Other new developments included: production of a much-needed protocol for data 
collection for studies on HIV prevalence and risk behaviour; inclusion of more countries 
in the project on laboratory surveillance of HCV; a preliminary analysis comparing the 
EU with some large countries (including the US and Russia) in terms of incidence of 
diagnosed HIV in injecting drug users and availability of HIV risk reduction programmes. 
In 2007, the more general work on drug-related infectious diseases focused on improving 
current guidelines and data reporting tools, including the preparation for transition to 
Fonte, and consolidating and improving the epidemiological database and improving the 
analysis of the available data. This has resulted in the improvement of reporting tools and 
a number of new analyses that were not feasible in previous years.
Finally, 2007 saw the decision to develop a Selected issue regarding drug injection and 
related health problems (combining data from both the DRD and DRID indicators), which 
will be worked on over the next two years.
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Crime, markets and supply data 
In 2007, the EMCDDA launched an internal reflection, in the form of an internal working 
document on supply reduction and how to better monitor this area. In parallel, an expert 
meeting reviewed national and international experiences in collecting drug prices. The 
meeting also launched a project to draft guidelines on collecting data on retail drug 
prices at national level, to be pursued in 2008 and finalised in 2009. The EPI unit's 
crime and market staff also played a major role in drafting the Drugs in focus policy 
briefing entitled 'Drugs and crime — a complex relationship' (see p. 23, p. 86).
Action on new drugs
Council Decision 2005/387/JHA of 10 May 2005 on the information exchange, risk 
assessment and control of new psychoactive substances (17) is in its third implementation 
year. The EMCDDA and Europol, in close collaboration with their networks — the Reitox 
national focal points (NFPs) and Europol national units (ENUs) respectively — played a 
central role in implementing the mechanism for the rapid exchange of information on new 
psychoactive substances which may pose public health and social threats. During 2007, 
16 new psychoactive substances were officially notified for the first time through the early 
warning mechanism. In addition, in the course of the year, new substance profiles and 
sections of the European database on new drugs (EDND) were regularly updated.
In compliance with the provisions of the Decision, in February the EMCDDA and Europol 
submitted to the Council, the Commission and the European Medicines Agency (EMEA) a 
joint report on the new psychoactive substance 1-benzylpiperazine (BZP). Based on the 
joint report’s recommendations, and in accordance with Article 6.1 of the Decision, on 
23 March 2007, the Council formally requested that ‘the risks, including the health and 
social risks, caused by the use of, the manufacture of, and traffic in, a new psychoactive 
substance, the involvement of organised crime and possible consequences of control 
measures, be assessed’ for BZP. In accordance with Article 6.2, the meeting to assess the 
risks of BZP was convened under the auspices of the EMCDDA Scientific Committee with 
the participation of experts from the Commission, Europol and the EMEA.
The risk assessment was carried out on the basis of information provided to the Scientific 
Committee by the Member States, the EMCDDA, Europol and the EMEA. In compliance 
with Article 6.4 on completion of the risk assessment, the ‘Risk assessment report’ was 
drawn up by the Scientific Committee and presents an analysis of the scientific and law 
enforcement information available, and reflects all opinions held by the members of the 
Committee.
Given concerns expressed about the drug 1-(3-chlorophenyl)piperazine (mCPP), and 
taking into account the relatively large quantities of mCPP detected by the Member 
States, the Commission proposed in 2006 that the EMCDDA and Europol ‘carry out 
further work in accordance with their mandates and the resources available to assess the 
importance of mCPP in the European Union illicit drugs market’. The findings published in 
2007 included a ‘scientific evaluation of the potential threat of mCPP and involved input 
from national experts, the Commission and the EMEA’ and ‘the lessons learned from the 
experiences (preventive and law enforcement) of the Member States that already control 
mCPP’ (Europol–EMCDDA Active monitoring report on a new psychoactive substance: 1-
(3-chlorophenyl)piperazine (mCPP)). 
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The revised Guidelines for risk assessment of new psychoactive substances were 
submitted to the Scientific Committee. The Committee discussed the guidelines, and 
prepared an opinion to the new Scientific Committee in order to finalise and adopt these 
guidelines in 2008. A document entitled the ‘EWS on new psychoactive substances — 
operating guidelines’, aimed at assisting the implementation of the Council decision on 
information exchange, risk-assessment and control of new psychoactive substances, was 
published in October 2007. The guidelines deal with phase 1 of the measures foreseen 
— the early-warning system.
Finally, the EMCDDA–Europol 2006 annual report on the implementation of the Council 
Decision 2005/387/JHA on new psychoactive substances was prepared and submitted 
to the Council, Commission and the European Parliament.
Cooperation
As outlined above, cooperation is an intrinsic part of the Centre’s activities as a 
monitoring centre. The items below are non-exhaustive, yet are representative of the main 
cooperative activities of the EPI unit during 2007. 
European institutional cooperation 
The EMCDDA increased and improved collaboration with EC institutions and in particular 
with the European Commission. 
• In the context of the EU action plan on drugs 2005–2008, the EPI unit contributed to 
the second European Commission Progress review of the action plan (see p.89). 
• The Centre participated in the DG Sanco working party on Information on lifestyle, 
specific and deprived population groups and in a related workshop on children. 
• The Centre drafted a chapter on drugs for the Global report on health in the European 
Union (EUROGLEH).  
• The Centre participated in various drugs-related steering groups or committees. These 
included: the steering committee of the European health survey system (DG Sanco and 
Eurostat); the JLS Steering Group on policy needs for crime statistics; the steering group 
for the evaluation of the EU action plan on drugs (2005-2008); the editorial board of the 
EU health portal. 
• The Centre supported DG Sanco in drafting an impact assessment and the preparation 
of a council recommendation of drug use in prisons. The recommendation will focus on 
‘prevention, treatment and harm reduction services for people in prisons, reintegration 
services on release from prisons and methods to monitor/analyse drug use among 
prisoners’. 
• The Centre cooperated on several EU projects during 2007, acting as an observer in 
the EU IATPAD project (Improvement of access to treatment for people with alcohol- and 
drug-related problems) and participating in the HIV/AIDS think tank.  
• A memorandum of understanding is under preparation after a fruitful meeting with 
ESTAT (Eurostat) in 2007. 
• The Centre participates in the Interservice drugs group of the European Commission. 
• The Centre contributed to the definition of priorities for the 2007 and 2008 programme 
Drugs prevention and information (DG JLS). 
• The Centre increased collaboration with DG RTD. 
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Council of the European Union 
• The Centre played a part in the drugs-related programmes of the German and 
Portuguese Presidencies of the European Union. Examples included: presentations during 
the thematic debates of the Horizontal working party on drugs; presentations during 
Troika meetings with third countries; and participation in the German and Portuguese 
meetings of national drug coordinators. 
• The Centre's close collaboration with the Presidencies also focused on theme-focused 
events: for example, European conferences on cannabis-related disorders, on the 
evaluation of public policies and programmes on drugs, and the conference of HIV/AIDS 
coordinators.
European agencies
• In June 2007 a cooperation agreement was signed between the EMCDDA and 
European Centre for Disease Prevention and Control (ECDC). Collaboration was initiated 
on hepatitis and HIV data collection with regard to injecting drug users (IDUs), together 
with close collaboration with EuroHIV regarding ongoing data collection during the final 
year of its existence (EuroHIV, active since 1984, is now being migrated into ECDC's 
activities). 
• Europol participated at an EMCDDA expert meeting on drug prices, with continuing 
dialogue on potential synergies with the Centre with regard to drug supply. 
• Council Decision 2005/387/JHA also requires intensive cooperation with Europol 
and the European Medicines Agency (EMEA). Cooperation with EMEA is intensifying: 
a technical meeting took place in 2007. It is expected that during 2008 a formal 
cooperation framework will be initiated. 
 
Inter-agency cooperation
• The Centre participated in an Inter-agency group meeting with the UNODC, Pompidou 
Group, WHO and Council of Europe in Warsaw.
UNODC cooperation
• The Centre participated in the two meetings of the UNODC experts consultations for 
the final review of the outcomes of the 1998 UNGASS declaration and action plans. 
A report on 'The development national drug strategies and drug-demand reduction 
interventions in Europe since 1998' was also provided by the EMCDDA in this context. 
• Experts from the UNODC participated in an EMCDDA expert meeting on drug prices 
and the launch of a joint project of guidelines for collecting drug prices. 
• The Centre participated in an expert seminar on HIV and drugs in Russia organised by 
the UNODC.
Cooperation with other international partners
• A cooperation framework was established through a formal exchange of letters 
between the EMCDDA Director and the ESPAD Coordinator. This set out an eight-point list 
of areas for collaboration.  
• Informal collaboration agreements with UNAIDS were reached and the EMCDDA 
participated in a UNAIDS conference of HIV epidemiologists of the Eastern European 
region (CIS countries). 
• In the context of Council Decision 2005/387/JHA, the WHO headquarters (Geneva) is 
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also consulted on new psychoactive substances when appropriate. 
• Cooperation between the WHO Health behaviour among school shildren survey and 
the EMCDDA provided early access to new prevalence estimates for cannabis from 
school surveys in 23 EU and candidate countries.   
• The Centre participated in the preparation of an international symposium on treatment 
needs organised by Canadian treatment experts with international treatment experts, 
including WHO and UNODC. 
• The EMCDDA provided assistance to CICAD, on their request, to develop a prototype 
of a drug-related death indicator protocol that is compatible with EMCDDA protocol. 
In October, the Centre also delivered a two-day international workshop on drug-related 
death indicator methodology in Buenos Aires (Argentina), with a view to helping CICAD 
to develop a DRD indicator in Latin-America countries.
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Interventions, law and policies
Activities and results
The Interventions, laws and policies (RES) unit (20) monitors responses to the drug problem 
in the EU. In particular, it reports on the measures taken in the EU Member States to curb 
the problem of drugs and drug addiction at individual or social level, and analyses the 
impact of national and Community strategies.
The former head of unit, Henri Bergeron, left the Centre at the end of 2006 to take on 
a professorship at the Ecole Libre des Sciences Politiques in Paris. He was replaced as 
head of unit at the start of 2007, by Roland Simon, former head of the German national 
focal point, and a close collaborator on EMCDDA projects since it was founded in the 
early 1990s. Additional recruitment increased the Centre’s capacity to analyse illicit drug 
markets, and health and social responses.
During the Portuguese presidency of the EU, the Centre — and specifically RES and EPI 
units — closely collaborated with the Portuguese National focal point and government 
representatives on a number of drug-related events. These included: the Conference on 
evaluation of public policies and programmes on drugs in September (21), the regular 
Meeting of the EU national drug coordinators in October, and a donors’ conference for 
Guinea–Bissau in December. At these events, the EMCDDA provided specific expertise on 
European drugs policy and cooperation, reported progress at the European level in terms 
of evaluating drugs programmes, and provided information on cocaine supply in Europe.
Routine activities for the unit continued throughout 2007. These included: data collection; 
quality assessment of reports from the national focal points; improvements and fine-tuning 
of data collection instruments, in particular, the Fonte project for data management; 
updates to the databases managed by the RES unit (EU drug activities, ELDD, EIB, PERK 
and EDDRA); the ongoing management of the EISDD (Epidemiological info system 
on drug data, a database that — until phased out 2008 with the migration to Fonte 
— comprises all RES-linked data collection tools); website updates and contributions to 
EMCDDA publications such as Drugnet Europe.
During 2007, the RES unit improved the quality of a number of monitoring instruments 
based on cooperation between the Centre and the future users of the instruments, the 
national focal points. The instruments for monitoring treatment and ’best practices’ 
benefited from specific focus, such as the development of Guidelines for the evaluation of 
treatment in the field of problem drug use.
Significant work was carried out during 2007 on a new ‘Best practice portal’ for the 
Centre, which will be launched in 2008. Tasks for the portal included: a complete 
revision of the EDDRA database (22), in collaboration with national EDDRA managers; 
development of quality standards for EDDRA; and a collection of quality standards in 
prevention from Member States, which was facilitated by an expert meeting. During 
the expert meeting, first findings were reported from a study on indicated prevention in 
Europe, while the EU-DAP schools prevention programme trial was also presented (23). A 
literature review on the efficacy of universal prevention, based on translating a German 
‘review of reviews’ into English, was also prepared for production by the Centre for its 
General report of activities 2007
32
(20) ‘RES’ is a term derived from ‘responses’, a catch-all term embracing the unit’s work on 
interventions, laws and policies. 
(21) http://www.idt.pt 
(22) http://eddra.emcdda.europa.eu 
(23) http://www.eudap.net/
Insights series, for publication in 2008. In addition, preparations began for the collection 
of information for the second module of the Best practice portal, which will focus on 
treatment. Preparations included a complete revision of the quality assurance part of 
Structured questionnaire 27.
Another key activity in the RES unit during 2007 was the revision of the reporting tools 
on treatment. Altogether four instruments — (i) characteristics of treatment provided 
(ii) availability (iii) treatment provision and (iv) treatment quality — were revised and 
streamlined on the basis of experiences with using them. 
Specific actions in 2007 were targeted at a number of priority areas, for example 
neuroscience, evaluation of national strategies, cost-effectiveness studies of interventions, 
as well as public expenditure. Two reports with a focus on neuroscience were finalised 
during 2007. A group of highly experienced researchers from the UK and Australia 
were contracted to analyse the ethical and social implications of new developments in 
neurobiological research on addiction, together with the implications of development of 
new technologies for the treatment of addiction. The contractors will also draft policy 
recommendations in terms of research in neuroscience as it relates to drug use and health 
responses. A report on indicated prevention also addressed aspects of neurobiology and 
ethics, outlining a theory base and rationale for indicated prevention and compiling data 
and evaluation findings on indicated interventions in the EU.
The EMCDDA regularly responds to requests from Member States which are preparing the 
evaluation of their drug strategy or action plan. The September conference on evaluation 
of public policies and programmes on drugs, organised by the Portuguese presidency, 
served to highlight important differences between national evaluation methods. In 2008, 
the EMCDDA plans to explore the possibility of developing guidelines on the evaluation 
of national drug strategies and action plans in the EU, based on input from some of the 
Member States which have the longest experience in the field.
Work carried out during 2007 on cost-effectiveness studies for interventions led to a 
status report on the evidence in this field. The main content of this report was presented 
at the 6th World Congress of the International Health Economics Association in 
Copenhagen in July.
A Reitox academy on public expenditure, jointly organised by the Centre and the 
Luxembourg national focal point, was held in Luxembourg in May. The academy provided 
a forum for discussion on public expenditure on drugs between European experts, the 
Reitox NFPs and the EMCDDA, leading to a better understanding of the issues involved 
in monitoring expenditure. The information provided by the NFPs after this meeting is 
currently under analysis, and publication of the results is foreseen within a Selected issue 
scheduled for June 2008. The subject was followed up again in December at an expert 
meeting at the Centre’s premises in Lisbon. Here, a common methodology to monitor 
drug-related public expenditure in the EU received the support of a group of international 
experts in the field, comprising 14 consultants in the area of drug policy and economics. 
The methodology aims to provide valid and reliable estimates of the value of goods and 
services bought by the Member States’ governments in order to execute actions related to 
illegal drugs. In addition, a report contracted to the Institute for International Research on 
Criminal Policy (University of Ghent, Belgium) provided insight on feasible plans for NFPs 
to monitor public expenditure linked to national drug policies.
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Legislation and analysis of European drug policies
Activities carried out by the RES unit’s legal team during the year included updates 
to the European Legal Database on Drugs (ELDD) (24) to cover European legislation 
on different drugs issues. Specific studies of national legislation looked at the laws 
addressing ‘controlled deliveries’ and ‘precursor trafficking penalties’. These took into 
account the new emphasis on developing knowledge of drug supply issues within the 
EU action plan on drugs, and the Centre’s Legal correspondents meeting in 2007 was 
dedicated to these two topics. In addition, the legal team worked on a number of topics: 
the legal framework of opioids substitution treatment; personal possession of cannabis; 
treatment as an alternative to prosecution or imprisonment for adults; and the legal status 
of hallucinogenic mushrooms. The ELDD’s comprehensive Substances and classifications 
table (25) was also updated during 2007.
The legal team also provided its expertise on a number of projects and publications 
elsewhere in the Centre. It contributed to the BZP risk assessment procedure (see p. 28). 
The Centre’s Structured Questionnaire 32 provided analysis on strategies, coordination 
mechanisms and evaluation methodology in EU Member States. The collected information 
was synthesised in the Policies and laws chapter of the 2007 Annual report, in two 
thematic papers, as well as through several presentations, including one during the 
September meeting of the EU national drug coordinators. Finally, the legal team invested 
significant time during 2007 in a web-based resource on legal issues. The resource was 
made available on the Centre’s extranet, but there is still a need of further development in 
technical respects before it will be made available on the Centre’s public website.
Health and social responses
The core activity within the health and social responses area of the RES unit during 2007 
was the revision of the reporting tools on treatment and harm reduction. The revision 
process included a thorough internal assessment of the quality of data collected with the 
previous tools.
In the area of treatment, the review benefited from cooperation with the European 
Commission's DG Sanco, which was working with a consultant on a project in this field. 
Efforts resulted in two new standard tables and two new structured questionnaires, which 
further increase the monitoring capacity of the Centre in the fields of treatment and harm 
reduction. This revision aimed to ensure that reporting addresses information needs at 
the EU level, and targets information on the basis that information is readily available at 
national level. The revision also enhanced monitoring of expanding areas of intervention 
such as substitution treatment and harm reduction programmes. The new tools were 
presented to the Heads of NFPs in November 2007 and have since been adopted, so 
ST10, ST24, SQ27, SQ23/29 will be submitted to the Centre in 2008 for the first time. 
The revision of the treatment and harm reduction tools also provided the opportunity 
to make an internal assessment of the Centre’s harm reduction and treatment reporting 
capacity. This will feed into the process of integrating data collection for epidemiological 
purposes, with the aim of monitoring intervention in the future. 
Other activities within health and social responses included a literature review on 
cocaine treatment, which was positively evaluated by the EMCDDA external evaluation 
as ‘providing an added value’, released in 2007. Targeted at the general public and 
professionals, the review summarises a variety of topics related to cocaine treatment: 
current issues in the treatment of cocaine dependence; pharmacological and psychosocial 
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treatment; harm reduction; inpatient treatment and aftercare. It also explored a number 
of innovative European and global responses to cocaine treatment. The review includes 
original information provided by a network of European researchers and practitioners, 
as well as other key opinion leaders and clinicians working in the field of treatment of 
cocaine dependence. Finally, the drug treatment overviews on the EMCDDA website 
were updated during 2007, providing a comprehensive overview of the availability of 
treatment of treatment for drug users, including social reintegration, in 27 EU Member 
States and Norway.
Best practices
Best practices are now specifically mentioned in the Centre’s recast regulation, and thus 
represent a more important part of the EMCDDA mandate. The Reitox academy on best 
practices in September targeted experts who work to collect data for the Reitox NFPs in 
the area of research/evaluation of prevention and treatment programmes. The academy 
familiarised participants with the concept of best practices, explored and discussed 
existing models of transfer of best practices across Member States, and also clarified the 
role of NFPs in facilitating the exchange of information on best practices in their country.
Considerable work was carried out to prepare for the 2008 launch of a Best practice 
portal. As the migration of EDDRA into Fonte and the new online interface was delayed 
for technical reasons, the launch of the portal was postponed to early 2008. The first 
modules available in the Best practice portal will be on universal prevention, with other 
topics to follow. During 2007, the Evaluation Instruments Bank, a collection of tools such 
as questionnaires for evaluating programmes, saw various updates, with a new structure 
and the addition of new instruments arising from the best practices portal project. An 
updated version of PERK (the prevention evaluation resources kit) in PDF (portable 
document file) format was prepared, and will be uploaded to the public website in 2008. 
At the end of 2007, a tender was issued for a study of the availability of treatment via 
internet, which will provide an overview of existing examples with a focus on evaluated 
programmes. The results of this contract are expected in late 2008. 
Cooperation
In keeping with its role as key provider of information on drugs in Europe, the EMCDDA 
continued its tradition of close cooperation with external bodies, particularly at the 
Community and United Nations levels. 
European institutional cooperation 
• During 2007, the RES unit represented the Centre at the Council’s horizontal working 
party on drugs and other relevant EU meetings, and actively supported the German and 
Portuguese EU presidencies with information and data.
• Throughout the year, staff from the RES unit supported in close cooperation with the 
Commission, the DG Sanco project on 'Drugs policy and harm reduction'. The project 
covers the areas of drug treatment and effectiveness and quality, together with responses 
to drug use in prison. Representatives of the DG Sanco project participated, for example, 
in the Reitox academy on best practices in September. In addition to the Centre’s role 
in the coordination of the project, RES staff also provided a large proportion of the 
information on which the consultants’ analysis and reports were based. 
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• The RES unit represented the EMCDDA on the Advisory Board of the DG Sanco-funded 
Correlation network on social inclusion and health (26), chairing a working group that is 
developing a European data collection tool for specialised harm reduction agencies.
UNODC cooperation 
• The EMCDDA participated in two meetings relating to UNODC expert consultations for 
the final review of the outcomes of the 1998 UNGASS declaration and action plans. A 
report entitled ‘The development of national drug strategies and drug-demand reduction 
interventions in Europe since 1998’ was produced for the UNGASS review.
• Discussions were held with the UNODC on how the RES unit can contribute in 2008 to 
the development of the EuropASI/Treatnet ASI (27). A presentation of EU drug laws was 
made at the UNODC’s seminar in Kiev, Ukraine. 
Pompidou group cooperation 
• The RES unit represents the EMCDDA at the treatment platform of the Pompidou Group. 
Following participation in the Pompidou Group’s Expert forum on criminal justice (28), a 
presentation was made on alternatives to prison at the Pompidou Group’s conference in 
Bucharest (see also SCD activities with the Pompidou Group). 
Cooperation with institutional partners 
• The existing strong cooperation with the WHO Regional Office for Europe was 
maintained. Specific collaborations included the database on Health in Prisons. The RES 
unit represented the EMCDDA in the steering group of the WHO project Health in Prisons 
Project (HIPP), and contributed to its yearly Network conference in Trençin, Slovakia, in 
October. The HIPP steering group has accepted the invitation to hold its 2008 meeting at 
the EMCDDA premises in Lisbon.
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Reitox and international cooperation
Activities and results
The tasks of the Reitox and International Cooperation (Reitox) unit, as its name suggests, 
cover two sectors of activities. Firstly, the unit manages the Reitox network of national 
focal points (NFPs) in the 27 Member States and Norway. This comprises daily 
interfacing with the Reitox network; training; financial and administrative management 
of grant agreements; quality assurance and capacity development. Secondly, the unit 
acts as the interface between the Centre, European and international bodies and 
organisations, and third countries, both within the EU and beyond. This sector of the 
unit’s activities gives the Centre a diplomatic and ‘outreach’ role with the wider world. 
Tasks include: coordinating the practical actions linked to international cooperation, 
for example communication and administrative tasks linked to enlargement; contacts 
with international peer organisations and third countries; organising official visits to the 
Centre; technical cooperation with candidate countries (such as Turkey and Croatia) and 
potential candidate countries to the EU; and responding to information requests from third 
countries.
There were notable achievements for both sectors of the unit during 2007. With regard 
to Reitox these included: 
• bringing the management of Reitox grants into line with the standard requirements, 
reaching for the first time a high level of execution and a positive evaluation from the 
Court of Auditors;  
• further development of work on quality assurance, and the presentation of updated 
Implementation needs profiles to the Centre’s Management Board (profiles for each 
country were delivered in July, and an overview for each indicator in December);  
• the revision of the reporting tools on treatment and on harm reduction was successfully 
conducted;  
• new Reitox academies were organised on key issues such as prevention of cannabis-
related disorders, public expenditure and best practices in demand reduction;  
• the intense involvement of the unit in the preparation for the switch to the new Fonte 
tool, together with the tool’s ongoing development.
The International cooperation sector is becoming more important as the Centre matures. 
The EMCDDA is increasingly considered a key international actor and interlocutor in the 
drugs debate, and the sector acts as the intermediary in maintaining contacts between 
external actors and other units of the EMCDDA, in particular the RES and EPI units. In 
addition to continued contacts with the Centre’s long-standing international partners — 
such as the Pompidou Group, UNODC, Europol, Interpol, WHO and WCO — in 2007 
cooperation framework agreements were signed with relevant international partners, such 
as the World Customs Organization, the European Centre for Disease Prevention and 
Control (ECDC), and the Federal Drug Control Service of the Russian Federation. The 
Centre also played host to numerous diplomatic and expert delegations throughout the 
year.
Technical assistance activities with Croatia and with Turkey were successfully implemented 
with the support of the Phare programme, and have led for the first time to the production 
of national reports in line with EMCDDA guidelines. The Centre launched in December 
its first ever cooperation project with the potential candidate countries of the Western 
Balkans, with financial support from the CARDS programme, bringing the number of 
countries either participating in or associated with the Reitox network to 35.
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Reitox
Network management and grant agreements
Work in the area of network management concentrated in 2007 on the further 
improvement of grant processes, in particular those related to the initiation of grants 
and settlement of grant payments. As a result, all the 2007 grants were signed by the 
EMCDDA in late February. By comparison, signatures in previous years had often taken 
place much later in the calendar year. As agreed at the Reitox meeting in November 
2006, a manual for the administrative and financial management of grant agreements 
by the NFPs was published in the first quarter of 2007. In addition, as regards balance 
payments, the EMCDDA considerably shortened the verification and payment processes: 
balance payments relating to 2006 grants were made, in general, between March and 
June 2007. Again, by comparison, in the past most of the payments occurred during 
the last second half of the calendar year. Finally, bilateral feedback on the financial 
and administrative management of the 2006 grants was sent to each NFP by the end of 
November 2007. This  contributed to the smoother and quicker handling of requests by 
NFPs for final payment. 
Quality assurance and capacity development
One of the unit’s cyclical tasks is the ongoing process of improving the Centre’s 
monitoring and reporting activities, and in particular the quality of data submitted by 
NFPs. During 2007, the unit further developed its quality assurance policy. Several 
meetings were organised with project managers and data managers, resulting in a clear 
improvement and conceptualisation of a quality report package, which was presented to 
NFPs in May 2007. 
Other work relating to data quality includes the unit’s preparation, in combination with 
the RES and EPI units, of short overviews of the status of the indicators across the Reitox 
network. These Implementation needs profiles were discussed at the Heads of NFPs 
meeting in November, and were presented to the Management Board in December. The 
criteria and categories that are currently used for assessing the level of implementation of 
the indicators will be further developed in 2008, in partnership with the NFPs. A further 
task, to which the unit contributed together with colleagues from the RES unit, related 
to the revision of reporting tools on treatment and harm reduction. The new tools were 
adopted at the heads of NFPs meeting in November.
A process of revision of the EMCDDA guidelines for national reporting will be launched 
in 2008. Its objective will be to rationalise the Centre’s guidelines for national reporting. 
The Centre’s Country situation summaries (27 Member States and Norway) (29) were 
updated from September to December 2006 and published in January 2007. These 
brief and concise overviews on the drug situation in the old and new EU Member States 
and Norway are published in English as well as the respective national languages of 
each country. As agreed with the European Commission, additional country situation 
summaries that were produced following the EMCDDA standards in the framework of the 
Community assistance programmes to the countries of the former Soviet Union (TACIS) 
were included. From 2008, a new concept will be adopted for the Country situation 
summaries, allowing for a better integration with the Statistical bulletin, National reports 
and Country data profiles.
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Reitox academies
The Reitox team provides training to NFPs via its Reitox academies. The Reitox team 
continued to promote ‘cluster’ training initiatives and national academies, and this 
decentralised approach was also adopted for training activities organised in the 
framework of the technical assistance projects with Croatia and Turkey. In order to 
improve the quality and relevance of training activities delivered via the Reitox academy 
and the Phare project, a project manager from a scientific department was closely 
associated with each academy, to assist with the training content, training methodology 
and selection of trainers.
The first Reitox academy in 2007 took place in March in Berlin, on cannabis prevention 
and treatment, and was organised in close cooperation with the German presidency 
of the EU and the German NFP. The academy discussed the state-of-the-art in current 
prevention and treatment programmes on cannabis in Europe, and targeted Reitox staff 
and consultants who are working in the field at the national or supranational level. The 
academy reflected strong work in the area of intensive cannabis use within the EPI unit.
A Reitox academy on public expenditure analysis in the field of drugs was organised 
in May, in cooperation with the Luxembourg NFP. It aimed to inform participants about 
general issues associated with public expenditure management, with the more specific 
goal of instructing NFPs on developing their own reports for the planned Selected issue 
on public expenditure.
A Reitox academy on best practices was organised in Oslo in September. The academy 
presented the general concepts surrounding science-based practices, and in particular 
criteria for evaluating evidence on the public health impact of interventions. On a 
wider note, it also focused on promotion and dissemination strategies for science-
based practices. The academy examined questions such as ´what counts as evidence?´ 
and ‘how can we assess and successfully disseminate evidence?’. The academy was 
of particular interest in the preparation and future launch of the Centre’s Best practice 
portal.
During 2007, the Reitox sector was closely involved in the preparation and 
implementation of Fonte, actively contributing to the activities of the internal Fonte 
steering committee. An overview of training activities — a Reitox academy in Turkey, and 
EU training initiatives for national experts — is provided later in this report.
Following up on a Europe-wide survey among former participants in Reitox academies 
and national experts, the unit implemented a joint project with the EPI unit to produce 
standardised methodological packages on the five key epidemiological indicators. These 
included training materials and sets of scientific references. 
International cooperation
The EMCDDA devoted a considerable effort to maintaining an active presence on the 
circuit of international drugs meetings during 2007. These included: 
• the Pompidou Group's Permanent correspondent meetings as well as various Pompidou 
Group expert meetings;  
• the United Nations Commission on Narcotic Drugs; 
• the World Customs Organization’s Enforcement Committee; 
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• Interpol’s General assembly; 
• the EU troika with countries of the Western Balkans; 
• CICAD’s Regular sessions; 
• The EU-LAC meeting in Brussels;  
• The high-level meeting of the EU-Latin America and Caribbean Cooperation and 
coordination mechanism on drugs in Port-of-Spain;  
• The EU-CAN high-level meeting in Bogota; 
• An International Conference on Guinea–Bissau, organised in Lisbon by the Portuguese 
Presidency.
Good contacts were also maintained with Europol, and Europol staff members attended 
several meetings at the Centre in Lisbon. 
Cooperation framework agreements were signed with relevant international partners, 
such as the World Customs Organization, the European Centre for Disease Prevention 
and Control (ECDC), and the Federal Drug Control Service of the Russian Federation. 
A high level Ukrainian delegation visited the EMCDDA, as well as another from Bosnia-
Herzegovina.
Relations with CICAD (the Inter-American Drug Abuse Control Commission) included 
an EMCDDA training activity on drug-related deaths in Buenos Aires. CICAD also 
participated at the EMCDDA expert meetings on treatment demand and on drug-related 
mortality indicators. Together with CICAD, the preparatory phase for drafting a joint 
handbook on establishing and assessing national monitoring centres was carried out.
The EMCDDA received an increasing number of official and study visits in 2007. 
Delegations were welcomed, for example, from Ambassadors to Portugal from several 
countries, a member of the INCB, the Council of Europe’s Secretariat, the National Anti-
drugs Organization of Venezuela. On the International Day against Drugs (26 June), a 
reception for the diplomatic corps in Lisbon took place at the EMCDDA’s headquarters. 
Several academic and expert delegations also visited the EMCDDA during 2007. These 
included researchers from several countries in Europe, Australia or the USA. 
With regard to enlargement activities, negotiations between the Commission and 
candidate or third countries for participation in the EMCDDA were followed up at various 
times during the year. In particular, the role and activities of the EMCDDA were presented 
to candidate countries and to third countries which have officially applied for membership 
of the EMCDDA. Formal relations were initiated in some cases. Activities included 
tracking the evolution of pre-accession instruments, including the programmes supporting 
the Western Balkans, and the preparation of a technical assistance programme based on 
the Phare model.
Technical cooperation
In 2007, the Reitox unit completed its technical assistance project with Croatia and 
Turkey for their participation in the EMCDDA’s activities. The project began in June 
2006 and ran for 18 months, with a total budget of 500,000 euros. It was concluded 
in December 2007. Despite some initial delays in the execution of the project-related 
national activities, the majority of the agreed tasks were executed and most of the 
objectives were reached to a satisfactory level. At the end of 2007, an external 
evaluation of the project was carried out, in order to assess both the project’s results and 
the state of preparedness of the Croatian and Turkish national focal points.
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In November, the EMCDDA signed an EC contribution agreement which aims at 
’assessing the capacity of the Western Balkan countries to establish a drug information 
system compatible with the EMCDDA‘. The project began in December 2007 with a total 
budget of EUR 550 000, and must be concluded by the end of December 2008. The first 
tasks included the appointment — through the permanent missions of the Western Balkans 
countries to the EU — of a national correspondent. The EMCDDA also launched a 
restricted call for tenders among its NFPs in order to select Reitox coaches and a project 
supervisor. The kick-off meeting of this first technical assistance project with the Western 
Balkan countries took place in January 2008.
41
Chapter 2 
Scientific partners and documentation 
Activities and results 
The Scientific partners and documentation (SCD) unit was created in 2005 as a 
contribution to the Centre’s commitment to scientific excellence. Its mission is to enhance 
scientific excellence by facilitating access to science, transfer between research and 
policy, exchange among researchers and to increase transparency in the European 
scientific agenda. The unit provides support to the EMCDDA Scientific Committee and 
includes the Documentation Centre of the EMCDDA. 
At the start of 2007 the unit consisted of the head of unit, the head of Documentation 
Centre, a library assistant and a secretary. A post for a research information manager 
was vacant for most of the year and filled only in November. Due to this vacancy, the 
development of a specific area on drug-related research on the EMCDDA public website 
did not progress substantially. 
The SCD unit’s main target groups are researchers, including EMCDDA scientific staff, 
policy makers and the Reitox national focal points. Important cooperation partners 
include the European Commission, particularly DG RTD and other international 
organisations, such as the Pompidou Group, WHO and UNODC, as well as relevant 
European research institutions and networks. Contacts are also maintained with other EU 
agencies with a scientific and information mandate.
At the National drug coordinators’ meeting during the German EU presidency, the 
Executive Director of UNODC, Antonio Costa, suggested that Europe is in need of a 
body such as the US National Institute of Drug Abuse (NIDA). Although it was generally 
felt that no new European institution was needed, the subsequent discussion brought drug-
related research on EU drug policy agenda. The SCD unit contributed to this debate with 
technical input, and it was agreed that the EMCDDA has a pivotal role in adding more 
value to drug-related research activities conducted in Europe. 
The 7th framework programme (FP7) for research became operational in 2007. The 
programme represents a significant source for potential funding of drug-related research, 
and the SCD unit disseminated information about relevant calls for proposals under the 
7th framework on its website, at various events and through its networks. The EMCDDA 
also participated at training sessions and meetings organised by DG RTD in order to 
improve its capacity to advise research teams interested in participating in FP7 activities. 
The SCD unit is involved in two platforms of the Council of Europe’s Pompidou Group: 
the Research platform (30) and the Ethics platform (31). The Research platform met twice 
in 2007 to discuss the evidence base for drug-related policies and to develop ‘signals’ 
on new issues in research. It also continued work on an online register of drug-related 
research. The Ethics platform finalised its documents on drug testing in schools and in the 
workplace. An initiative to focus on new developments in research and ethics has been 
launched.
Support for scientific research and publishing
During 2007, the SCD unit was involved in early steps to provide staff with a more 
supportive environment with respect to scientific research and publishing. The Centre 
seeks in particular to encourage publishing by its staff in scholarly journals. A scientific 
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writer was recruited in the EPI unit, with the RES unit deciding to provide a scientific 
writer resource in 2008. These resources will thus offer a team of two experienced writers 
who, besides their responsibilities in the preparation of EMCDDA texts and publications, 
will be available to support other staff members. 
In addition, the EMCDDA, in coordination with its Scientific Committee and Management 
Board and as far as budget allows, seeks to use renowned external experts to support 
the EMCDDA’s work. This was taken into account as far as possible in the preparation of 
the 2008 work programme. Identifying drug-related research in Europe is an important 
ongoing need, and analysis of research in Europe will be integrated in the 2008 Annual 
report, based on extensive information provided by the NFPs in this area in 2007.
Scientific journals are a vital element of scientific work, and the unit cooperates with the 
International Society of Addiction Journal Editors (ISAJE) (32). In March, a representative 
of the organisation gave a presentation entitled 'Publishing addiction science: practical 
and ethical issues' to EMCDDA staff. The yearly ISAJE meeting was held in Dresden and 
provided an opportunity for networking and knowledge exchange. In parallel, an internal 
strategy to motivate and encourage scientific staff to publish in scientific journals was 
developed. 
The EMCDDA hosted a meeting in January of the Network of European researchers in 
the use of drugs and alcohol (NERUDA). NERUDA brings together researchers working 
on funded research in drugs and alcohol, to examine issues in substance use and misuse 
from a pan-European perspective, and to develop research, education and training. The 
meeting provided an opportunity to update participants on current research and common 
research project proposals, via presentations by network members and EMCDDA staff. 
The network also discussed a European masters programme in drug and alcohol studies 
or addiction, and a Marie Curie initial training network. 
During 2007, two highly experienced researchers who were attending the EMCDDA for 
other meetings were asked to deliver training sessions on scientific writing to interested 
staff members. This concept of getting ‘double value’ out of expert visits to the Centre will 
be further developed in future. 
Documentation Centre
In 2007, the Documentation Centre was able to substantially enhance its capacity for 
providing tailored information services. Services include:
• A library containing about 6 000 hard copy journals and reports relevant to the area, 
in particular:
–- EMCDDA’s technical and scientific reports;
– National reports produced by the national focal points;
– Documents and other publications of the EU bodies, relating to community policy and 
strategies covering the drugs domain in its broadest sense.
– Access to international online services, as well as to reference and full-text databases, 
through the internet.
– Intranet-based services, including access to a selection of full text journals;
– Subject-specialised information bulletins.
– Subject-specialised bibliographies and reading lists. 
– General reference information services and selective individual alert services.
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The EMCDDA is participating in the ELISAD (European libraries and information services 
for alcohol and other drugs) (33) network, and participated in its yearly meeting entitled 
'Addictions information in the Google era: dealing with the challenges'. The meeting 
discussed the development of the SUIL (substance use information and literature) 
information resource. SUIL aggregates the digital scientific and scholarly content that is 
currently held by a range of information services, and provides a multi-lingual platform 
for connecting substance use research providers.
The EMCDDA also participated at the EUROLIB (European institutional libraries) (34) 
annual meeting. EUROLIB aims to promote awareness of the contribution libraries make to 
the work of the institutions they serve, and seeks to enhance the professional performance 
of the staff of the institutional libraries. 
A meeting of representatives from European drug-related documentation services and 
other EU agencies was organised at the EMCDDA in December. This was held in 
response to two issues: the closure or scaling down of drug-related information centres, 
and the need for information professionals to examine their role in their organisations in 
the light of the changing needs and expectations of their users.  
Finally, a call for tender was launched to replace the library management system, which 
had become obsolete. The new system became operational at the beginning of 2008.
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Communication 
Activities and results 
The Communication unit (COM) aims to produce both printed and online publications 
addressing the most important aspects of the drugs phenomenon in Europe. It also plays 
a wider role in marketing and communications for the Centre, with varied tasks including 
editorial services, media relations, marketing, internal communications, institutional 
relations, public relations, knowledge management and events. 
The unit’s activities for 2007 were strongly linked to the planned outputs of the Centre. 
The key annual cyclical task remains production of the Annual report, the launch of 
which in 2007 built on the strong investment in positioning in 2006. 
Other highlights of 2007 included: a revised Communication strategy, approved by the 
Management board in July 2007; the operational launch of the Fonte software; renewed 
momentum for the Centre’s Drugs in focus series of policy briefings; early phases of 
a redesign of the Centre’s website; a role in the external evaluation of the Centre, in 
particular its follow-up during the end of 2007 and 2008; and ongoing population of 
the Centre’s intranet, which at the end of 2007 incorporated content and documents 
essential to the activities of all units of the agency. 
During 2007, the unit also engaged in recruitment, focused specifically on the output-
oriented focus of the new triennial work programme. A new editor began work at the 
end of 2007 and a proofreader was recruited for start early in 2008. These resources, 
in combination with the scientific writer employed in the EPI unit, will provide the 
necessary boost to handle an ambitious publications list planned for 2008, and in 
particular work on a planned harm reduction monograph. 
Publications
The EMCDDA public website remains the key channel for publishing information and 
documents about the Centre and the European drugs situation. Many of the website’s 
innovations in 2007 were technical: an RSS newsfeed was launched for the site; the 
Annual report package of sites was fully integrated into the main website (as opposed 
to the separate site approach of previous years); the Statistical bulletin was tagged with 
meta-data to make it easier to find statistics of interest; and a templating mechanism 
was added to the content management application to allow for more flexible page 
designs. The key benefit of these changes are that the website is better able to ‘map’ 
and ‘repurpose’ information: detailed metadata (tags) can now be associated with online 
content, and, based on an XML-based workflow, 'raw' web content (e.g. Statistical 
bulletin tables and charts) is separated from its presentation.
An exhaustive list of publications is included in the outputs section of this report (pp. 
85–98). Beyond the Annual report, a shorter list serves to illustrate some of the main 
products: the three Selected issues of the Annual report covered issues of prevailing 
policy interest — cocaine, drugs and driving, and drug use among under-15s; Drugs 
in focus policy briefings covered hallucinogenic mushrooms, drugs and crime, and 
provision of cocaine treatment services. A priority of the 2007–2009 work programme, 
which is enshrined in the new Communication strategy, is that the Centre's ‘outputs’ 
need to be tailored to the needs of the EMCDDA’s key audiences. This was exemplified 
in 2007 by the publication of several different publications about cocaine: a literature 
review (audience: researchers, clinicians, practitioners); the annual chapter in the Annual 
report and Statistical bulletin tables (audience: epidemiologists, policymakers, statisticians); a 
Selected issue on cocaine (audience: researchers, policymakers) and a Drugs in focus policy 
briefing (audience: policymakers, national ministries and practitioners).
An exceptional publication during the year, combining with Portugal’s presidency of the EU, 
was a brochure titled Europe in Portugal, describing the various EU agencies and bodies with 
a presence in Portugal. 
Media relations
Eight news releases, four fact sheets, one feature article and additional press materials were 
produced in 2007, along with four editions of the quarterly newsletter Drugnet Europe. The 
Drugnet Europe newsletter was also launched in January 2007 in an online version, which is 
published in parallel with the printed versions. As in previous years, media actions focused 
on two events: International day against drug abuse and illicit trafficking (26 June) and the 
launch of the Annual report in November in Brussels. 
In line with the current ‘going local’ thrust of EU communications — promoted by 
Commissioner Wallström as an essential means of communicating Europe to its citizens — the 
EMCDDA drew up an action plan for reaching the local and regional media in 2007, both 
in Portugal and at the EU level. This began with visits to the Committee of the Regions press 
office and the European Commission (DG–COMM) in Brussels in April and contacts in May 
with the press officer at the European Commission representation in Lisbon specifically tasked 
with targeting these media. 
The date of 26 June was chosen as a hook for disseminating news from the Centre to local 
media in Portugal, in partnership with the EC representation. A feature article with a local 
focus was prepared in the name of the Director to mark the occasion, exploring the role of 
local authorities in dealing with the social repercussions of drug use and addressing drug-
related crime. The article was distributed by the EC representation to the local and regional 
media in mainland Portugal, the Açores and Madeira ahead of the event, and over 60 % 
coverage was achieved. In July, in a move to reach this target in all EU Member States, 
the national focal points were asked to nominate local and regional media in their country. 
This allowed for national-level contacts to be added to the EMCDDA’s press database in 
September, in preparation for the Annual report launch. 
The Annual report launch strategy in 2007 included a new internal communication 
initiative to assist staff in preparing better for the event, and to ensure a common corporate 
presentation of the product at the European and national launches. In September, 16 staff 
members received training in interview techniques from an experienced journalist using 
before-camera exercises. Early in November a new area of the intranet was launched, 
offering staff the Annual report information package, event details, interview tips and briefing 
notes on issues likely to generate press interest.  
A pre-launch briefing and public press conference were held in Brussels on 21 and 22 
November, following a presentation to the European Parliament. Events in Brussels were 
complemented by decentralised national events in 14 EU Member States, largely press 
conferences organised by the NFPs. To support the above communications, a comprehensive 
press pack and a Powerpoint presentation were released in 23 languages along with 
additional promotional items and materials.
Based on ongoing investment by the unit in media scanning activities, coverage on the 
Annual report was monitored in ‘real time’ and clippings made available on a daily basis 
to staff via the press area of the intranet. Of note, compared with previous years, was: 
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the ‘deep and wide’ coverage gained in the Bulgarian, German-speaking, Czech, 
Hungarian, Italian and Spanish media; a stronger presence in the local and regional 
press; a featured slot on CNN; and greater take-up in the media worldwide, from 
Canada to Australia and Brazil to India. The final press review amounted to 1300 
articles. 
To mark the EU 50th anniversary celebrations in March 2007, the EMCDDA published 
on its press web page a document entitled 'A clearer insight into Europe’s drug 
problems'. This presented how Europe has addressed drugs issue over the years: by 
monitoring the situation, informing drug policy and detecting potential threats to public 
health. Also in March, the Centre marked International women’s day with an online 
presentation of issues surrounding gender differences in drug use and drug addiction, 
including reflections on drug use among ethnic minority women.
In November, contacts were made with the Russian media following the signing, during 
the EU–Russia summit in October, of a Memorandum of Understanding between the 
EMCDDA and the Federal Service of the Russian Federation for Narcotics Traffic and 
Control (FDCS). 
Finally, impact assessment of press actions was carried out on a regular basis and seven 
press reviews were produced during the year (quarterly, 26 June, EMCDDA–FDCS, and 
the Annual report press review).
Marketing
In the first half of 2007, the Centre’s marketing activity focused on brand-related 
activities, kicking off in January with a training course for newcomers on using and 
maintaining the EMCDDA corporate identity. The course was also an opportunity to 
introduce newcomers to the project 'Representing the EMCDDA', designed to groom staff 
as ambassadors of the agency and ensure that they sing from the same song sheet when 
representing the agency externally. 
As a follow-up to the training course, work was carried out in the spring to complete a 
marketing repository on the intranet, conceived to support staff in the above goals. New 
additions included: a 'dos and don’ts' section on applying the EMCDDA brand; a stock 
of Powerpoint presentations; a speech pool; and a promotional checklist and guidelines 
for presentations. In the first half of the year, time was also invested in updating 
corporate identity materials — stationery, business cards — and producing six new 
promotional gadgets for marketing purposes — lanyards, briefcases etc.
To coincide with the Portuguese presidency of the EU, the EMCDDA 'went local' again 
in July, joining forces with other EU bodies based in the country in the project 'Europe 
in Portugal'. This led to the publication in September of a brochure in English and 
Portuguese, a bookmark and webpage, explaining the work of the EU bodies present 
in Portugal. During the Presidency the materials were distributed, among others, to: the 
Portuguese public via the Europe Direct network; Portuguese schoolchildren via the EU 
'Back to schools' project; Portuguese MEPs at the European Parliament; policymakers 
at a major international conference on drug policy and European citizens via the EU 
Bookshop.
Following the preparation earlier in the year of an action paper to maximise use of the 
EU Bookshop, the unit met with the head of the bookshop in Lisbon in September to 
clarify and explore the bookshop's features and developments, and practical working 
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channels. The 2007 Annual report was promoted via the bookshop’s Publishers’ Choice 
and regular contacts subsequently took place between the EMCDDA and bookshop 
services in the context of the EMCDDA publications database project.
New EMCDDA products were promoted throughout the year via the newsletter Drugnet 
Europe, the public website and promotional mailings, and publications were displayed at 
the Frankfurt book fair in October.
In the context of the joint EU agencies’ information activities, January and February saw 
the EMCDDA publish a web banner to support the interagency Whatever we do, we 
work for you advertising campaign, which was launched with a series of advertisements 
in EU in-flight magazines in December 2006. In the autumn the EMCDDA provided 
updated information in 25 languages for the latest joint agency brochure (print run: 
55,000 copies). This entered production at the end of the year and provides information 
on 29 EU agencies.
The EMCDDA also participated in two meetings of the agencies’ Heads of information 
network in 2007. The first, in April, hosted by DG COMM, was dedicated largely 
to the going local theme, and opportunities for communicating Europe’s successes to 
the citizen. The second, in October, focused on address management and distribution 
issues and updates on ongoing projects. Throughout the year the EMCDDA, as member 
of the network’s seven-member steering group, provided regular input on a variety of 
communication issues brought before the group.
Interinstitutional communication
The EMCDDA collaborated with the Committee on civil liberties, justice and home 
affairs (LIBE committee) of the European Parliament in the context of the presentation 
of the Annual report in November, on the eve of the official press launch. Again in 
2007, in line with an EMCDDA strategy to increase the impact and visibility of the 
report by boosting the national component, national parliamentarians were invited to 
the presentation. Parliamentarians responsible for drugs from nine Member States — 
Belgium, Ireland, Greece, Italy, Cyprus, Latvia, Hungary, Slovenia and Sweden — and 
Turkey replied to the invitation and attended the presentation to the LIBE Committee. The 
presentation was followed by a lunch with national and European parliamentarians, as 
well as representatives of the European Commission.
14 countries — Bulgaria, Czech Republic, Denmark, Germany, Italy, Cyprus, Lithuania, 
Hungary, Austria, Poland, Portugal, Romania, Slovakia and Norway — organised 
national presentations of the Annual report. The majority of events were organised 
by, or in collaboration with, the national focal points. The EMCDDA provided human 
and logistical support for these events according to the requirements of the national 
authorities.
Fonte
Fonte is the EMCDDA’s web application that manages the entry and retrieval of data. 
It acts as the interface between the EMCDDA, its national focal points (NFPs) and 
other national partners. Fonte handles the main stages in the data lifecycle: filling in, 
submitting, validating, and retrieving data for reports (see Figure 1, p. 49). 
The EMCDDA 2007 work programme contained three objectives related to the launch 
of Fonte: (i) to introduce the new data collection and validation support system, Fonte; 
(ii) to ensure the online data acquisition and management tools developed as part of the 
first phase of the Fonte system are launched successfully, allowing the Centre to extend 
implementation during 2008 (iii) to streamline the reporting process on the EMCDDA’s 
activities. 
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In practice these were translated into four activities: (a) to finalise testing of the Fonte 
application; (b) to develop Fonte functions; (c) to provide Fonte training; (d) to provide 
Fonte help and assistance.
(a) To finalise testing of the Fonte application: 2007 saw a cycle of releases of the 
Fonte software, with associated user feedback, bug-reporting, resolution and releases. 
Priority was given to resolve those bugs that affected NFP reporting, followed by bugs 
impacting the work of the EMCDDA. After internal testing, pre-launch testing also 
took place with the Austrian and Slovenian NFPs, which delivered both technical and 
usability improvements from the NFPs’ standpoint. Although a few technical problems 
were experienced at launch, this did not jeopardise reporting. By the end of 2007 the 
EMCDDA had received a total 14 updated versions of Fonte that were tested. 
Figure 1: Full data lifecycle in Fonte
(b) To develop Fonte functions: Between the reception of the functional version of Fonte in 
December 2006 and its foreseen launch in July 2007, it became evident that additional 
functions were needed in order to ensure that the new application would be well received 
by both NFPs and EMCDDA staff. One example was to have a copy-paste function, 
which allowed copying large tables of data from, for instance, Excel into Fonte. The 
EMCDDA assembled a wish-list for new Fonte functions, which were delivered by the 
external contractor in incremental packages prior to launch. 
(c) To provide Fonte training: In-house training sessions for Fonte for EMCDDA staff were 
organised twice during 2007, in April and September. The EMCDDA also organised two 
Reitox academies on Fonte for NFPs. These comprised a half-day Fonte training session for 
heads of NFPs, and a two-day session at the premises of the Turkish NFP in Ankara for the 
NFP end users who will work most intensively with Fonte. The Ankara academy focused not 
only on using Fonte, but also on understanding organisational aspects of using the system, 
and, in particular, to get to know the Fonte project team and helpdesk at the EMCDDA. 33 
delegates from 24 countries attended the Ankara academy, and an evaluation form showed 
a high rate of satisfaction, at nearly 90 %. Feedback sessions at both academies were useful 
for gaining NFP input on how and what could still be further improved in Fonte.
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In addition to these training events, the Centre conducted two specific training sessions 
during 2007, for the Spanish and Cypriot NFPs. Fonte was also presented at other 
EMCDDA meetings: the population survey meeting; treatment demand indicator meeting, 
Reitox meeting and Scientific Committee meeting. 
(d) To provide Fonte help and assistance: To accompany the launch of Fonte, the 
EMCDDA produced a series of help documents: a full Fonte user manual which covers 
all functions and modules; a shorter, NFP-focused user manual covering those modules 
used by NFPs; a 6-page Fonte Quick reference; and a Frequently asked questions list. 
The EMCDDA also set up a Fonte help desk, comprising a telephone support for urgent 
requests and an e-mail service for less urgent problems. Specifically for technical and 
connectivity matters, ICT contact persons at many NFPs were also established during 
2007.
Fonte progress report
Fonte was launched on 11 July; a mild slippage of ten days that was largely due to the 
development of new, unplanned functions. Considering that 2007 was Fonte’s first year 
as one the Centre’s three reporting channels — the other two being the EISDD and the 
Reitox upload tool — the launch went smoothly. A progress report was made on 23 
November, four weeks after the NFP deadline for reporting. This proved encouraging: 
246 reports had been submitted, and 20 countries had submitted all the data they were 
supposed to through Fonte. Seven countries were missing one to three reports, and three 
countries had not yet submitted anything. There were 175 ongoing validations, and 
70 concluded reports in the system. By comparison, 19 countries had submitted their 
National report through the Reitox upload tool. Thus in terms of volume of data and 
timeliness of reporting, this start for Fonte was promising. While Fonte was expected to 
lag behind the other data collection channels in its first year, its benefits were already 
becoming apparent. 
The result of this workflow is that key data in the field of drugs and drug addiction 
is centralised in a single place, and that the process is tracked at each stage. Fonte 
thus constitutes a major leap forward in the EMCDDA’s aim to provide a unique and 
comprehensive data and knowledge base. 
Distribution and information requests
EMCDDA dissemination activities in 2007 concentrated on executing dissemination 
plans, in particular in relation to the Centre’s Drugs in focus policy briefings and 
Manuals. Mailing lists were also restructured in close cooperation with the Publications 
Office (OPOCE), with more than 5 000 updates during 2007. To handle more efficiently 
addresses within the agency, the development of a centralised address management 
system was begun in 2007. An external contractor was chosen after a call for tender, 
and a prototype delivered for testing at the end of 2007. The system should be installed 
by the middle of 2008.
An increased number of conferences and meetings were supported with publications and 
brochures. The Portuguese presidency led to an increase in publication and subscription 
requests. The 2007 Annual report was published in 23 languages with a total print run 
of nearly 35 000 copies. More than 20 000 copies were distributed around the week of 
the launch, 16 000 of those to national focal points, to support more than 15 national 
events and for general stock.
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In October, the EMCDDA also participated in the annual information meeting 
with decentralised agencies in Luxembourg, which included a seminar on contacts 
management and dissemination. The seminar included a presentation by OPOCE on its 
services, and exchange of best practices in contacts management between agencies. 
Training in this area may be developed by the agencies’ network and OPOCE during 
2008.
Considerable work was invested during 2007 on improving the tracking of information 
requests, the majority of which reach the Centre via the website. In May, procedures for 
answering and tracking information requests were published on the Centre's intranet. 
A pool of standard replies was introduced, which has helped both to speed up the 
answering process and deliver consistent responses. Standard replies for the categories 
publications, copyright, support and jobs were drafted, as well as a general reply 
template. The templates were sent for translation into German, Spanish, French and 
Portuguese and have been in use since July 2007. 
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(35) http://ec.europa.eu/environment/emas/documents/guidance_en.htm3
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Administrative support
Activities and results 
In 2007 the EMCDDA continued to improve both in terms of effectiveness and efficiency its 
internal processes and the activities aimed at supporting its core business. Special attention 
was paid to implementing a more structured and effective human resources policy and to 
enhancing effectiveness and efficiency in the use of resources. 
Planning, evaluation and legal matters
An amending and supplementary budget was adopted in October 2007. The new budget: 
• revised the amount of the contribution by Turkey to the EMCDDA 2007 budget (a 'pour 
mémoire' value placed at 0 euros instead of 100 000 euros); 
• entered the actual amount (550 000 euros, instead of 700 000 euros) and a breakdown of 
the specific appropriations provided under the CARDS programme for the implementation of 
an EMCDDA-specific project for technical assistance to the countries of the Western Balkans 
(Albania, Bosnia-Herzegovina, Serbia, Montenegro, FYROM); 
• used part of the surplus existing in the EU budget appropriations earmarked for the EC 
subsidy to the EMCDDA, as resulting from the relevant 2005 accounts, to cope with some 
supplementary and unplanned needs which were not covered by the 2007 EMCDDA budget 
initially adopted.
In accordance with the posts authorised in the EMCDDA’s establishment plan, a new staff 
member was recruited at the end of 2007 to strengthen the operating capacity in this 
area. The new staff member is tasked with improving and streamlining the planning and 
reporting processes concerning the Centre's activities. Special attention was paid in 2007 
to those legal processes that relate to: (i) implementation of the CEOS (staff regulations); 
(ii) notification processes to the European Data Protection Supervisor; (iii) application of the 
protocol established between the Centre and the Portuguese Government; (iv) operations 
concerning the new EMCDDA premises.
Financial management and accounting
The internal capacity of the financial management sector was further strengthened and 
reorganised in 2007. The team ended the year better able to cope with the workload 
entailed by the management of transactions concerning meetings and missions. In order to 
improve existing financial reporting, a set of accounting reports for asset management and 
accrual accuracy cross-checks was developed.
Procedures and tools for regular supervisory and ex-post controls were set up to develop 
ex-post control of financial transactions. Within the context of the financial and contractual 
assistance provided to the EMCDDA core business, 334 tendering and contracting processes 
were initiated. The daily management of the contracts and the related budgetary transactions, 
including the ex-ante verification and the bank transfers, represented a total of 3 886 
operations. 
In order to improve the EMCDDA internal processes and activities aimed at supporting its 
core business, specific measures were taken to improve the execution of the EMCDDA work 
programme and budget, as well as the processes for financial and contractual management 
and internal control (see Part II, below).
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Human resources management
Work on the implementation of the reform of the EU CEOS (staff regulations) which entered 
into force in May 2004 continued throughout 2007, and were intensified to enable the 
EMCDDA to complete the legal framework of its human resources policy by 2008.
Development of best practices continued during the year. In particular, the human resources 
team sought to improve communication with staff, in particular with regard to disseminating 
and circulating relevant information. A dedicated human resources portal was published 
and enhanced on the Centre's intranet, which includes information on applicable rules and 
processes, together with general information about working conditions. Training also remains 
an important aspect of human resources work. During 2007, 73% of the staff participated 
in training courses. The most frequented type of training (42 %) was classed as 'specific' (i.e. 
related to an employee's tasks) with language courses also comprising a large share (31 %). 
19% of staff participated in at least in one training course, while 16 % participated on two 
courses, and 16% on three courses. 
During 2007, ten selection processes were successfully carried out, and 10 new staff 
members took up their functions at the EMCDDA (see part II). In terms of general workforce 
information, at the end of 2007 there were 93 people working for the EMCDDA. The 
Centre's staff is made up of nationals of 17 different countries, with Portugal in first place 
(30 %), Germany second (11 %) and Belgium third (10 %). Interestingly, 6 staff (6.5 %) 
are nationalities of the Member States that have joined the EU since 2004. There are no 
significant differences between gender (female: 47 %; male: 53 %). By age group, the most 
common group are staff aged 41–50 years (43 %) following by staff in the range 30–40 
(35.5 %). 54 % of the staff have children. Most of the staff are employed as Temporary 
Agents (65.6 %), while 44 % are classed as administrators (AD staff). 
Infrastructure and logistics 
In terms of the daily management of the EMCDDA movable and immovable property, 
infrastructure and logistics, emphasis was placed on improving health, safety and security 
at work. Tasks included the training of fire wardens and installation of colour CCTV. The 
infrastructure and logistics team aimed to provide an improved service, and continuous effort 
was made to improve communication to colleagues through a dedicated intranet section. 
The reorganisation of the reception and driver services also facilitated more efficient and 
effective distribution of workload.
Physical stock-taking of the EMCDDA’s assets was successfully carried out in October, and 
declassification of assets in December, in accordance with the Centre's rules for inventory 
and asset management. 
In accordance with the legal framework defined by the Management Board, a security 
rulebook was completed in 2007 which defines the policy, actors and procedures for the 
security of the EMCDDA’s premises, staff and data/information.
The EMCDDA participated in the inter-agency Greening network set up and organised by 
the European Environment Agency. The aim of the Greening Network is to reduce pollution 
and building-related utility costs. The EMCDDA was also requested by the ETF in Turin to 
present, together with the EEA, the EMAS standards (35) to selected audiences of the ETF. 
(35) EMAS is the Eco-Management and Audit Scheme 
http://ec.europa.eu/environment/emas/documents/guidance_en.htm
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The project for the new EMCDDA headquarters at the Ribeira das Naus in Lisbon has 
progressed. Construction works were almost completed by December 2007. The completion 
of the construction project is foreseen for March 2008. To prepare the future move to the 
new premises, several activities were initiated, for example the procurement for cleaning 
services which was launched together with EMSA, the other European agency with which 
the premises will be partially shared.
Information and communication technology 
Activities and results 
The bulk of the ICT unit’s work in 2007, as in previous years, involved providing routine 
support to the Centre’s operations: network and server administration; web-related projects 
and services; office hardware and software; and the ICT helpdesk.
The 2007 work programme for the ICT unit focused on improving efficiency and 
effectiveness, and a number of processes, together with the structure of the team, were 
revised during the year. For example, the ICT Project management office, which offers 
support to all new ICT projects, now provides horizontal support to other EMCDDA units. 
Internal work processes for operations management were reorganised into two services: 
ServiceDesk and ServiceSupport. Central planning and monitoring was introduced for ICT 
infrastructure, and this will continue into 2008 to reflect changes in available personnel and 
expertise.
To improve project organisation and related documentation, a technical documentation 
and deployment policy was introduced in 2007. The policy is now firmly established at the 
Centre for its major tailor-made applications. A basic test environment was also set up, in 
order to distinguish better between development, test and production phases of new tools. 
In the area of infrastructure and systems, 2007 saw the complete renewal of the Centre’s 
firewall and security infrastructure, which also boosted network performance. Out-of-date 
server hardware was also replaced and additional equipment acquired. The year also 
brought with it a long-awaited upgrade of central collaboration services, both on the 
software and hardware level. This took the form, for example, of an email-based calendar 
for contacts and tasks. Ensuring the stability and security of such services during the early 
stages of the project was a major concern, and the launches were successful.
The expansion of the Centre's second office in Lisbon, in the Avenida Almirante Reis, 
continued during the year, and required ICT support where necessary. In addition, 
construction of the new EMCDDA headquarters at the Ribeira das Naus complex was 
closely monitored. ICT preparation for the move to the new premises during 2008 is under 
way. During 2007, this included a tender for acquiring a VoIP telephony system and related 
services 
With over ten years of accumulated documents, the EMCDDA now requires technology for 
document management and records management, with in-built workflow support. 2007 saw 
a project to collect requirements for this project, based on input from representatives from all 
units, together with information from the Medicines Agency (EMEA) in London, which has a 
similar system already in place. Based on these requirements, the Centre engaged in follow-
up interviews with vendors, to gain insight into the available technology and services in the 
market which will be able to meet the Centre's needs. 
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The launch of Fonte involved considerable work for the unit. The internal ServiceDesk 
experienced an increase in the scope of its work, and now also responds to Fonte users 
from National focal points and other partners. After completing formal development of 
Fonte, preparations for spin-off projects began towards the end of 2007. These are aimed 
at solutions for analysing collected data, and at supporting further data migration and later 
phases in the Fonte project. 
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Finally, the ICT unit carried out numerous other projects during 2007, and some will 
continue into 2008. These include the migration to ABAC, the new system for accrual 
accountancy defined by the European Commission, for which the migration date was 
postponed, on request from the Commission, in 2007. 
Chapter IV: Statutory bodies and executive management 
General report of activities 2007
60
Public tion title
4
61
Chapter 4
Chapter 4 
Statutory bodies and executive management 
Management Board
Main decisions
The recast of the EMCDDA regulation entered into force in January 2007. The 35th 
meeting of the Management Board in Lisbon in July 2007 discussed the implications of 
the recast on the Centre's mandate and tasks, together with its impact on the EMCDDA’s 
working processes. In keeping with the recast, the board amended its rules of procedure, 
and adopted procedures for the selection and appointment of the members of a new 
EMCDDA Scientific Committee.
The July Management Board meeting also approved the EMCDDA’s new communication 
strategy. 'Communicating more effectively’ is one of the three priorities of the EMCDDA’s 
2007–2009 strategy and work programme. The communication strategy document 
focuses on the Centre’s various communication activities (publications, web, marketing, 
distribution, media), aiming to support the output-oriented thrust of the Centre’s overall 
strategy. Also at the July meeting, the Management Board gave a favourable opinion on 
the final accounts of the EMCDDA for 2006.
In a second meeting in December 2007, the Management Board elected Mr Franz 
Pietsch (Austria) and Mr Piotr Jablonski (Poland) as members of the Executive Committee 
for a mandate of three years. The Management Board also appointed 15 high-level 
scientists from the EU Member States, from across different areas of expertise to become 
members of the EMCDDA’s new Scientific Committee for a three-year period. A scientist 
from Norway, also selected for scientific excellence and independence, will sit on the 
Committee as an observer. In case the need arises to replace an outgoing member during 
this period, the Management Board will appoint a substitute from the reserve list it also 
adopted at the meeting. 
At the December meeting the UK-based Centre for Strategy and Evaluation Services 
(CSES) presented to the board its final report of the external evaluation of the EMCDDA. 
The overall purpose of the evaluation, undertaken at the initiative of the European 
Commission in 2007, was to assess the effectiveness of the agency and to examine ways 
of enhancing its operations. The exercise covered the period of two EMCDDA three-year 
work programmes (2001–2003 and 2004–2006). According to the evaluators, the 
EMCDDA is ‘performing well’ in its core mission to provide ‘factual, objective, reliable 
and comparable information at European level concerning drugs and drug addiction’ 
— information that is needed as an evidence-base by policy-makers at both national 
and European level. The agency’s priority-setting was also found to be ‘closely aligned 
with wider EU policy aims’, such as those set by EU drugs strategies and action plans. 
The EMCDDA was also found to be ‘almost certainly providing a more cost-effective 
way of monitoring the drugs situation in Europe than could be undertaken by the 
Commission itself’. ‘The EMCDDA’s work has also had a direct impact on EU Member 
States’ drugs policies and practices’, found the research, by ‘encouraging a higher 
degree of coordination between them and the adoption of comparable structures’. The 
development across the Member States of harmonised data-collection mechanisms ‘would 
Publication title
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not have taken place, at least in the same timeframe, without the EMCDDA’, says the report. 
It also noted that achievements were played out against the challenging backdrop of two EU 
enlargements and the resultant demands from new EU countries for capacity-building support.
Also at the December meeting, the Management Board took note of a strategy on 
international cooperation, which defines and prioritises the objectives of the Centre in this 
area. The EMCDDA should act as a Centre of excellence for providing information on the 
European drug situation, and develop a better understanding of the evolution of the drug 
phenomenon worldwide. The Board further welcomed an overview on the implementation of 
the five key indicators in the Member States and Norway.
A budget of 13 927 579 euros for 2008 (27 Member States, Norway and Turkey) was 
adopted on the basis of an EC subsidy of EUR 13 400 000 euros. The overall amount for 
Reitox co-financing in 2008 will remain the same as in 2007. The Management Board also 
gave the Chair and the Chair of the Budget Committee the mandate to meet with the heads of 
the national focal points to listen to their concerns about the co-financing scheme.
The 2008 work programme was welcomed for its output-oriented approach and coherence 
with the 2007–2009 work programme. The 2008 work programme places emphasis on the 
activities highlighted in the recast regulation, taking into account inputs from the Centre for 
the evaluation of the EU action plan. The work programme was adopted by written procedure 
after the meeting, on the basis of the opinion of the European Commission.
The Management Board further adopted a preliminary draft budget of 14 582 856 euros for 
2009 (27 Member States, Norway, Turkey and Croatia) on the basis of an EC subsidy of EUR 
13 861 626 euros. The budget for 2008 and the preliminary draft budget for 2009 represent 
a status quo in real terms with the budget of the previous year. The Management Board 
approved the staff policy plan of the agency for the years 2009–2011, subject to the final 
opinion of the European Commission.
Executive Committee
Main decisions
The Executive Committee met five times in Lisbon during 2007 (36). At its May meeting, the 
Executive Committee commented on amendments proposed by a working group to align 
the rules of procedure of the Management Board with the recast of the EMCDDA founding 
regulation. One of the major changes concerned the composition of the Executive Committee. 
Following the change, only two members of the Management Board representing the 
Member States — as opposed to three previously— are elected by the Management Board 
to be members of the Executive Committee for a period of three years. Previously three 
members were elected for a period of one year, renewable twice. Furthermore, the European 
Parliament is no longer represented on the Executive Committee.
The Executive Committee also commented on a first draft for the procedures and 
arrangements for the selection and appointment of the members of the EMCDDA Scientific 
Committee, as proposed by a working group. This working group was composed of the 
EMCDDA Director, acting as Chairman, two members of the EMCDDA Management Board, 
two members of the EMCDDA Scientific Committee (who would not stand for another term) 
and two representatives of the EMCDDA senior staff, nominated by the Director. The working 
(36) 10 May, 4 July, 25 October, 19 November, 5 December.
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group had met during February 2007. The Executive Committee also adopted at the May 
meeting the rules on the secondment of national experts to the EMCDDA, and agreed by 
written procedure to reallocate appropriations under the 2007 Reitox budget. 
At the July meeting, the Chair of the Budget Committee reported the conclusions of a previous 
budget meeting to the Executive Committee, and the committee prepared for the subsequent 
July Management Board meeting. 
At the October meeting, the Executive Committee approved, based on a proposal by the 
Budget Committee, an amendment to the 2007 budget of the Centre. The amendment 
concerned modifications in the provision for Turkey's contribution to the 2007 budget, in 
the amounts for a technical assistance project to countries of the Western Balkans under the 
CARDS programme, and provisions to cope with unplanned, supplementary needs for IT 
supplies and services.
An extraordinary meeting took place in November to establish a shortlist of members and 
a reserve list for the Scientific Committee, to be adopted by the Management Board at its 
December meeting. The Executive Committee adopted with only minor changes the proposal 
established by a pre-selection panel composed by the EMCDDA Director, two former 
Chairmen of the Scientific Committee and two senior staff members.
The Executive Committee decided at its December meeting to adopt the implementing 
rules on promotion of officials, reclassification of temporary agents and contractual staff, 
and performance appraisals by written procedure after the Commission’s agreement, in 
accordance with the staff regulations.
Director
In accordance with the Centre’s founding regulation, the Director is responsible for, among 
others: a) preparing and submitting the Management Board proposals for deliberation as 
well as for implementing the Board’s decisions; b) deciding on staff matters; c) managing the 
Centre’s day-to-day activities; and d) representing the Centre externally. 
Preparation and implementation of Board’s decisions
In 2007, the Director implemented the 2007 work programme and budget; prepared and 
submitted to the Board for approval the 2007–2009 and 2008 work programmes, the 2008 
budget and the 2009 preliminary draft budget, and the final accounts for 2006. Furthermore, 
the Director also submitted to the Board for approval: the 2006 General report of activities; 
the staff policy plan 2009–2011; a communication strategy; a strategy for international 
cooperation; a Memorandum of Understanding with the Federal Drug Control Service of the 
Russian Federation; and a revised Memorandum of Understanding with the European Centre 
for Disease Prevention and Control (ECDC).
Staff matters and day-to-day administration 
In his capacity as both authorising officer and appointing authority (AHCC), the Director took 
37 written decisions throughout the year, ranging from the reassignment of staff members 
to new functions to delegating some of his powers, with a view to achieving the more 
decentralised and effective management of the Centre. Decisions included the adoption of 
internal administrative instructions, and the publication of notices to ensure the functioning of 
the Agency.
General report of activities 2007
64
Representation 
The external activities of the Director were largely oriented towards building bridges and 
reinforcing cooperation, in particular with the EU institutions and Member States with a 
view to finding better ways to provide them with the service they require. They also covered 
meetings with representatives from third party organisations and countries oriented to building 
and improving partnerships in the area of drugs information. 
EU level representation
European Parliament: The key event with regard to the European Parliament was the 
presentation in November of the 2007 Annual report to the Committee on Civil Liberties, 
Justice and Home Affairs (LIBE Committee) in Brussels, including a press launch co-organised, 
as in previous years, by the European Parliament and the EMCDDA. 
In June, the Director presented the General report of activities for 2006 and the 2007 work 
programme to the LIBE Committee of the European Parliament in Brussels. Also in June, Mr 
Götz jointly attended, together with the Director of EMSA, a working dinner in Lisbon with a 
delegation from the European Parliament Committee on Budgets. The delegation was headed 
by the Committee’s Chairman Mr Reimer Böge, and included, among other MEPs, the budget 
rapporteur for 2008 Mr Kyösti Virrankoski, and the standing rapporteur for agencies, Mrs. 
Jutta Haug. Mr Götz attended in Brussels in June the Annual Meeting of the Budget Committee 
with the agencies. Following contacts established in the context of the Annual report in 2006, 
the Director had many bilateral meetings with MEPs throughout the year.
In the framework of establishing a closer relationship with the EU institutions' offices in Lisbon, 
the Director met the Director of the European Parliament Information Office in Lisbon.
European Commission: The dialogue between the Director and the European Commission 
comprised numerous meetings throughout the year. Mr Götz met with representatives of the 
Cabinet of Vice-president Franco Frattini, as well of the DG JLS. The Director paid a visit to 
DG Sanco and, for the first time, to Eurostat, in Luxembourg. Other Commission contacts 
during 2007 included meetings in Lisbon with OLAF representatives. In the framework of 
establishing a closer relationship with the EU offices in Lisbon, the Director met the Head of 
the Commission representation in Lisbon. Two visits of representatives of the CSES, the Centre 
for Strategy and Evaluation Services, a UK-based company selected by the Commission to 
perform an external evaluation of the EMCDDA, took place in Lisbon in February and April. 
Mr Götz also held meetings with representatives of the Commission’s Internal Audit Service.
In May, the Director met with the representatives of the Court of Auditors in the framework of 
the standard audit visit regarding the annual accounts of the financial year 2007.
With regard to relations with the other EU agencies, a key development was that the 
Director was elected in January as Coordinator of the network of Heads of EU Agencies 
for the period March 2008 to March 2009. Within this network, the Director took part for 
the first time in the Agencies’ troika meeting in Brussels in June and in Cologne in October. 
The Chairperson’s role demands, among others tasks, that the EMCDDA organises the three 
annual meetings of Heads of EU Agencies in 2008-2009. These meetings are: in January, 
a discussion with the Secretary General of the European Commission and a hearing at the 
Committee on Budgetary Control of the European Parliament; in June, the annual meeting 
with the Committee on Budgets of the European Parliament; in October, a regular meeting at 
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the Coordinator's agency.
In addition to such ‘pan-agency’ activities, bilateral activities with other agencies also 
took place. The Director of the European Centre for Disease Prevention and Control 
(ECDC) visited the EMCDDA in June and a Memorandum of Understanding was signed 
with the ECDC. In October in Lisbon, the Director met the Director of Eurojust. Regular 
meetings were held with the Director of the Maritime Safety Agency (EMSA) mainly 
concerning the building project of Ribeira das Naus. Mr Götz also attended the annual 
hearing by the Committee on Budgets and Committee on Budgetary Control of the 
European Parliament with all Heads of Agencies.
A number of activities were undertaken in the context of the Portuguese presidency. 
Mr Götz attended the celebration on the occasion of the opening of the Portuguese 
presidency in Porto on 1 July. The Director also took part in the Conference on the 
Evaluation of Public Policies and Programmes on Drugs which was held in September in 
Lisbon, where he gave a joint presentation with the Director of Europol. On 24 October 
he participated in the National Drug Coordinators meeting in Lisbon. Finally, a working 
group to strengthen relations between the Directors of the Representation of the European 
Commission, the Information Office of the European Parliament and the two EU agencies 
based in Lisbon resulted in an information brochure, Europe in Portugal. 
Member States
Portugal: Relations with the Portuguese authorities were particularly important and 
intensive during 2007, particularly in the light of the Portuguese EU Presidency and 
negotiations on the building at Ribeira das Naus in Lisbon. In January, the Director 
hosted a visit of a delegation of the Health Committee of the Portuguese Parliament. 
Mr Götz invited the Director of the Criminal Police (Polícia Judiciária), for a visit to the 
Centre with a view to discussing sources of supply-side data. Invited by the Portuguese 
President Cavaco Silva, the Director  attended in May a dinner on the occasion of 
the visit to Portugal of the Lithuanian President. The Director also attended the official 
ceremony to celebrate the Portuguese National day. Earlier in June, Mr Götz accepted 
the invitation to integrate the honorary committee for the celebration of the 20th 
anniversary of the Centro das Taipas (a treatment centre within the IDT, the Portuguese 
Drugs and Drug Addiction Institute).
Numerous meetings were held relating to the new building in Lisbon. In January, a 
meeting of the Political Steering Committee on the building took place, chaired by 
the Portuguese Secretary of State of National Defence and Maritime Affairs. On 
three occasions, the Director met the President of the Lisbon Port Authority, and once 
the President of the General Assembly of the Lisbon based Jacques Delors European 
Information Centre, in the context of its integration in the Ribeira das Naus complex.
Other EU Member States: Together with the Centre’s Chairman Mr Reimen, the Director 
visited Bucharest in Romania in March. The visit included meetings with the Secretary of 
State of the Ministry of Health, the Secretary of State of the Ministry of Administration 
and Interior, the President of the Senate’s Health Commission and the representative of 
Romania in the Centre’s Management Board. The Minister of Justice of Sweden visited 
the Centre in April. Under the German Presidency of the Council of the EU, the Director 
attended the meeting of the National Drug Coordinators held in Berlin in May. Following 
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up on from a similar event in 2006, the Director welcomed again at the Centre the diplomatic 
corps in Lisbon on the occasion of the International day against drug abuse and illicit 
trafficking – 26 June. In August the Director met the Vice-President of the Slovakian Statistical 
Office. Moreover, in September the Director welcomed at the Centre the Italian ambassador 
in Portugal. On 25 October the Dutch National Drug Coordinator paid a visit to the Centre. 
In November, the Director participated in two national launches of the 2007 Annual report. 
The first was in Germany on 27 November, where together with the drug commissioner he 
participated in the press conference on the occasion of the launch of the German report on 
the drug situation. The second was in Poland, where on 29 November he gave a speech 
during the national launch scheduled at the National HIV and AIDS conference in Warsaw.
In 2007 the Director welcomed at the EMCDDA the Lisbon based ambassadors of Germany 
and Sweden. In February, the Director welcomed the General Director for Drug Addiction of 
the Region of Valencia (Spain).
Other organisations and bodies 
A key event in this context was the signature of a Memorandum of Understanding with the 
World Customs Organization (WCO) in January. In March the Director met with the Executive 
Director of the UNODC, at which a new joint work programme between the EMCDDA and 
UNODC was agreed upon. A meeting with the Secretary General of Interpol took place in 
Lyon in February. The EMCDDA was also visited in March by the Head of the Secretariat 
of the Pompidou Group of the Council of Europe. The Director took part in the ceremony of 
the signature of an agreement with MAOC-N (Centre to coordinate actions to prevent the 
maritime trafficking of cocaine) in Lisbon in September. On invitation from the Presidency of 
the Pompidou Group, the Director attended the Pompidou Inter-agency meeting in Warsaw 
held in November.
Non-Community countries 
In 2007 the Director welcomed at the EMCDDA several Lisbon-based ambassadors of the 
following countries: Cape Verde, Croatia, Ukraine and Russia. In May, the Director received 
a visit from the Vice-Minister for European Affairs of Venezuela. The Vice Minister was 
accompanied by Venezuela’s Ambassador to Portugal. A representative of the Swiss Embassy 
visited the Centre in January. Further to an invitation from the Hong Kong’s Commissioner for 
Narcotics, the Director visited Hong Kong in late January and early February.
In March the Director met in Brussels representatives of the Russian mission to the EU. In 
October, the Director signed a Memorandum of Understanding with the Federal Drug Control 
Service of the Russian Federation. The FDCS Director signatory was Mr Viktor Cherkesov. The 
signature took place in Mafra on the occasion of the EU-Russia summit. During the second 
half of the year, the Director welcomed in October a delegation from the American JIATF 
(Joint Interagency Task Force).
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Scientific Committee
Activities and results
The EMCDDA’s Scientific Committee has three major tasks: (i) to be consulted by the 
Director on three-year work programmes, annual work programmes and adjustments of 
work programmes; (ii) to provide opinions on any scientific matter concerning the Centre’s 
activity, which the Management Board or the Director may submit to it; (iii)  to assist in risk 
assessment of new psychoactive substances.
2007 was a particularly eventful year for the Scientific Committee (SC) as it involved 
both continuing and completing activities under the previous Scientific Committee, and the 
transition to a new organisational set-up under the new EMCDDA regulation. 
Meetings and main 2007 tasks
The Scientific Committee in its ‘old’ composition — that is, comprising one representative from 
each EU Member State and Norway — held two meetings during 2007, in May/June and 
November, under the chairmanship of Professor Henk Garretsen (NL). At the May meeting, 
two SC members presented the Cochrane Collaboration and its Drugs and Alcohol Review 
Group. The Committee debated how to bridge the gap between basic research and clinical 
work, and how to translate evidence into practice. Close cooperation with the Cochrane 
Collaboration is of particular value for the EMCDDA’s best practice portal. The May meeting 
also discussed research funding in Europe. Debate included: a ‘European NIDA’ (37), an idea 
raised by the Director of the UNODC and discussed in the Horizontal Drugs Group and other 
forums; EU drug research funding within the 7th EU framework programme for research; the 
importance of lobbying for EU funding for drug research.
Opinions
An SC opinion entitled 'Drug-related deaths — Comment on comparability' was submitted to 
the Management Board. The opinion reported progress in improving data quality in many 
EU countries, and that the available data on drug-related deaths genuinely reflect underlying 
phenomena. However, it also emphasised that strong conclusions should not be drawn based 
on small differences, and that conclusions are stronger when supported by other indicators.
Members of the Scientific Committee provided comments on the Annual report and Selected 
issues. In addition, individual tasks were undertaken such as peer reviews of EMCDDA 
publications (cannabis monograph), participation in expert groups (ESPAD, prevalence data 
for TDI, the EDDRA and best practice portal projects) and lectures given to EMCDDA staff 
(e.g. Fernando Rodríguez Fonseca’s lecture on The cooperative Spanish network on drug 
addiction research).
In its opinion on the 2008 EMCDDA Work programme, the SC praised the Centre’s 
development into a centre of excellence for drug information in Europe. However, it also 
warned that prioritisation of the Centre’s tasks would be required if supplementary resources 
were not provided, cautioning against an indefinite broadening of the Centre’s scope based 
on existing resources. The opinion also underlined that NFPs require ongoing nurturing 
(37) NIDA, The United States National Institute on Drug Abuse, is a United States federal 
which (i) supports research across a broad range of disciplines linked to drugs and (ii) 
disseminates the results of this research to improve prevention, treatment and policy. NIDA 
has an annual budget of over USD 1 billion.
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and support to deliver high quality input to the Centre, and that new demands on their 
time must be carefully balanced against existing requirements. The opinion also called for 
more extensive and innovative use of key indicator data, together with a move towards 
cross-analysis of data, best practice and evidence-based intervention guidelines. Promoting 
best practices may be best developed through the identification of examples of innovation, 
together with the promotion and dissemination of such new, evidence-based interventions.
Prof. Henk Garretsen participated in the steering committee supporting the external evaluation 
of the EMCDDA. An important remark by the evaluators was made on the ‘under-usage’ of 
the Scientific Committee and the Committee hoped this situation would change in the future. 
In its last formal opinion on an EMCDDA work programme by the Scientific Committee in its 
present composition, the SC looked back at considerable scientific progress in the Centre’s 
work and output in recent years. The growing interest in drug-related research in Europe, as 
mirrored by activities of the European Commission and the Horizontal Drugs Group, together 
with the enhanced scientific excellence of the EMCDDA, would promise a bright future for 
science-based policies and practices in the EU.
Risk assessment on BZP and risk assessment guidelines
A meeting of the extended SC was held in May, to assess the risks of BZP. The SC’s opinions 
were reflected in the Risk Assessment Report on BZP, which was submitted to the Commission 
and the Council. The overall conclusion of the Committee was that due to its stimulant 
properties, risk to health and the lack of medical benefits, there is a need to control BZP. 
However, the Committee felt that the control measures should be appropriate to the relatively 
low risks of the substance.
The Centre’s Risk Assessment Guidelines (RAG) on new synthetic drugs had been in place 
since 1999, and a revision was initiated in 2007 to reflect the changes introduced by 
Council Decision 2005/387/JHA (which replaced the 1997 Joint Action). The RAG were 
adapted, in particular to widen the scope of actions vis-à-vis new drugs, for example a 
decision to monitor all new psychoactive substances, natural and synthetic alike. Two main 
concepts were introduced into the new RAG: a numerical scoring system, and the use of 
the Delphi method to exploit expert knowledge. The ‘old’ SC therefore prepared a RAG 
document with the aim of informing its successor in their future work.
The selection of a new Scientific Committee
The recast regulation of the EMCDDA introduced new rules for the composition of the 
EMCDDA Scientific Committee and the appointment of its members: ‘The Scientific Committee 
shall consist of at most fifteen well-known scientists appointed in view of their scientific 
excellence and their independence by the Management Board, following the publication of a 
call for expressions of interest in the Official Journal of the European Union'.
The Management Board decided in December 2006 to set up a working group for the 
appointment of the members of the EMCDDA Scientific Committee. This working group 
comprised two members of the EMCDDA Management Board, two members of the current 
EMCDDA SC, who would not stand for another term, the EMCDDA Director, acting as 
chairman, and two representatives of the EMCDDA senior staff. The working group drafted 
rules for procedures and arrangements for the selection and appointment of the members of 
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the Scientific Committee of the EMCDDA, partly based on documents and experiences 
from other European agencies and the European Commission.
At its July 2007 meeting, the Centre’s Management Board adopted the procedures for 
appointment of the members of the new Scientific Committee. The three phases of the 
selection foreseen were carried out in the second half of 2007. A call for expressions 
of interest for membership in the EMCDDA Scientific Committee was published in the 
Official Journal of the European Union and on the EMCDDA website in September, with 
a deadline for applications in mid-October. Applicants could apply for one or several 
areas of expertise:
– Epidemiology  
– Best practice and interventions  
– Political and institutional framework  
– Legal and criminal justice issues  
– Economic issues  
– Methodological issues  
– Risk assessment of psychoactive substances and basic research 
In total, 108 applications were received from 76 candidates. Five applications from four 
candidates were not eligible, i.e. a total of 103 eligible applications from 72 candidates 
from 22 EU Member States and Norway. A pre-selection committee, chaired by the 
EMCDDA Director and consisting of two former chairpersons of the Scientific Committee 
and two EMCDDA senior scientists, carried out a first evaluation of candidates in 
November. Based on the results of the pre-selection committee, the Executive Committee 
established a shortlist of 15 researchers from 11 EU Member States and one scientist 
from Norway, as an observer, selected for scientific excellence and independence, and 
a reserve list of 15 names.
At its December 2007 meeting, the Management Board adopted the proposed list of 
members to the 'new' Scientific Committee, appointing the members for a three-year 
period. It also adopted the proposed reserve list, in case of replacement of an outgoing 
member during this period.
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1 (38) http://eur-lex.europa.eu/smartapi/cgi/sga_doc?smartapi!celexapi!prod!CELEXnumdoc&lg=EN&numdoc=32002R2343&model=guichett 
Chapter 1 
Characteristics and nature of the EMCDDA 
management, internal and external control systems 
In accordance with the financial regulation applicable to the EMCDDA, which transposes 
integrally the text of the Framework financial regulation 2343/2002 (38), the EMCDDA 
has set its internal procedures for budget execution and internal control, while defining 
and implementing a partially decentralised management model.  As a consequence both 
operational and financial decisions required for the implementation of the EMCDDA work 
programme and budget have been decentralised by delegation to the heads of the unit on 
which the EMCDDA's activities and working organisation relies. 
The administrative unit provides the support to operational managers for financial 
management and to ensure internal planning and monitoring, as well as the ex ante 
verification of transactions. These procedures have been codified and all the heads of 
unit/deputy authorising officers have received specific training and information on their 
role, duties and liability, in accordance with the relevant provisions of the financial and staff 
regulations.
The key actors and steps of the EMCDDA procedures for budget execution can be 
summarised as follows:
• Project manager: initiation and operational input for the administrative and financial 
operations required to implement projects (technical specifications for tendering procedures, 
cost estimate, 'certified correct' sign-off for payments)  
• Financial management team, financial helpdesk: preparation of the required 
administrative and contracting supporting documents with the input of the concerned Project 
manager. 
• Planning and evaluation team: checking of compliance with the adopted work programme 
and budget. 
• Financial management team, Si2 initiating officers: operations in the EMCDDA Si2 
electronic management and accounting system, to prepare the decision of the authorising 
officer.  
• Financial management team, verifying officer: ex ante verification 
• Head of unit: authorisation of the required budgetary and legal operations, acting as 
deputy authorising officer by delegation (from the Director, as EMCDDA authorising officer), 
for the execution of the concerned programme, within the limits of the appropriations 
earmarked for this execution under the adopted EMCDDA annual budget. 
• Accountant: execution of the required financial transactions.
These procedures are consistent with the EMCDDA project-based working methods, which 
aim to integrate activities and resources management in accordance with ABM/ABB 
accounting principles. In this context, the Centre has established procedures for planning, 
monitoring and reporting, with a clear indication of the actors involved, their role and 
responsibilities. 
Following the adoption by the EMCDDA Management Board in January 2003 of the new 
'Operating framework for the Reitox system', a new grant agreement model has been 
introduced for the annual co-financing of the activities of the Reitox national focal points, 
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Key features of the EMCDDA’s partially decentralised management model
Actors/level of operations Role/operations
Decentralised level (operational and 
technical units)
Operational initiative/input and operational and financial decisions by 
delegation in order to implement the work programme (WP) and budget
Central level (Directorate and 
administrative units)
Coordination and management of executive planning, monitoring, 
reporting and assessment of the implementation of the WP and budget
Administrative and financial support, management and control of 
implementation
 
Key features of the process for the execution of the EMCDDA work programme and budget
Level of operations Actors Role/operations
Decentralised level 
(operational and technical 
units)
Concerned project manager 
and Head of unit
Initiative and operational input for the operations required 
to implement projects
Central level (administrative 
unit)
Planning and evaluation 
team
Check compliance of operations with adopted WP and 
budget plan. Budgetary appropriations to be committed 
are set aside
Human resources 
management team
Define rights and check compliance with staff regulations 
for missions and staff-related expenditure
Financial management 
team
Prepare the required administrative and legal supporting 
documents and control compliance with applicable 
regulations. Process and control the required SI2 
operations
Decentralised level 
(operational and technical 
units)
Head of unit/deputy 
authorising officer
Authorise budgetary and legal commitments and 
payments (and recovery orders)
Central level (administrative 
unit)
Accountant Execute and record financial transactions
which fully complies with the relevant provisions of new financial regulation applicable to the EMCDDA. This agreement 
requires that an external annual audit be carried out by an independent body or expert officially authorised to carry out 
audits of accounts, in order to certify that: (i) the financial documents submitted to the EMCDDA by the beneficiary comply 
with the financial provisions of the agreement; (ii) the costs declared are the actual costs; and (iii) that all receipts have been 
declared. 
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Key external control mechanisms on the EMCDDA's management 
 
Body Actors and processes Role/operations
Management Board Representatives of 
all Member States, 
plus the European 
Commission and 
European Parliament  
Meetings: twice a year
- Decisions on work programmes, budgets, general reports of 
activity 
- Election of Director
Management Board 
Executive Committee
Members of four 
Member States, 
plus the European 
Commission 
Meetings: four times a 
year
- Detailed examination of budgetary, financial and work 
programme issues 
- Preparation of Management Board decisions
European Parliament LIBE Committee - Presentation of work programmes, general reports of 
activities and annual report 
- Auditis of Director and Chairman as requested 
- Opinion on the draft annual budget 
- Approval of the establishment plan (once a year) 
- Discharge of agency's activities (once a year)
COBU - Hearing of agency directors before preparing decision 
(through Plenary) on annual budget
COCOBU - Hearing of agency directors before preparing decision 
(through Plenary) on discharge for execution of annual budget
European 
Commission 
DG JLS 
DG Sanco 
Internal Audit Service 
EPSO 
- Preparation of all policy decisions regarding the agency 
- Decision on budget proposal for budget authority 
- Opinions on work programmes, administrative and 
financial issues 
- Opinion on staff policy plan (once a year) 
- Agreement by the EC on implementing rules to Staff 
Regulations (for each rule) 
- Regular audits through the Commission's Internal Audit DG, 
external evaluation (every 6-years) 
- Decision on shortlist for election of Director 
- Internal Audit Service (once a year) 
- EPSO: validation of recruitment procedures
Other EU bodies European Court of 
Auditors 
European Data 
Protection Supervisor 
Civil Service Tribunal – 
Court of First Instance, 
European Court of 
Justice 
OLAF
European Court of Auditors 
- Two annual on-site control visits per year 
- Audit for specific projects (e.g. PHARE, CARDS) 
European Data Protection Supervisor: 
- Regulation 45/2001 compliance: action by prior 
notification and upon complaint 
Civil Service Tribunal: 
- Action upon complaint 
OLAF (European Anti-Fraud Office OLAF) 
- Action upon complaint
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Assessment and improvement of management and 
internal control systems
The following measures were taken in 2007 by the EMCDDA in order to improve its 
management and internal control systems, and to follow up on the observations and 
recommendations expressed by the European Court of Auditors and the EU Budget Authority 
within the framework of the discharge given for the 2006 financial exercise. The measures 
were also the result of the audit of the EMCDDA internal control system carried out by the IAS 
in 2005 and followed up in 2007.
• Tendering and contracting procedures for the execution of the Budget/WP to be launched 
by 1st June at the latest. 
• Budget transfers to be decided by end of July at the latest.
• Exceptionally, and for the reassigned non-used budget, the first week of September shall be 
the final deadline for sending invitations to tender (projects may start in December). 
• Six-month cyclical assessment of the budget execution, with eventual proposals for de-
commitment and/or re-assignment of resources.
• Quick and effective de-commitment and re-assignment of unused appropriations, namely for 
appropriations committed for meetings and missions.
• Improvement of the planning of calls for tenders, to keep emergency cases to a minimum. 
• More structured use of framework contracts and calls for expression of interest.
• A procedure to document and justify exceptions.
• The archiving of the Si2 transactions was reorganised in order to be more efficient and 
effective.
• Internal rules for online purchases via the 'MBNET' payment system were adopted and 
implemented.
• The payment timeframes for missions and meetings were shortened.
Furthermore, 2007 saw some positive results in the management of the Centre's general 
ledger accounts, for example:  
• Better coordination for the management of the assets among infrastructure and logistics, 
financial and accountancy teams (reporting, purchase list, declassification etc.).
• Better result of the VAT not yet recovered from the Portuguese authorities at the end of 2007 
(EUR 54 277 compared with EUR 121 783 in 2006). 
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• A new accounting procedure was put in place in order to record and trace on a daily basis 
all transfers orders to the bank, in order to ensure the better control and follow-up of the flow 
of the monthly payments to be executed by the bank.
• A new administrative procedure was implemented by the financial team in agreement with 
the accountancy team, with a view to ensuring improved follow-up on the management of the 
amounts to be recovered by the EMCDDA (receivables) during the year. 
• A new table of reconciliation was put in place between the Centre's budgetary accounts 
and the general ledger, with a view to controlling on a monthly basis the impact of the 
budget execution in accordance with accrual-based accountancy requirements.
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Declaration of assurance of the authorising officer
I, the undersigned, Director of the European Monitoring Centre for Drugs and Drugs 
Addiction, 
in my capacity as authorising officer: 
• declare that the information contained in this report gives a true and fair view (*).
• state that I have reasonable assurance that the resources assigned to the activities 
described in this report have been used for their intended purpose and in accordance with 
the principles of sound financial management, and that the control procedures put in place 
give the necessary guarantees concerning the legality and regularity of the underlying 
transactions.
This reasonable assurance is based on my own judgment and on the information at my 
disposal, such as the results of the self-assessment, ex post controls, the observations of the 
Internal Audit Service and the lessons learnt from the reports of the Court of Auditors for 
years prior to the year of this declaration.
• confirm that I am not aware of anything not reported here which could harm the interests 
of the Agency and the institutions in general.
Done in Lisbon, on 2 June 2008
(*) True and fair in this context means a reliable, complete and correct view on the state of affairs in the 
service.
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Annex 2 
Breakdown of EMCDDA staff in 2007
EMCDDA staff: contract type, grades, function groups, nationalities, gender
EMCDDA Temporary Agents 
Function Group
Grade AST AD Total
1 1 1
3 9 9
4 5 5
5 1 6 7
6 3 6 9
7 2 2 4
8 2 1 3
9 - 9 9
10 - 2 2
11 - 9 9
12 2 2
13 1 1
15 1 1
Total 23 38 61
EMCDDA Officials
Function Group
Grade AST AD Total
3 1 1
5 1 - 1
6 2 - 2
7 1 - 1
8 - 1 1
10 - 1 1
11 1 4 5
Total 6 6 12
EMCDDA Contract Agents
Function Group Total
I 3
II 10
III 7
Total 20
EMCDDA staff: nationalities
Country Total
BE 10
BG 1
DE 11
DK 1
ES 5
FR 7
GR 2
HU 2
IE 2
IT 6
LU 3
NL 1
PL 2
PT 30
SE 1
SK 1
UK 8
Total 93
EMCDDA staff: gender
Gender Total
Male 44
Female 49
Total 93
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Outputs
Publications
Annual report 2007: the state of the drugs problem in Europe
A yearly overview of the drug phenomenon in Europe.
Available in 23 languages — all EU official languages (except Maltese), plus Turkish and 
Norwegian.
Cat.: TD-AC-07-001-BG/CS/DA/DE/EL/EN/ES/ET/FI/FR/HU/IT/LT/LV/NL/NO/PL/PT/RO/
SK/SL/SV/TR-C
http://www.emcdda.europa.eu/publications/online/ar2007 
Annual report 2007: selected issues
Three in-depth reviews that accompany the report: Drugs and driving, Drug use related problems 
and responses among very young people (under-15s), Cocaine and crack cocaine.
Available in EN.
Cat.: TD-SI-07-001-EN-C, TD-SI-07-002-EN-C, TD-SI-07-003-EN-C
Also available as a website: 
http://www.emcdda.europa.eu/publications/selected-issues
http://www.emcdda.europa.eu/publications/selected-issues/driving
http://www.emcdda.europa.eu/publications/selected-issues/minors 
http://www.emcdda.europa.eu/publications/selected-issues/cocaine 
Statistical bulletin 2007
The epidemiological basis on which the Annual report is written. Over 350 tables and almost 
100 graphics collated by the EMCDDA from the information submitted by the network of Reitox 
national focal points.
Available as a website in EN: 
http://www.emcdda.europa.eu/stats07/main 
Reitox national reports 2006
National reports provide an overall picture of the drug phenomenon at national level in each EU 
Member State. 
General report of activities 2006
A detailed progress report of the EMCDDA’s activities over a 12-month period.
Available in EN:
http://www.emcdda.europa.eu/publications/general-report-of-activities
Drugnet Europe 
The EMCDDA’s newsletter provides regular and succinct information on the Centre’s activities to 
a broad readership.
4 editions (57, 58, 59 and 60) 
Available in EN, also available as a website:
http://www.emcdda.europa.eu/publications/drugnet/
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Drug profiles
Objective and scientifically sound descriptions of controlled drugs. Six published in 2007.
Available as a website in DE, EN and FR.  
Amphetamine, Cannabis, Cocaine and Crack, Heroin, MDMA, Methamphetamine.
http://www.emcdda.europa.eu/html.cfm/index25328EN.html 
Drugs in focus
Policy briefings published in all official EU languages plus Turkish and Norwegian.
http://www.emcdda.europa.eu/publications/drugs-in-focus
Drugs in focus 15: Hallucinogenic mushrooms: the challenge of responding to naturally 
occurring substances in an electronic age 
Cat.: TD-AD-07-001-BG/CS/DA/DE/EN/EL/ES/ET/FI/FR/GA/HU/MT/IT/LT/LV/NL/NO/PL/
PT/RO/SK/SL/SV/TR-C
Drugs in focus 16: Drugs and crime - a complex relationship 
Cat.: TD-AD-07-002-BG/CS/DA/DE/EN/EL/ES/ET/FI/FR/GA/HU/MT/IT/LT/LV/NL/NO/PL/
PT/RO/SK/SL/SV/TR-C
Drugs in focus 16: Cocaine use in Europe: implications for service delivery
Cat.: TD-AD-07-003-BG/CS/DA/DE/EN/EL/ES/ET/FI/FR/GA/HU/MT/IT/LT/LV/NL/NO/PL/
PT/RO/SK/SL/SV/TR-C
EMCDDA manuals
Manuals are practical handbooks aimed at professionals and grassroot practitioners working in 
the drugs field. Available in EN.
http://www.emcdda.europa.eu/publications/manuals 
EMCDDA Manual 3: Guidelines for the evaluation of treatment in the field of problem drug use.
Cat.: TD–76–06–662–EN–C 
EMCDDA literature reviews
Literature reviews aim to compile and summarise current knowledge of a specific issue, for use 
by drugs practitioners.  
Treatment of problem cocaine use: a review of the literature
Cat.: TD-XB-06-001-EN-N 
http://www.emcdda.europa.eu/?nnodeID=18945 
Marketing brochures
Europe in Portugal 
Joint publication on the EU bodies in Portugal, published in the context of the Portuguese 
presidency of the EU. Available in EN and PT.
Cat. no: TD-78-07-317-EN/PT-C 
http://www.emcdda.europa.eu/publications/brochures 
EU Agencies: Whatever you do, we work for you
Joint publication by the EU agencies (contribution by EMCDDA, coordination by ETF). Available 
in EN.
Cat. no: TA-77-07-059-EN-C 
http://www.emcdda.europa.eu/attachements.cfm/att_49172_EN_agenciesFeb08_EN_low.pdf 
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Media products 
News releases 
8 news releases
No 1 – Broader role for EU drugs agency 
New mission statement helps Centre respond to new challenges in drugs field 
(16.1.2007) DE/EN/FR/PT
No 2 – Heads of EU and UN drugs agencies meet in Vienna
EMCDDA and UNODC reinforce partnership and launch treatment demand toolki
(14.3.2007) EN
No 3 – New drug under formal scrutiny 
Council asks EMCDDA to assess risks of BZP
(23.3.2007) DE/EN/FR/PT
No 4 – Responding to ‘magic mushroom’ use in an electronic age
Magic mushroom business presents law-makers with dilemmas
(7.6.2007) DE/EN/FR/PT
No 5 – 26 June: International day against drug abuse and illicit trafficking
EU calls for ‘common language’ to describe drug-related crime
(25.6.2007) DE/EN/FR/PT
No 6 – EU–Russia relations
EU and Russian drugs agencies sign agreement in Mafra
(26.10.2007) DE/EN/FR/PT/RU
No 7 – latest on the drugs problem across Europe
2007 Annual report from the EU drugs agency
BG/ES/CS/DA/DE/ET/EL/EN/FR/IT/LV/LT/HU/NL/PL/PT/RO/SK/SL/FI/SV/TR/NO
No 8 – Annual report 2007: highlights
Positive messages from EU drugs report marred by high levels of drug-related deaths and 
rising cocaine use
(22.11.2007) BG/ES/CS/DA/DE/ET/EL/EN/FR/IT/LV/LT/HU/NL/PL/PT/RO/SK/SL/FI/
SV/TR/NO
Message from Wolfgang Götz, Director of the EMCDDA
(22.11.2007) BG/ES/CS/DA/DE/ET/EL/EN/FR/IT/LV/LT/HU/NL/PL/PT/RO/SK/SL/FI/
SV/TR/NO
Summary – Selected issues
(22.11.2007) BG/ES/CS/DA/DE/ET/EL/EN/FR/IT/LV/LT/HU/NL/PL/PT/RO/SK/SL/FI/
SV/TR/NO
Drugs and driving
Drug use and related problems among very young people
Cocaine and crack cocaine: a growing public health issue 
The 2007 headlines and key facts PowerPoint presentation 
(22.11.2007) BG/ES/CS/DA/DE/ET/EL/EN/FR/IT/LV/LT/HU/NL/PL/PT/RO/SK/SL/FI/
SV/TR/NO 
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Fact sheets 
4 Fact sheets 
Available in EN. 
http://www.emcdda.europa.eu/html.cfm/index45919EN.html 
Fact sheet 1: EMCDDA and WCO step up cooperation in international drug control
(12.1.2007) EMCDDA and ECDC to join forces in tackling drug-related infectious diseases 
Fact sheet 2: Online descriptions of controlled drugs
(29.3.2007) EMCDDA launches ‘drug profiles’
Fact sheet 3: Directors of two EU agencies sign agreement today in Lisbon
(29.6.2007) EMCDDA and ECDC to join forces in tackling drug-related infectious diseases
Fact sheet 4: Towards scientific excellence
(5.12.2007) New Scientific Committee for EU drugs agency
Press reviews
4 quarterly press reviews
1 ad hoc press review for International day against drug abuse and illicit trafficking (26 June)
1 ad hoc press review covering the EU-Russia Summit and MoU signing between EMCDDA and 
FCDS
1 extended press review of the coverage of the Annual report launch (1287 articles)
Websites
EMCDDA public website
The gateway to drug information in Europe. Ongoing updates and content development.
http://www.emcdda.europa.eu 
Country situation summaries
Country situation summaries are available for the EU Member States and Norway as well as 
several countries of the former Soviet Union. They offer a rich pool of national drug data in 
Europe. Their main purpose is to provide brief synopses of up-to-date national data and trends. 
They also include selected links to other national information sources. They are updated once a 
year.
http://profiles.emcdda.europa.eu/
Drug treatment overviews
The ‘Drug treatment overviews’ describe the national drug treatment systems operating in the 25 
EU Member States, Bulgaria, Romania and Norway.
http://www.emcdda.europa.eu/?nnodeid=7613
European legal database on drugs
The European legal database on drugs (ELDD) is the EMCDDA’s online database of information 
on European drugs-related legislation for the EU Member States and Norway. Ongoing updates 
and content development.
http://eldd.emcdda.europa.eu
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Evaluation instruments bank
The EMCDDA’s Evaluation instruments bank (EIB) is a document archive of tools created 
to encourage evaluation using reliable methods, and to help to standardise these tools at 
European level. The Instruments Bank contains tools for evaluating both prevention and treatment 
programmes. Ongoing updates and content development.
http://eib.emcdda.europa.eu
Exchange on drug demand reduction action
The Exchange on drug demand reduction action (EDDRA) is a multilingual online information 
system and data-collection tool on best practice in responding to drug use in the European 
Union. Ongoing updates and content development.
http://www.emcdda.europa.eu/?nnodeid=1580
ELDD legal reports and topic overviews
Topic overview: Legal frameworks of opioid substitution treatment (21/11/2007)
Topic overview: Legal aspects of controlled deliveries (01/12/2007)
Topic overview: Precursor trafficking penalties (01/12/2007)
Legal report: substances and classifications, significant update (20/12/2007)
http://eldd.emcdda.europa.eu/ 
Contributions to the second European Commission progress review of the EU action 
plan (2007)
Thematic papers were submitted to the Commission in June and July 2007. A number of 
thematic papers developed for the first progress review in 2006 were updated for the second 
review.
Thematic paper on objective 1 of the EUAP 2005–2008: ‘National strategies and action plans 
in the field of drugs’ )
Thematic paper on objective 2 of the EUAP 2005–2008: ‘Coordination in the field of drugs’ 
Thematic paper on objective 7 of the EUAP 2005–2008: ‘Coverage and effectiveness of drug 
demand reduction measures’ 
Thematic paper on objective 13.1 of the EUAP 2005–2008: ‘Alternatives to prison for drug 
abusers’
Thematic paper on objective 25.1 of the EUAP 2005–2008: ‘Drug-related crime – progress 
towards a common definition’
Thematic paper on objective 43.2 of the EUAP 2005–2008: ‘HIV/AIDS literature review on 
protective factors’
Updates of 2006 thematic papers
Thematic paper on objective 10 of the EUAP 2005–2008: ‘methods for early detection of risk 
factors and early intervention’ 
Thematic paper on the objective 11 of the EUAP 2005–2008: ‘Ensure the availability of and 
access to targeted and diversified treatment and rehabilitation programmes’ 
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Thematic paper on the objective 15 of the EUAP 2005–2008: ‘Availability and access to harm 
reduction services’
Thematic paper on the objective 17 of the EUAP 2005–2008: ‘Reduction of drug-related deaths’ 
Thematic paper on the objective 16 of the EUAP 2005–2008: ‘Prevention of the spread of HIV/
AIDS, hepatitis C, other blood borne infections and diseases’
Thematic paper on the objective 32 of the EUAP 2005–2008: ‘Provide the necessary technical 
and other assistance to the candidate and stabilisation and association process countries’ 
Thematic paper on the objective 39 of the EUAP 2005–2008: ‘Provide reliable and comparable 
data on the key epidemiological indicators’
Thematic paper on the objective 40.1 of the EUAP 2005–2008: ‘provide reliable information on 
the drug situation’
Thematic paper on objective 41.1 of the EUAP 2005–2008: ‘Identifying emerging trends’ 
Technical reports
Arnaud, S., Zobel, F., Gervason, J-P., Schnotz, D., Dubois Arber, F. with the collaboration of 
Isenring, G-L., Vuille, J., Killias, M. (2007), Monitoring de la problématique du cannabis en 
Suisse: étude sentinelle 2004-2006, Institut Universitaire de Médecine Sociale et Préventive 
(Raisons de santé 127 A), Lausanne.
Backmund, M., Reimers, K., Reimer, J., Krausz, M., Zachoval, R., Gölz, J., Klempova, D., 
Wiessing, L. (2007), Protective factors for HIV infection in IDUs, EMCDDA literature review. Final 
report CT.06.EPI.149.1.0, EMCDDA, Lisbon.
De Ruyver, B., Van Malderen, S., Vander Laenen, F. (2007), 'Study into public expenditures with 
regard to national drug policies: a feasible plan for the national focal points', EMCDDA Internal 
Report.
EMCDDA (2007), International Women’s Day 2007: Drugs and gender, Report on gender 
differences in drug use, EMCDDA, Lisbon.
http://www.emcdda.europa.eu/index.cfm?fuseaction=public.Content&nnodeid=26412&sLangu
ageiso=EN 
EMCDDA (2007), Risk Assessment Report of a new psychoactive substance: 1-benzylpiperazine 
(BZP), in accordance with Article 6 of Council Decision 2005/387/JHA on information 
exchange, risk assessment and control of new psychoactive substances, EMCDDA, Lisbon.
https://ednd-cma.emcdda.europa.eu/assets/upload/Risk_Assessment_Report_BZP.pdf 
EMCDDA (2007), The treatment demand indicator: 2007 annual expert meeting, Minutes of 
annual expert meeting on TDI, September 2007, EMCDDA, Lisbon. 
http://www.emcdda.europa.eu/html.cfm/index35170EN.html 
EMCDDA (2007), The treatment demand indicator: assessment and improvement of data 
coverage, Minutes of working group on treatment demand data coverage EMCDDA, Lisbon. 
http://www.emcdda.europa.eu/html.cfm/index35170EN.html 
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Europol–EMCDDA (2007), Europol-EMCDDA Joint Report on a new psychoactive substance: 
1-benzylpiperazine (BZP) (6645/07 CORDROGUE 17), EMCDDA, Lisbon. 
http://www.emcdda.europa.eu/html.cfm/index16775EN.html 
Europol–EMCDDA (2007), Europol–EMCDDA Joint Report on a new psychoactive 
substance: 1-(3-chlorophenyl)piperazine (mCPP), EMCDDA, Lisbon. 
http://www.emcdda.europa.eu/html.cfm/index16775EN.html 
Europol–EMCDDA Active Monitoring Report on a new psychoactive substance: 1-(3-
chlorophenyl)piperazine (mCPP), EMCDDA, Lisbon. 
http://www.emcdda.europa.eu/html.cfm/index16775EN.html 
Kretzschmar, M., Wiessing, L. (2007), Coordination of a working group to develop 
mathematical and statistical models and analyses of protective factors for HIV infection 
among injecting drug users, Final Report CT.06.EPI.205.1.0, EMCDDA, Lisbon.
Santos, S., Sedefov, R., Vicente, J. (2007), Literature review about the pharmacological 
effects and medical complications with cocaine use, February 2007, EMCDDA, Lisbon.
Scalia Tomba, G., Rossi, C., Taylor, C., Klempova, D., Wiessing, L. (2007), Guidelines for 
estimating the incidence of problem drug use, Final Report CT.06.EPI.150.1.0, EMCDDA, 
Lisbon.
Articles
Articles in journals
Chinet, L., Stéphan, P., Zobel, F., Halfon, O. (2007), ‘Party drug use in techno nights : 
A field survey among French-speaking Swiss attendees’, Pharmacology, Biochemistry & 
Behavior 86, 2007, pp. 284–289.
Costa Storti, C., De Grauwe, P. (2007), 'Globalisation and the price decline of illicit drugs', 
CESifo Working Paper 1990, May 2007.
Griffiths, P., Mracvic, V., Lopez, D., Klempova, D. (2007) ‘Quite a lot of smoke but very 
limited fire – the use of methamphetamine in Europe’, Drugs and Alcohol Review (submitted).
Morgan, O., Vicente, J., Griffiths P., Hickman M. (2007), ‘Trends in overdose deaths from 
drug misuse in Europe: what does the data tell us?’, Editorial, Addiction (submitted).
Prieto, L. (2007), 'Ökonomische Implikationen de Suchttherapie: Die Europäische 
Perspecktive', Suchttherapie 2007:8, pp. 63–66.
Simon, R. and Kraus, L. (2007), 'Validität von cannabisbezogenen Diagnosen in 
Suchtberatungsstellen', Sucht 53 (5), pp. 308–314.
Vicente, J. and Wiessing, L. (2007), 'European Monitoring Centre for Drugs and Drug 
Addiction Annual report 2007: positive assessment of HIV in IDUs though hepatitis C still 
very high', Euro Surveillance 2007, 2(11):E071122.6.  
http://www.eurosurveillance.org/ew/2007/071122.asp#6
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Book chapters and other articles
Ballotta, D. (2007), ‘Posición internacional frente al cannabis’, in Instituto Deusto de 
Drogodependencia (2007) Hablemos del Cannabis, Universidad de Deusto, Bilbao, pp. 45-51.
Balthasar, H., Huissoud, T., Zobel, F., Arnaud, S., Samitca, S., Jeannin, A., Schnoz, D., 
Gervasoni, J-P., Dubois-Arber, F. (2007) ‘Evolution de la consommation et des pratiques à risques 
de transmission du VIH et du VHC chez les consommateurs de drogue par injection en Suisse 
1993-2006’, in Bulletin de l’Office fédéral de la santé publique Suisse, No 45, 2007, pp 804-
809.
Burkhart, G., Benedusi, M., Scorra, M. (2007), 'Finalità ed obiettivi della prevenzione: uno 
sguardo sull’ Europa', in: Marino, V., Serpelloni, G. (eds), Marketing preventivo: appunti per 
una nuova prevenzione al consumo di droghe, ASL Varese, 2007.
Balthasar H., Huissoud T., Zobel F., Arnaud S., Samitca S., Jeannin A., Schnoz D., Gervasoni 
J-P., Dubois-Arber F. (2007) ‘Evolution de la consommation et des pratiques à risques de 
transmission du VIH et du VHC chez les consommateurs de drogue par injection en Suisse 1993-
2006’, Bulletin de l’Office fédéral de la santé publique Suisse, No 45, 2007, pp 804-809.
Griffiths, P. (2007), ‘Foreword’, in Fountain, J. and Korf, D. (eds.) (2007), Drugs in society: 
European perspectives, Radcliffe publishing, Oxford.
Griffiths, P. and Meacham, M. (2007), ‘Global illicit drug trends’, in  Heggenhougen, K. and 
Quah, S. (2008), International encyclopedia of public health, Elsevier Ltd., Amsterdam.
Hedrich, D., 'Entrevista sobre dispositivos consumo assistido em Europa', Revista Dependências, 
March 2007.
UNODC (2007), UNODC Global Assessment programme on Drug Abuse (GAP), Toolkit 
Module 8, Guidance for the measurment of drug treatment demand*, New York (*main editor: 
Michael Donmall; editorial board: Stefano Berterame, Michael Donmall, Riku Lehtovuori, Linda 
Montanari). 
http://www.emcdda.europa.eu/html.cfm/index26895EN.html
Published abstracts and oral presentations at scientific conferences and meetings
Ballotta, D., ‘The drug situation in the EU’, Troika meeting with Ukraine, EU-Troika, Brussels, 1 
June 2007.
Ballotta D., ‘The drug situation in the EU’, Informal Dialogue with ECOWAS, EU-Troika, Brussels, 
6 September 2007.
Ballotta, D., ‘The situation of drug users in EU prisons’, Horizontal Working Party on Drugs, 
Brussels, 10 October 2007.
Ballotta, D., ‘The state of the drugs phenomenon in the EU’ EMCDDA Presentation of the Annual 
Report, Rome, 27 November 2007.
Ballotta, D., ‘The evaluation of the EU drug strategy and action plan on drugs’ Rome, 13 July 
2007.
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Ballotta, D., ‘Preventing distribution of drugs at street level’, Horizontal Working Party on Drugs, 
Brussels, 11 December 2007.
Ballotta, D., ‘ The drug situation in the EU’, Troika meeting with Pakistan, EU-Troika, Brussels, 12 
December 2007.
Burkhart, G., 'Prevenzione in Europa', Viterbo, 26 January 2007.
Burkhart, G., '(Re-)orientaciones en prevención comunitaria en la Unión Europea, and 
'Programación, calidad y evaluación en la prevención', Medina Sidonia, 12–14 February 
2007.
Burkhart, G., 'Prevención comunitaria en la Unión Europea', St. Boi del Llobregat, 28 February 
2007. 
Burkhart, G., 'Selective prevention in the European Union', Society for prevention research: 
annual meeting, Washington, 29 May–1 June 2007.
Burkhart, G., 'Overview on school-based drug prevention of in Europe', ICAA conference, 
Stockholm, 10–13 June 2007.
Burkhart, G., 'Prevenzione nelle scuole in Europa', National Prevention Conference, Padova 
28–30 June 2007.
Burkhart, G., 'Problemi etici della prevenzione in Europa', Seminar on mass media campaigns 
evaluation at the Ministry of Health, Rome, 19 September 2007.
Burkhart, G., 'The state of drug prevention in the European Union – connecting to families', 
Pompidou Group Conference on 'Families, lifestyles and drugs - reaching families in prevention', 
Porto, 19–20 November 2007. 
Burkhart, G., 'Early intervention, selective and indicated prevention', National conference on 
early intervention and Annual Report launch, Vilnius, 22 November 2007.
 
Burkhart, G., 'Prevention, its evaluation and science-base in the European Union', National 
Prevention Conference, Prague, 26–27 November 2007.
Burkhart, G., 'Environmental strategies in Europe', IREFREA conference on nightlife prevention, 
Coimbra, 6 December 2007. 
Carpentier, C., ‘Monitoring retail drug prices in the European Union’, Seminar ‘How science 
speaks to drug policy’ organised by the UNODC, 3–6 November 2007.
Griffiths, P., ‘Review of the European data and approach to data collection’, Expert consultation 
on the ‘Ten-year review of the implementation of the declarations and measures adopted by the 
General Assembly at its twentieth special session on the world drug problem (UNGASS 1998)’, 
Vienna, 6–8 February 2007.
Griffiths, P., ‘Synthetic drug use in the European Union: an overview’, Europe - Asia cooperation 
on synthetic drugs and their precursors, organised by the ‘Service de Coopération Technique 
International de Police’ in collaboration with the ‘Ministère des Affaires Etrangères’, Paris, 6–7 
March 2007.
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Griffiths, P., ‘Overview of  cannabis use in Europe’, 1st Reitox Academy 2007: Cannabis – new 
developments in prevention and treatment, Berlin, 29–30 March 2007.
Griffiths, P., ‘Monitoring and reporting on drug use in Europe: an overview of the work of the 
EMCDDA’, International Research Symposium, Monitoring alcohol and other drug related harm: 
building systems to support better policy, Vancouver Island, 8–10 May 2007.
Griffiths, P., ‘Cannabis – the current situation in Europe’, EU National Drug Coordinators 
Meeting, Berlin, 14–15 May 2007.
Griffiths, P., ‘Trends in substance dependence in Europe: Epidemiology, Policy, Treatment issues’, 
European Association of Addiction Therapy Conference 2007, Vienna, 10–12 September 2007.
Griffiths, P., ‘Update on the European situation’, Second expert consultation on the ‘Ten-year 
review of the implementation of the declarations and measures adopted by the General 
Assembly at its twentieth special session on the world drug problem (UNGASS 1998)’, Vienna, 
18–20 September 2007.
Griffiths, P., ‘2006 Annual Report on the state of the drugs problem in Europe’, Launch 2006 
EMCDDDA Annual Report, Brussels, 21–22 November 2007.
Griffiths, P., Simon, R., 'Relatório anual 2007 sobre a evolução do fenómeno da droga na 
Europa', Presentation of the 2007 Annual Report to the Portugese Parliament, Lisbon, 27 
November 2007.
Griffiths, P., ‘An overview of the EMCDDA', European Medicines Agency (EMEA), London, 18 
December 2007.
Hedrich, D., Pirona, A. and Wiessing, L., ‘From margin to mainstream: the evolution of harm 
reduction responses to problem drug use in Europe', 33rd Annual Alcohol Epidemiology 
Symposium of the Kettil Bruun Society, Budapest, 4-8 June 2007.
Hedrich, D., ‘Harm Reduction in the European Union – Follow-up to the Council Recommendation 
on the prevention and reduction of health-related harm’, Paper presented at the 18th 
International Conference on the Reduction of Drug-related Harm, Warsaw, 13–17 May 2007. 
Hillebrand, J., ‘Improving treatment standards across Europe‘, Conference of the European 
Federation of Therapeutic Communities, Ljubljana, 7–9 June 2007.
Hillebrand, J., ‘Evidence-based practices- concepts and EMCDDA initiatives‘, XX Encontro das 
Taipas, V Congresso International, Lisbon, 1 June 2007
Hillebrand, J., ‘Improving treatment standards across Europe. Status quo and challenges‘,  
Conference on 'Rehabilitation of Drug Addicted Persons: Experience of Lithuania and European 
Countries', Vilnius, 18 October 2007.
Hillebrand, J., ‘Evidence-based practices- background and concepts‘, Reitox Academy on best 
practices, Oslo, 12–13 September 2007.
Hillebrand, J., ‘Evaluation–concepts and practice‘, Workshop for main multipliers in Latvia on 
evaluation, Riga, 16–17 October 2007.
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Hughes, B., 'Overview of laws and practices of EU states concerning personal consumption of 
drugs', Workshop: challenges in investigation and adjudication of drug-related offences, Kiev, 
18 June 2007.
Hughes, B., 'A comparison of drugged-driving laws and their roadside enforcement procedures 
across the EU and Norway', T2007 Joint international meeting of ICADTS/ TIAFT/ IIS, Seattle, 
26–30 August 2007.
Hughes, B., 'Treatment alternatives to prison/punishment; overview of existing mechanisms 
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Key meetings, visits, participation in conferences and technical meetings 
Participation in external scientific conferences and meetings + internal meetings (KI expert 
meetings, other experts meetings)
 
Date Venue Title Participants EMCDDA 
programme, 
where 
relevant
Director's office, institutional bodies and high-level meetings
12 January Lisbon Political Steering Committee for new 
building 
Portuguese 
authorities, 
EMSA
ADM
12 January Lisbon Signature of MoU between WCO and 
EMCDDA
EMCDDA 
staff
EPI, Crime 
and supply
16 January Lisbon Visit of Ambassador of Croatia in Portugal EMCDDA 
staff
17 January Lisbon Visit from Swiss Embassy in Portugal EMCDDA 
staff
22 January Lisbon Visit to the Jacques Delors European 
Information Centre
Portuguese 
EU bodies
EU relations
23 January Lisbon Seat agreement, Portuguese Director of 
Customs
Portuguese 
authorities
ADM
24 January Lisbon Visit from Health Committee, Portuguese 
Parliament
EMCDDA 
staff
EPI
26 January Lisbon International customs day session at 
Portuguese customs 
EMCDDA 
staff
International 
relations
28 
January–3 
February
Hong Kong Visit to Hong Kong, invited by Narcotics 
Division Government Secretariats, Hong 
Kong.
Director International 
relations
29 January Maastricht European Institute of Public Administration: 
seminar on EU agencies
EMCDDA 
staff, EU 
agencies
ADM
29 January Brussels Heads of EU agencies meeting EU agencies ADM
8–9 
February
Lisbon Visit from Centre for Strategy and Evaluation 
Services, in relation to evaluation of the 
Centre
EMCDDA 
staff
ADM
9 February Lisbon National day of Iran, Iranian Embassy EMCDDA 
staff
13 
February
Lyon Visit to the Secretary General of Interpol Police RES, Crime 
and supply
15 
February
Lisbon Visit of Ukrainian Ambassador in Portugal EMCDDA 
staff
16 
February
Lisbon Visit of Croatian Ambassador in Portugal EMCDDA 
staff
27–28 
February 
Lisbon Visit of General Director of Drug Addiction, 
Region of Valencia (Spain)
EMCDDA 
staff
EPI, RES
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6 March Lisbon Visit of Director of the Criminal Police of 
Portugal (Policia Judiciária)
EMCDDA 
staff
RES, Crime 
and supply
7–9 March Bucharest Meetings with Romanian Government Director, 
Chairman
EPI, RES
14 March Vienna Meeting with UNODC Director Policymakers EPI, RES
22 March Lisbon Visit of Russian Ambassador in Portugal EMCDDA 
staff
25 March Lisbon Concert to commemorate the 50th 
Anniversary of the Treaty of Rome
EMCDDA 
staff
26 March Lisbon Visit of Head of the Secretariat of the 
Pompidou Group
EMCDDA 
staff
27–29 
March
Brussels Various meetings with European Commission Policymakers ADM
28 March Brussels Ingeborg Gräßle, MEP, member of 
the Budget and the Budgetary Control 
Committees
Policymakers ADM
2–3 April Lisbon Visit from Centre for Strategy and Evaluation 
Services, in relation to evaluation of the 
Centre
EMCDDA 
staff
ADM
30 April Lisbon Visit of Minister of Justice from Sweden EMCDDA 
staff
2 May Lisbon Conference about Europe: Portuguese 
Parliament
Director, 
EMCDDA 
staff
2–8 May Lisbon Visit of the European Court of Auditors Court of 
Auditors
ADM
7 May Lisbon Visit of Ambassador of Cape Verde in 
Portugal
EMCDDA 
staff
9 May Lisbon Commemoration of Europe Day Director, 
EMCDDA 
staff
10 May Lisbon Visit of Vice-Minister for European Affairs of 
Venezuela
EMCDDA 
staff
10 May Lisbon Executive committee and Budget committee EMCDDA 
staff, 
Management 
Board
ADM
11 May London Annual meeting of EU agencies’ internal 
audit/quality management staff
EMCDDA 
staff, EU 
agencies
ADM
14–15 
May
Berlin EU National Drugs Coordinators Meeting Policymakers EPI, RES
14–15 
May
Lisbon Visit of Chief Police Officers, North Wales EMCDDA 
staff
29 May Lisbon Visit of ECDC, Infectious diseases expert EMCDDA 
staff
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30 May Lisbon Visit of national antidrug agency, Romania EMCDDA 
staff
EPI, RES
31 May Lisbon Portuguese President's banquet on the 
occasion of the visit of Lithuanian President
Portuguese 
authorities
31 May–1 
June
Lisbon Scientific Committee Meeting Scientific 
Committee, 
EMCDDA 
staff
2 June Lisbon 20th Anniversary of Centro das Taipas (IDT 
treatment centre)
Portuguese 
authorities
RES
4 June Brussels Presentation of General report of activities 
2006, 2007 Work programme to the LIBE 
Committee of European Parliament
Policymakers ADM, EU 
institutional 
relations
9–10 June Lisbon Portuguese National Day Ceremony Director, 
Portuguese 
authorities
11 June Brussels Annual meeting of Heads of agencies 
network, and Budget Committee of the EU 
agencies
Director, EUI 
agencies
12 June Brussels Meeting with Manfred Weber, MEP and 
Member of Committee of Civil Liberties, 
Justice and Home Affairs
Policymakers
14 June Lisbon Visit of the European Parliament Committee 
on Budgets (COBU)
Policymakers
21 June Lisbon Visit of German Ambassador in Portugal EMCDDA 
staff
21 June Lisbon Dianova network and cooperation meeting EMCDDA 
staff
19 July Lisbon Meeting with Advisor on Crime Prevention to 
the JLS Director General
EU institution
21 
September
Lisbon Visit of Madrid-based customs liaison 
officers of Norwegian Embassy and Belgian 
Embassy 
EMCDDA 
staff
21 
September
Lisbon Visit of Ukrainian Embassy in Lisbon EMCDDA 
staff
26 
September
Lisbon Visit of Ambassador of Italy in Portugal EMCDDA 
staff
1 October Lisbon Visit of Joint Interagency Task Force EMCDDA 
staff
30 
September
Lisbon Signature ceremony of MAOC-N agreement Policymakers, 
police, navies
2 October Cologne EU agencies' troika meeting EU agencies
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3 October Luxembourg Visit to Eurostat EU institution
3 October Lisbon Universidade Lusíada honorary doctorate 
ceremony: Giscard’Estaing
EMCDDA 
staff, 
Portuguese 
authorities
8 October Lisbon Visit of Ambassador of Finland in Portugal EMCDDA 
staff
11–12 
October
Dublin Agencies’ meeting on network buidling and 
data collection, Eurofound 
EMCDDA 
staff
16 
October
Brussels Internal audit service conference 'What 
assurance to expect from internal audit? 
From piecemeal audits towards an overall 
audit opinion' 
EMCDDA 
staff, EU 
agencies
17 
October
Brussels Meeting of agencies’ Internal Audit 
Capabilities, Internal Audit Service
EMCDDA 
staff, EU 
agencies
23 
October
Lisbon Budget Committee, Lisbon Management 
Board
24 
October
Lisbon EU National drugs coordinators' meeting Policymakers
25 
October
Lisbon Visit of Belgian Foreign Affairs Ministry EMCDDA 
staff
25 
October
Lisbon Visit of Dutch National Drugs Coordinator Policymaker
26 
October
Mafra Signing of MoU with Russian Federal Drugs 
Control Service
Director
26 
October
Lisbon Visit of delegation from Slovenia EMCDDA 
staff
31 
October
Lisbon Visit of Eurojust Director EU institution
5 
November
Lisbon Executive Committee Management 
Board
12 
Novembet
Lisbon Meeting with diplomatic adviser of 
Portuguese Prime Minister
Portuguese 
authorities
15 
November
Lisbon Meeting with Portuguese Cabinet of 
Secretary of State for European Affairs
Portuguese 
authorities
16 
November
Lisbon Visit of International Crisis Group EMCDDA 
staff
21 
November
Brussels From safe food to healthy diets: EU risk 
assessment past present and future
EMCDDA 
staff, EU 
agencies
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21–22 
November
Brussels Presentation of the Annual report Policymakers, 
media
26–27 
November
Lisbon 27th Scientific Committee Meeting Scientific 
Committee
28–30 
November
Lisbon Visit of Ukraine drugs monitoring centre EMCDDA 
staff
28–29 
November
Warsaw Pompidou Group Interagency meeting Policymakers
4–7 
December
Lisbon Meeting of the Management Board Management 
Board
7 
December
Lisbon EU-Africa summit meeting, Portuguese 
Presidency
EMCDDA 
staff
17 
December
Lisbon Visit of Ambassador of Sweden EMCDDA 
staff
Drug policy, law and international relations
11 January Brussels Horizontal Working Party on Drugs Policymakers
12 January Brussels EU Troika Policymakers
18 January Brussels Methodological study: impact of the EU 
action plan on drugs
Policymakers
22 January Brussels Evaluation meeting of 'progress report' on 
EU action plan
Policymakers National & 
community 
strategies
25–26 
January
Amsterdam United States/Netherlands thematic 
workshops and planning meeting on 
evidence-based information in addiction and 
mental health
Experts EPI
25 January Bristol Advisory Council of Drugs (ACMD) 
Prevention, Working Group on the 
prevention of Hepatitis C
Policymakers
29 January Brussels EU Troika, Afghanistan Policymakers
6–8 
February
Vienna Ten-year review of the implementation of the 
declarations and measures adopted by the 
General Assembly at its 20th Special session 
on the world drug problem (UNGASS 1998)
Policymakers National & 
community 
strategies
9 February Paris Collège Scientifique de l'OFDT Policymakers, 
experts
National & 
community 
strategies
11–12 
February
Brussels EU Troika Policymakers
12–14  
February
Brussels Horizontal Working Party on Drugs Policymakers
13–15 
February
Paris Latin America/Asia conference on 
universities and drug use/abuse, Federation 
of Catholic Universities
Policymakers, 
professionals
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15–17 
January 
Strasbourg 6th meeting of the expert forum for criminal 
justice
Policymakers, 
experts
Drugs 
legislation
22–23 
February
Berlin ECHIM (European Community Health 
Indicators) 4th core group meeting
Policymakers EPI
22 
February
Strasbourg 59th meeting of Permanent Correspondents 
of the Pompidou Group
Policymakers
26 
February–
2 March
Brussels 26th session of the WCO enforcement 
committee
Policymakers, 
professionals
28 
February–
1 March
Paris Pompidou Group ethics platform Policymakers
1–2 March Brussels Horizontal Working Party on Drugs and GID Policymakers
6–7 March Paris Service de coopération technique 
international de police: Europe/Asia 
cooperation on synthetic drugs and their 
precursors
Policymakers, 
police
13–17 
March
Vienna 50th Session of the United Nations 
Commission on Narcotic Drugs (CND)
Policymakers
22–23 
March
Oslo First annual conference of the International 
Society for the Study of Drug Policy
Policymakers, 
researchers
EPI
23 March Brussels DG research: social platform on cities and 
social cohesion
Policymakers
2–3 April Brussels First meeting of the DG JLS Expert group 
on the policy needs of data on crime and 
criminal justice
Policymakers, 
experts
Crime and 
supply
16–17 
April
Brussels DG Sanco coordination group: drugs policy 
and harm reduction
Policymakers Best practices
16–17 
April
Paris Pompidou Group: 5th meeting of the 
Research Platform
Policymakers, 
researchers
17–19 
April
Brussels Horizontal Working Party on Drugs, EU 
Troika (Western Balkans, EU/LAC Technical 
Committee)
Policymakers
18 April Rome National meeting: 'Research on drugs and 
addiction: which priorities? Which roles for 
institutions and services?'
Policymakers
23–25 
April
Bern Pompidou Group: Annual meeting of the 
co-operation group of drug control services 
at European airports and session devoted to 
general aviation
Policymakers, 
experts
Crime and 
supply
25–26 
April
Luxembourg 8th HIV/AIDS Think Tank meeting Policymakers, 
experts
DRID
27 April Luxembourg DG Sanco C, EMCDDA, ESTAT meeting Policymakers
2–4 May Washington 41st regular session of CICAD Policymakers
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7–10 May Vienna UNODC global workshop on 'drug abuse 
information systems: assessing progress and 
outlining future directions'
Policymakers, 
experts
EPI
7–10 May Vancouver International symposium: monitoring alcohol 
and other drug-related harm, Centre for 
Addictions Research of British Columbia
Policymakers, 
experts
EPI
13–15 
May
Vienna 50th Session of the United Nations 
Commission on Narcotic Drugs (CND)
Policymakers EPI, RES
14–15 
May
Berlin EU National drugs coordinators meeting Policymakers EPI, RES
22–23 
May
Port of Spain High Level meeting of the EU/LAC 
coordination and cooperation mechanism 
on drugs 
Policymakers
24–25 
May
Stockholm 5th European Workplace Drug Testing 
Symposium
Policymakers RES
29 May Lisbon Meeting with ECDC, discussion on hepatitis 
B and C data in Europe
EU agencies DRID
31 May Paris Collège Scientifique de l'OFDT Policymakers National & 
community 
strategies
31 May–1 
June May
Brussels Horizontal Working Party on Drugs, Troika 
with Ukraine, informal meeting on Russia
Policymakers
1 June Brussels EU-Troika meeting with the Ukraine Policymakers
4–6 June Loures European conference on 'Visions for Europe: 
crime, policing and justice in the 21st 
century'
Policymakers, 
experts
Crime and 
supply
14–15 
June
Luxembourg Meeting with DG Sanco Policymakers, 
experts
Treatment 
and harm 
reduction
18–19 
June
Wiesbaden 12th German congress on crime prevention 
(GCOCP): 1st annual international forum 
Policymakers RES
18–21 
June
Kiev Workshop: challenges in investigation 
and adjudication of drug-related offences, 
UNODC Regional Office
Policymakers Drugs 
legislation
20–21 
June June
Brussels Horizontal Working Party on Drugs, 
Information dialogue with the United States
Policymakers
28 June Brussels European Commission: GHK workshop on 
evaluation of the EU action plan on drugs 
Policymakers
28–29 
June
Vienna Joint OSCE/UNODC conference on fighting 
the threat of illicit drugs
Policymakers, 
experts
EPI
4 July Luxembourg NCA meeting Policymakers, 
professionals
5–6 July London Drug treatment across Europe, Turning Point, 
European Institute of Social Services, The 
Beckley Foundation
Policymakers, 
professionals.
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8–10 July Copenhagen 6th world congress of the International 
Health Economics Association
Policymakers, 
professionals
11 July Brussels Horizontal Working Party on Drugs Policymakers
13 July Rome Presentation of the Italian national drugs 
action plan 
Policymakers
26–30 
August
Seattle T2007 Joint International meeting of 
ICADTS/TIAFT/IIS
Policymakers
5–6 
September
Brussels Horizontal Working Party on Drugs, EU 
Troika ECOWAS (West African States), 
Technical Committee of EU/LAC Mechanism 
on Drugs
Policymakers
6 
September
Brussels EU-Troika informal dialogue with ECOWAS Policymakers
10–12 
September
Vienna European Association of Addiction Therapy 
2007 Conference
Policymakers, 
professionals
13–14 
September
Warsaw Policing drugs conference Policymakers RES
18 
September
Lisbon Meeting on the role of NGOs in influencing 
the UN review of global policies illegal 
drugs, International Drug Policy Consortium, 
International Harm Reduction Association
Policymakers
18–20 
September 
Vienna UNGASS second expert consultations, ten-
year review of UNGASS 1998
Policymakers, 
experts
19–20 
September
Lisbon Evaluation of public policies and 
programmes on drugs, Portuguese 
presidency
Policymakers
24 
September
Ankara Evaluation of EU strategy/Action plan Policymakers National & 
community 
strategies
27–28 
September
London 9th Annual Summit on combating drugs and 
alcohol in the workplace
Policymakers, 
professionals
RES
1–2 
October
Paris Pompidou Group ethics platform Policymakers
3 October Luxembourg Meeting with Eurostat EU institutions
4 October Brussels Evaluation committee DG JLS on tender for 
'detailed analysis of the operation of the 
world market in illicit drugs and the policy 
measures to curtail it'
Policymakers, 
experts
EPI
9–10 
October
Paris Pompidou Group research platform Policymakers
10–11 
October
Brussels Horizontal Working Party on Drugs, Russia 
Troika
Policymakers
11–12 
October
Brussels EU-Troika, Russia and Pakistan Policymakers
11–12 
October
Bucharest Conference on the quasi-coerced treatment 
and other alternatives to imprisonment
Professionals Drugs 
legislation
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12 
October
Brussels Final evaluation of the EU action plan on 
drugs 2005–2008: 2nd Meeting of the 
Steering Group 
Policymakers
18–19 
October
Buenos Aires CICAD/OEA-SEDRONAR-EMCDDA meeting Policymakers, 
professionals
DRD
19 
October
Kiev Meeting of the EU-law enforcement liaison 
officers 
Policymakers
19 
October
Vienna ReDUse_07: new aspects and developments 
in recreational drug use
Experts RES
19 
October
Paris Collège Scientifique de l'OFDT Policymakers National & 
community 
strategies
22 
October
Luxembourg Analysis of the outcome of the call for tender 
on drugs and prison, DG Sanco
Policymakers Treatment 
and harm 
reduction
24 
October
Lisbon EU National drugs coordinators meeting Policymakers
1–2 
November
Bogoto EU-CAN high level specialised dialogue on 
drugs 
Policymakers
3-6 
November
Rome UNODC seminar on 'How science speaks to 
drug policy'
Policymakers Crime and 
supply
8–9 
November
Venice 3rd conference on local, integrated and 
participative responses to the issue of drugs 
use 
Policymakers
9–10 
November
Rome Transnational Institute/Andreas Papandreou 
Foundation informal drug policy dialogue 
Policymakers EPI
12–13 
November
Madrid 26th meeting of the monitoring group of the 
anti-doping convention, Council of Europe 
Policymakers
13–14 
November
Brussels Horizontal Working Party on Drugs, EU-USA 
dialogue and AU/LAC meetings
Policymakers
14 
November
Brussels EU Troika Iran, EU-LAC meeting Policymakers
15 
November
Helsinki Alcohol programme 2004–2007 – Final 
Seminar
Policymakers RES
15–16 
November
Brussels WCO meeting: 'Une coopération 
internationale dynamisée au service de la 
lutte contre le trafic de drogues' (dynamised 
international cooperation to enable the fight 
against drug trafficking)
Policymakers, 
customs and 
police
Crime and 
supply
15–16 
November
Brussels HIV/AIDS Think Tank 9th meeting Policymakers, 
professionals
DRID
20 
November
Luxembourg DG Sanco workshop on children Policymakers
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22–23 
November
Strasbourg Réunion du forum des experts sur la justice 
pénale
Experts, 
researchers, 
policymakers
Crime and 
supply
28–29 
November
Warsaw Interagency Group meeting facilitated by the 
Presidency of the Pompidou Group 
Policymakers
28–29 
November
Sofia Regional Seminar on drug demand 
reduction in South East Europe 
Policymakers
3 
December
Brussels 2nd Meeting of DG JLS expert group on the 
policy needs of data on crime and criminal 
justice 
Policymakers Crime and 
supply
3–4 
Decemberr
Vienna UNODC: Paris pact policy consultative 
group meeting 
Policymakers
5 
December
Brussels Evaluation committee on DG JLS tender 
'comparative analysis of research into illicit 
drugs in the European Union' 
Policymakers, 
experts
EPI
5 
December
Luxembourg DG Sanco 'harm reduction and drug policy' 
meeting
Policymakers Treatment 
and harm 
reduction
11–13 
December 
Brussels Horizontal Working Party on Drugs, Troika 
with Pakistan, conference on EU and civil 
society forum on drugs
Policymakers
18 
December
London Visit to the European Medicines Agency 
(EMEA)
Experts, EU 
agencies
EPI
19 
December
Lisbon International conference on drugs in Guinea-
Bissau, Portuguese Presidency
Policymakers Crime and 
supply
Annual report European Parliament launch and national launches
21–22 
November
Brussels Annual report launch at European 
Parliament
Policymakers, 
media
22 
November
Sofia Annual report launch in Bulgaria Policymakers, 
media
22 
November
Prague Annual report launch in Czech Republic Policymakers, 
media
22 
November
Copenhagen Annual report national launch in Denmark Policymakers, 
media
22 
November
Nicosia Annual report launch in Cyprus Policymakers, 
media
22 
November
Vienna Annual report launch in Austria Policymakers, 
media
22 
November
Budapest Annual report launch in Hungary Policymakers, 
media
22 
November
Vilnius Annual report launch in Lithuania Policymakers, 
media
22 
November
Oslo Annual report launch in Norway Policymakers, 
media
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22 
November
Bucharest Annual report launch in Romania Policymakers, 
media
22 
November
Bratislava Annual report launch in Slovakia Policymakers, 
media
27 
November
Rome Annual report launch in Italy Policymakers, 
media
27 
November
Berlin Annual report launch in Germany Policymakers, 
media
27 
November
Lisbon Annual report launch in Portugal, Portuguese 
Parliament
Policymakers, 
media
27 
November
Warsaw Annual report launch in Poland, scheduled 
with National HIV/AIDS Conference
Policymakers, 
media, 
professionals
Reitox meetings, academies and workshops
29–30 
March
Berlin Reitox academy on cannabis: new 
developments in prevention and treatment
EMCDDA 
staff, Reitox 
staff, 
professionals
11 May Luxembourg Reitox academy on drug-related public 
expenditure
EMCDDA 
staff, Reitox 
staff, 
professionals
22 May Lisbon Reitox academy Fonte introductory course EMCDDA 
staff, Reitox 
staff
23–25 
May
Lisbon 36th Reitox heads of NFPs meeting EMCDDA 
staff, Reitox 
staff
14–15 
June
Lisbon 7th annual meeting of the Reitox early 
warning system network
EMCDDA 
staff, Reitox 
staff
Action on 
new drugs
5–6 July Ankara Fonte training: specialised course Reitox staff, 
professionals
12–13 July Bucharest Training on evaluation (Perk and EDDRA) Reitox staff, 
professionals
Best practices
12–13 
September
Oslo Reitox academy on best practices EMCDDA 
staff, Reitox 
staff, 
professionals
16–17 
September 
Riga Training seminar on EDDRA Experts, 
Reitox staff
Best practices
18–19 
September
Ankara Turkish Early Worning System conception 
seminar
Reitox staff, 
professionals
Action on 
new drugs
18 
September
Vilnius Conference: rehabilitation of drug-addicted 
persons, training course on EDDRA
Experts Best practices
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16–17 
October
Riga Evaluation: concepts and practice Reitox staff, 
professionals
7–9 
November
Lisbon 37th Reitox heads of NFPs meeting EMCDDA 
staff, Reitox 
staff
Expert meetings (key indicators, EWS etc.)
5 February Lisbon Expert meeting on data coverage EMCDDA 
staff, Reitox 
staff, 
professionals
Treatment 
demand
23 March Lisbon EWS technical meeting on the potential 
threat of mCPP
Experts Action on 
new drugs
12–13 
April
Lisbon Meeting on modelling protective factors for 
HIV infection in IDUs
Experts DRID
16–17 
April
Lisbon In aquae veritas? 1st interdisciplinary 
meeting on 'drugs in water'
Experts
21–22 
May
Lisbon European Perspectives on Drugs (E-POD) 
expert meeting
EMCDDA 
staff, Reitox 
staff, 
professionals
E-POD
23–25 
May
Lisbon 36th Reitox focal point meeting EMCDDA 
staff, Reitox 
staff, 
professionals
28–29 
June
Lisbon Annual expert meeting on prevalence and 
patterns of drug use among the general 
population
EMCDDA 
staff, Reitox 
staff, 
professionals
Population 
surveys
14 August Lisbon Expert meeting on quality criteria for EDDRA 
projects
EMCDDA 
staff, Reitox 
staff, 
professionals
Best practices
6–7 
September
Lisbon Expert meeting on quality standards in drug 
prevention
EMCDDA 
staff, Reitox 
staff, 
professionals
Prevention
18–19 
September 
Lisbon Expert meeting on towards improving data 
on retail drug prices
Experts Crime and 
supply
24–25 
September
Lisbon Annual expert meeting on the treatment 
demand indicator and meeting with 
international organisations
EMCDDA 
staff, Reitox 
staff, 
professionals
Treatment 
demand
3–4 
October
Lisbon Expert meeting on the revision of treatment 
reporting tools SQ27 and ST27
EMCDDA 
staff, Reitox 
staff, 
professionals
Treatment 
and harm 
reduction
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9–10 
October
Lisbon Annual expert meeting on the drug-related 
infectious diseases indicator
EMCDDA 
staff, Reitox 
staff, 
professional
DRID
11–12 
October
Lisbon Annual expert meeting on the problem drug 
use indicator
EMCDDA 
staff, Reitox 
staff, 
professionals
Problem drug 
use
27–28 
November
Lisbon Hospital and ambulance emergency services 
meeting
Experts E-POD
29–30 
November 
Lisbon Expert meeting on KI drug-related deaths 
and mortality among drug users
EMCDDA 
staff, Reitox 
staff, 
professionals
DRD
11–12 
December
Lisbon Expert meeting on towards estimating the 
size of European drug markets: European 
drug consumption estimates
Experts Crime and 
supply
External and practitioner-focused meetings (treatment, prevention, harm reduction, new drugs)
26 January Viterbo Prevenzione in Europa (Prevention in 
Europe)
Professionals
30–31 
January
Luxembourg 8th meeting of the network of competent 
authorities
Policymakers, 
experts
Health 
information 
networks (DG 
Sanco)
8–9 
February
Medina 
Sidonia
Programación, calidad y evaluación en la 
prevención (Planning, quality and evaluation 
in prevention)
Professionals Prevention
12–14 
February
Granada Doctoral course: public interventions on 
drugs
Experts Prevention
14 
February
Berlin Meeting in Berlin organised by Akzept Experts RES
28 
February
St. Boi del 
Llobregat
Prevención comunitaria en la Unión Europea 
(Community prevention in the European 
Union)
Professionals Prevention
1–2 March Ulm/
Ravensburg
Kick-off meeting for study on indicated 
prevention
Experts Prevention
2–3 March Bratislava 1st transnational cork meeting of the 
European IATPAD project
Experts, 
researchers
Treatment 
demand
6 March Lisbon Meeting of the Portuguese National 
Coordination for HIV/aids and International 
Experts
Professionals
6–7 March Paris Europe–Asia cooperation on synthetic drugs 
and their precursors
Professionals Action on 
new drugs
13–14 
March
Bremen ‘Responsibility and partnership — Together 
against AIDS/HIV’, German Presidency
Professionals
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15 March Luxembourg Steering Committee on the European Health 
Survey System
Policymakers, 
experts
Health 
information 
networks (DG 
Sanco)
22–23 
March
Milan EU proposal on quality standards for 
prevention programmes
Experts Prevention, 
best practices
25–26 
March
Frankfurt Visit to the Frankfurt Drug Policy Department Experts Treatment 
and harm 
reduction
17 April Rome Conference on drug-related research Experts, 
researchers
RES
19 April Luxembourg 5th meeting of the working party on lifestyle 
and other health determinants, Public Health 
Executive
Policymakers, 
experts
Health 
information 
networks (DG 
Sanco)
26–27 
April
Thessaloniki Conference: construction and evaluation of 
new intervention materials
Experts Prevention
7–10 May Loures Cepol course: 'Southwest Europe organized 
crime organizations
Professionals, 
police
Crime and 
supply
7–10 May Vienna UNODC global workshop: 'Drug abuse 
information systems: assessing progress and 
outlining future directions'
Professionals
8–10 May Copenhagen 13th European Network of Forensic Institutes 
Drugs Working Group
Professionals
8–9 May Dubrovnik Seminar on synthetic drugs and precursors 
for the Western Balkan countries
Professionals Action on 
new drug
9–10 May Copenhagen 13th ENFSI Drugs Working Group meeting Experts Action on 
new drugs
11 May Porto Drugs and their metabolites in surface/
sewage waters: a new approach to assess 
population prevalence of drug abuse
Experts
13–17 
May
Warsaw International Conference on the Reduction of 
Drug-related Harm
Professionals Treatment 
and harm 
reduction
15 May Brussels European Parliament Open Discussion Forum 
on hepatitis C
Professionals, 
policymakers
DRID
16 May Madrid II reunión de validación de escalas de 
dependencia de cannabis en Estudes 2006
Professionals Population 
surveys
17 May Madrid Internal expert meeting on assessment of 
cocaine use, Plan nacional sobre drogas
Professionals
21 May Edinburgh WHO-HIPP Steering Group meeting International 
partners
Treatment 
and harm 
reduction
21–22 
May
Edinburgh Steering group meeting for prison and 
health 
Professionals Treatment 
and harm 
reduction
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29–31 
May
Lisbon CEPOL conference on 'Youth: anti-social 
behaviour and crime', Superior Institute of 
Police Sciences and Internal Security
Experts, 
police
Crime and 
supply
29 May–1 
June
Washington Society for prevention research annual 
meeting
Professionals Prevention
30 May Lisbon Extended Scientific Committee risk 
assessment meeting on BZP
Scientific 
Committee, 
EMCDDA 
staff
Action on 
new drugs
31 May Wiesbaden 2nd EUCPN Board Meeting under the 
German Presidency and adjacent Seminar 
'Dangers of the internet for children and 
juveniles' 
Professionals, 
policymakers
Crime and 
supply
31 May–1 
June
Oslo 6th meeting of the treatment platform Experts, 
NGOs
Treatment 
and social 
rehabilitation
1 June Lisbon XX Encontro das Tapias Professionals
31 May–1 
June
Vienna 4th Meeting of the Central and South Asia 
Counter Narcotics Security Working Group 
(CSACNSWG) 
Professionals, 
policymakers
4–6 June Lisbon Conference on Visions for Europe: crime, 
policing and justice in the 21st century, 
Instituto Superior de Polícia Judiciária e 
Ciências Criminais
Professionals, 
police
4–8 June Budapest 33rd Annual Alcohol Peidemiology 
Symposium of the Kettil Bruun Society
Professionals, 
researchers
Treatment 
demand, 
treatment 
and harm 
reduction
5–8 June Ljubljana 11th EFCT European conference on 
rehabilitation and drug policy
Experts, 
policymakers
Best practices
6–7 June Lisbon Consultation on HIV/AIDS testing and 
counselling (T&C) issues, WHO Regional 
Office
Professionals
6–8 June Stockholm EU-DAP II prevention trial meeting Experts Prevention
7–8 June Lisbon European conference on the right to 
HIV/AIDS prevention, treatment, care and 
support for migrants and ethnic minorities in 
Europe
Professionals
7 June Zagreb Workshop on harmonisation of treatment 
data collection
Professionals
7–9 June Ljubjana European conference on rehabilitation 
and drug policy,  European Federation of 
Therapeutic Communities
Professionals
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11–12 
June
Budapest Applied M&E and effective lobbying: 
essential parts of successful policy-making 
Professionals, 
policymakers
National & 
community 
strategies
11–14 
June
Warsaw Twinning project meeting to implement the 
TDI indicator in Poland
Experts, NFPs Treatment 
demand
10–15 
June
Stockholm 50th International ICAA conference on 
dependencies
Professionals Prevention
20–21 
June
Wiesbaden Twinning Light Project Experts, NFPs RES
25–27 
June
Moscow UNAIDS: 2nd Monitoring AIDS pandemic 
MAP meeting in the former Soviet Union 
countries 
Professionals DRID
28–30 
June
Padova National Prevention Conference Professionals Prevention
28–29 
June
Vienna OSCE/UNODC expert conference on 
Fighting the threat of illicit drugs 
Professionals, 
policymakers
28 June Padova National prevention conference: school and 
community prevention
Experts Prevention
2 July Ravensburg Steering meeting for indicated prevention 
project
Experts Prevention
2–7 July Warsaw Training on incidence and survival in cohort 
population studies (twinning project, PHARE)
Experts, NFPs Population 
surveys
3–4 July Luxembourg 9th meeting of the network of competent 
authorities
Policymakers, 
experts
Health 
information 
networks (DG 
Sanco)
5 July London Crossing frontiers conference Experts RES
8–11 July Copenhagen 6th World Congress ‘Explorations in Health 
Economics’
Professionals, 
researchers
6–7 
September
Stockholm Annual meeting of EuroHIV National 
correspondents (WHO, ECDC)
Experts, EU 
agencies, 
international 
partners
DRID
10–12 
September 
Vienna 2007 European association of addiction 
therapy conference,
Professionals, 
experts, 
researchers
EPI
15 
September
Brussels Meeting on awareness raising and scientific 
data on universal access to HIV services in 
Europe (EATG, European Aids Treatment 
Group)
Experts DRID
17–18 
September
Varna Seminar on capture-recapture Experts, NFPs Population 
surveys
19 
September
Rome Seminar on mass media campaigns at 
Italian Ministry of Health
Policymakers, 
professionals
19 
September
Prague Cepol course Experts Treatment 
and harm 
reduction
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20 
September
Manchester British Aerosol Manufacturers Association Industry, 
professionals
Youth and 
ESPAD
20–22 
September 
Vienna Multi city study on quantities and financing 
of illicit drug consumption ('QUAF') 
Professionals Crime and 
supply
20–22 
September 
Brussels 19th Elisad annual meeting Professionals
20–22 
September
Rome DAP steering group on evaluation 
instruments
Experts Prevention
27–29 
September
Sofia Social inclusion and health: crossing the 
borders, correlation network conference
Professionals Treatment 
and harm 
reduction
27–28 
September
Barcelona Seminar: 10 years of risk reduction in 
Spanish
Experts, 
NGOs
Treatment 
and social 
rehabilitation
27–29 
September
Dresden ISAJE annual meeting Professionals
1–2 
October
Lisbon FESAT conference, 'Taking a call on 
cannabis: drug helplines response’
Professionals EPI
2 October Lisbon Opening Session of the International 
Conference 'Guerras, Mulheres e Direito' 
Professionals, 
policymakers
11–13 
October
Krakow 18th annual conference of the European 
Society for Social Drug Research, European 
Society for Social Drug Research 
Professionals EPI
12–13 
October
Lisbon National AIDS coordinators meeting: 
translating principles into action 
Policymakers, 
professionals
16 
October
Santarêm Commission for dissuasion of drug abuse Experts Crime and 
supply
16 
October
Milan Progetto'Progettare con qualità e valutare 
l'efficacia'
Experts Prevention
18 
October
London Meeting at EMEA (inc. new drugs) Experts, EU 
agencies
Action on 
new drugs
18 
October
Vilnius Conference on rehabilitation of drug-
addicted persons: experience of Lithuania 
and European countries
Professionals
18–19 
October
Trençin Annual conference and meeting of WHO EU 
network for prison and health
Professionals Treatment 
and harm 
reduction
19 
October
London London Toxicology Group meeting Experts, 
researchers
Action on 
new drugs
19 
October
Vienna Conference 'Reduce_07', Check-it 10 Years 
Anniversary
Professionals
19 
October
Utrecht Meeting at Trimbos Institute Experts Action on 
new drugs
19 
October
Brussels Collège médical Experts Prevention
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27 
October
Barcelona Jornadas 10 años de reducción de riesgos 
en espacios de ocio
Professionals
29-31 
October
Naples III FeDerSed National Congress Experts National & 
community 
strategies
30 
October
The Hague Meeting at Europol EU agencies Action on 
new drugs
1–2 
November
St. 
Petersburg
International seminar in drug abuse and HIV 
monitoring among intravenous drug users 
(UNODC)
Professionals DRID
8–9 
November
Venice 3rd conference on local, integrated, 
participative responses to the issue of drug 
use
Experts National & 
community 
strategies
9 
November
Luxembourg 6th working party on information on lifestyle 
of specific subpopulations, Public Health 
Executive
Professionals Health 
information 
networks (DG 
Sanco)
12 
November
Madrid 27th meeting of the Monitoring Group of the 
Anti-doping Convention
Experts, 
policymakers
Action on 
new drugs
12–13 
November
Lisbon 2nd plenary meeting of the EUROGLEH 
2007 project partners 
Professionals
13–15 
November
Helsinki National Seminar in conjunction with the 
end of the current Alcohol Programme 
Professionals
15–16 
November
Madrid International conference on current cocaine 
problems
Professionals EPI
19–20 
November
Porto Pompidou Group conference on 'Families, 
lifestyles and drugs'
Professionals, 
policymakers
Prevention
20 
November
Luxembourg Children Workshop, DG Sanco Professionals, 
policymakers
Health 
information 
networks (DG 
Sanco)
22 
November
Vilnius National conference on early intervention Professionals
22–23 
November
Pisa ESPAD 2007 meeting Professionals Youth and 
ESPAD
26–27 
November
Prague National Prevention Conference Professionals
26–27 
November
Brussels Conference 'HIV in Europe 2007: Working 
together for optimal testing and earlier care' 
Professionals DRID
28–29 
November
Amsterdam 1st meeting to initiate RIVM-WHO/Europe 
project on HIV modelling in Europe 
Professionals DRID
6 
December
Coimbra IREFREA conference on nightlife prevention Professionals Prevention
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6–7 
December
Vienna Meeting of the EU-DAP coordination group Professionals Prevention
14 
December
Porto Conferência sobre segurança urbana e 
toxicodependência
Experts Treatment 
and harm 
reduction
18 
December
London EMEA–EMCDDA technical meeting on EWS 
and new drugs
Professionals
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Prof. Dr. Brice DE RUYVER Institute for International Research on Criminal Policy 
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Prague
Denmark (Danmark)
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Prof. Dr. Horst BOSSONG Universität Essen 
Essen
Eesti (Estonia)
Prof. Toomas VEIDEBAUM National Institute for Health Development 
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Ireland (Éire) 
Prof. Dr. Desmond CORRIGAN School of Pharmacy, Trinity College Dublin 
Dublin
Greece (Ελλάδα/Elláda)
Dr. Ioannis DIAKOGIANNIS Aristoteleio University of Thessaloniki 
Thessaloniki
Spain (España)
Dr. Fernando RODRIGUEZ DE 
FONSECA
Fundación IMABIS, Fundación Hospital Carlos Haya 
Málaga
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Dr. Jean-Pol TASSIN Collège de France, Unité CNRS 
Paris
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Marina DAVOLI Department of Epidemiology, ASL, RM E 
Rome
Cyprus (Κύπρος/Kypros)
Dr. Katerina KONARI Forensic Science and Toxicology Laboratory 
Nicosia
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Luxembourg
Prof. Dr. Robert WENNIG Laboratoire National de la Santé, Centre Universitaire du 
Luxembourg, Luxembourg
Hungary (Magyarország)
József RÁCZ, Phd. Research Institute for Drug Studies (RIDS), Eotvos 
University, Budapest
Malta
Dr. Maja Miljanic 
BRINKWORTH 
Ministry for the Family and Social Solidarity 
Valetta
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Prof.Dr. Henk F. L. GARRETSEN Faculty of Social and Behavioural Sciences, Tilburg 
University, Tilburg
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Area of Expertise Institution
Legal and criminal justice issues
Dr. Krzysztof KRAJEWSKI Department of Criminology, Jagellonian University, 
Krakow
Prof. Dr. Brice DE RUYVER Institute for International Research on Criminal Policy 
(IRCP), University of Ghent, Ghent
Risk assessment and basic research
Dr. Fernando RODRIGUEZ DE 
FONSECA
Fundación IMABIS, Fundación Hospital Carlos Haya 
Málaga
Dr. Jean-Pol TASSIN Collège de France, Unité CNRS 
Paris
Political and institutional framework
Dr. Henri BERGERON Ecole Libre des Sciences Politiques 
Paris
Prof. Dr. Irmgard EISENBACH-
STANGL
European Centre for Social Welfare Policy and Research 
Vienna
Prof.Dr. Henk F. L. GARRETSEN Faculty of Social and Behavioural Sciences, Tilburg 
University, Tilburg
Epidemiology
Marina DAVOLI Department of Epidemiology, ASL, RM E 
Rome
Prof. Dr. Björn HIBELL CAN: Swedish Council for Information on Alcohol and 
other Drugs, Stockholm
Prof. Dr. Dirk J. KORF Bonger Institute of Criminology, Universiteit Amsterdam 
Amsterdam
Prof. Dr. Jürgen REHM Klinische Psychologie und Psychoterapie, Technische 
Universität Dresden, Dresden
Methodological issues
Prof. Dr. Gerhard BUEHRINGER Addiction Research Unit, Technische Universität Dresden, 
Dresden
Prof. Dr. John STRANG National Addiction Centre, Institute of Psychiatry, King's 
College London, London
Best practice and interventions
Dr. Michael FARRELL South London and Maudsley Trust 
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Prof. Dr. Richard VELLEMAN Mental Health Research and Development Unit 
Bath
Observer
Economic issues
Dr. Anne-Line BRETTEVILLE 
JENSEN
Norwegian Institute for Alcohol and Drug Research 
Oslo
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Budget out-turn account 2007: revenue and 
expenditure 
Commission subsidy (for the operating budget - titles
1, 2 and 3 - of the agency)
Phare funds from the Commission
Other funding and contributions received via the
Commission
Other donors
Other revenue
Fee income
13 469 321.00 12 100 000.00
2007 2006
380 600.00
521 125.00333 482.13
250 504.08 93 190.96
14 053 307.21 13 094 915.96
-7 116 660.47 - 6 395 351.14
- 88 421.24 -165 574.68
-1 328 549.75 -1 077 021.35
-449 884.13-786 181.65
-4 885 285.41 -4 340 082.72
-382,592.76 -613,624.35
-14 587 691.28 -13 041 538.37
-534 384.07 -53 377.59
104 499.99 59 139.82
792 539.19 424 448.24
-293.19 1 291.45
362 361.92 538 257.10
538 257.10
-538 257.10
1 416 730.76
-1 416 730.76
362 361.92 538 257.10
13 106 959.08
362 361.92
83 481.91 60 548.57
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2007 budget appropriations and execution by nature of expenditure
Financial and accounting management 
A budget of € 13 881 027 was adopted for the implementation of the 2007 work programme. The budgetary figures for 
2007 are presented in the tables below. 
Budgetary provisions and appropriations, 2007
Title Description EUR
1 Expenditure relating to persons working in the office
Staff in active employment 7 118 224
Other staff-related expenditure (exchange of officials etc.) p.m.
Total under Title 1 7 118 224
2 Buildings, equipment and sundry operating expenditure 
Investment in immovable property, rental of buildings and associated costs 777 027
Data processing 949 550
Movable property and associated costs 122 063
Current administrative expenditure + postal charges and telecommunications 196 965
Socio-medical infrastructure 47 849
Total under Title 2 2 093 454
3 Expenditure resulting from special functions carried out by the institution
Statutory meetings 298 260
Expenditure on formal and other meetings + representation expenses 454 922
Studies, surveys, consultations 125 330
European network on drugs and drug addiction: Reitox 2 519 382
Missions 338 955
Total under Title 3 4 669 349
Total core budget 13 881 027
4 Expenditure relating to other subsidies
EC financing of specific projects 
CARDS financing for implementing pre-accession strategy 550 000
Total under 4 550 000
10 Other expenses (reserve)
Total under 10 0
Total budget 14 431 027
Execution of budget: credit consumption (commitments), 2007
Title Description % consumption of available credit
1 Staff
Staff salaries, allowances etc. 99.71%
2 Buildings, equipment and sundry operating expenditure 98.58%
3 Operating expenditure 96.32%
4 Expenditure relating to other subsidies
 Total consumption (Titles 1, 2, 3 ) 98.40%
Annexes
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Balance sheet at 31 December 2007 — Assets
426 082.27
31.12.2007 31.12.2006 VariationAssets
374 168.13 51 914.14
2 725 399.84 2 809 014.66 -83 614.82
2 450 495.84 2 538 920.13 -88 424.29
18 364.66 14 196.54 4 168.12
230 992.91 247 156.18 -16 163.27
25 546.43 8 741.81 -16 804.62
0.00 0.00 0.00
0.00 0.00 0.00
0.00 0.00 0.00
0.00 0.00
0.00
0.00
0.00
0.00 0.00 0.00
0.00 0.00
0.00 0.00 0.00
0.00 0.00 0.00
0.00 0.00 0.00
0.00 0.00 0.00
0.00 0.00 0.00
0.00 0.00 0.00
0.00
0.00 0.000.00
0.00 0.000.00
3 151 482.11 -31 700.683 183 182.79
Long-term pre-financing
0.00 0.000.00
0.00 0.000.00
Short-term pre-financing 0.00 0.00 0.00
0.00 0.000.00
0.00
556 231.63 140 510.46415 721.17
228 458.35 -55 154.34283 612.69
0.00
22 357.33 -9 791.4732 148.80
305 415.95 205 456.2799 959.68
0.00
86 015.95 -13 943.7399 959.68
Deferrals and accruals with
consolidated EC entities
219 400.00 219 400.00
0.00 0.000.00
0.00 0.000.00
1 846 415.08 -34 679.991 881 095.07
2 402 646.71 105 830.472 296 816.24
5 554 128.82 74 129.795 479 999.03
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Balance sheet at 31 December 2007 — Liabilities
Accrued charges
Deferrals and accruals with
31.12.2007 31.12.2006 VariationLiabilities
2 707 517.77 2 487 890.30 219 627.47
0.00 0.00 0.00
2 487 890.30 2 872 481.28 -384 590.98
219 627.47 -384 590.98 604 218.45
0.00
0.000.00 0.00
0.00 0.00 0.00
0.00 0.00 0.00
0.00 0.00 0.00
0.00 0.00 0.00
0.00 0.00 0.00
0.000.00 0.00
0.00 0.00 0.00
0.00 0.00
0.00 0.00 0.00
0.00
0.000.00 0.00
2 707 517.77 2 487 890.30 219 627.47
2 846 611.05 2 992 108.73 -145 497.68
148 996.50182 569.80 33 573.30
0.000.00 0.00
0.00 0.00 0.00
0.00 0.000.00
0.00
2 664 041.25 2 843 112.23 -179 070.98
199 880.46219 500.82 19 620.36
0.00 0.000.00
51 497.4533 425.22 -18 072.23
1 568 968.591 547 323.91 -21 644.68
0.00
231 321.15 50 944.96 180 376.19
863 791.30 1 022 765.73 -158 974.43
777 359.39 953 254.57 -175 895.18
86 431.91 69 511.16 16 920.75
1 316 002.76 1 518 023.63 -202 020.87
2 846 611.05 2 992 108.73 -145 497.68
5 554 128.82 5 479 999.03 74 129.79
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Negotiated procedures launched in 2007
Supplies Services Total
Number 
of 
contracts
Volume of 
contracts 
(EUR)
Number 
of 
contracts
Volume of 
contracts 
(EUR)
Number of 
contracts
% Volume of 
contracts 
(EUR)
> 5 000 & < 25 000 
EUR
3 25 396.84 23 242 233.13 26 63.41 % 267 629.97
=/> 25 000 EUR 7 258 360.84 8 453 730.96 15 36.59 % 712 091.61
Total 10 283 757.49 31 695 964.09 41 100 % 979 721.58
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About the EMCDDA
The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) 
is one of the European Union’s decentralised agencies. Established in 1993 
and based in Lisbon, it is the central source of comprehensive information on 
drugs and drug addiction in Europe.
The EMCDDA collects, analyses and disseminates factual, objective, 
reliable and comparable information on drugs and drug addiction.In doing 
so, it provides its audiences with an evidence-based picture of the drug 
phenomenon at European level.
The Centre’s publications are a prime source of information for a wide range 
of audiences including policy-makers and their advisors; professionals and 
researchers working in the drugs field; and, more broadly, the media and 
general public.
The General report of activities is an annual publication providing a detailed 
progress report of the EMCDDA’s activities over a 12-month period. Published 
every spring, it catalogues the Centre’s achievements in each area of its 
annual work programme. The report is a useful information source for all 
those seeking comprehensive information on the Centre and its work.
